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Abstract
3B-hydroxysteroid dehydrogenase (3B-HSD) catalyses the conversion of 3B-hydroxy- 
A5-steroids into the corresponding A4-3-ketosteroids and is essential for the 
biosynthesis of mineralocorticoids, glucocorticoids and sex hormones. Two isoforms 
encoded by two highly homologous, closely linked 3B-HSD genes (HSD3B1 and 2) 
are known to be expressed in humans. However, Southern blot analysis and 3B-HSD 
type II mutation screening suggested that there was more than two HSD3B genes in 
humans; therefore, two human genomic Àgemll libraries were screened with 3B-HSD 
type I cDNA and bacteriophage clones containing novel 3B-HSD sequences were 
identified. Two of the phage clones were characterised and the segments equivalent to 
HSD3B1 coding regions were sequenced. The 3B-HSD coding sequence deteimined 
from both of these clones contained frameshift mutations resulting in premature stop 
codons, and it was concluded that these sequences were unprocessed pseudogene 
members of the 3B-HSD gene family.
The library screens generated 5 new members of the 3B-HSD gene family and these 
were mapped by fluorescent in situ hybridisation (FISH) to chromosome lp l3 , the 
same region of the genome as HSD3B1 and 2. Specific oligonucleotide primer pairs 
were designed for each gene and using PCR the genes were mapped to a set of 3 
overlapping yeast artificial chromosomes (YACs) and 9 overlapping bacterial artificial 
chromosomes (BACs). The gene order was subsequently confirmed using restriction 
analysis and 3B-HSD-specific oligonucleotide probes. The orientation of HSD3BI, 
2, \j/l and \|/4 was determined by extensive restiction analysis of the BACs and the 
positions of the endpoints in three BAC clones. The estimated length of the entire 
contig is 500kb with the 3B-HSD gene cluster over a centrally-based 235kb fragment.
cDNA selection techniques were established to detect expressed sequences from the 
region of the 3B-HSD gene cluster. Three BAC clones from the contig were 
biotinylated and hybridised to a placental PCR-amplifiable cDNA libraiy. The hybrids 
produced were isolated using streptavidin coated magnetic beads. Many 3B-HSD 
transcripts were detected from these experiments indicating that the selection process 
was successful, however no previously identified genes were detected that could be 
localised to the 3B-HSD locus. Although, several unknown sequences were 
discovered which may belong to unidentified genes present within or close to the 3B- 
HSD gene cluster.
IX
CHAPTER 1
Introduction
1.1 The definition of a hormone
The regulation of many biological processes in a multicellular organism requires 
communication between cells. This cell-cell communication is mediated in part by the 
endocrine system and molecules known as hormones. The classical definition of a 
hormone is a chemical substance produced by specialised tissues and secreted into the 
blood, within which it is earned to target organs. However, it is becoming clear from 
continued research that this definition is not quite correct (Bern, 1990). Hormones are 
no longer synthesised only by "specialised tissues". Chemical substances with 
hormonal activity exist throughout the animal and plant kingdom where discrete 
endocrine glands are not found, and hormones exist that exert their effects locally and 
these tend to have almost ubiquitous distribution (Carmeliet and Collen, 1997). 
"Blood" is not necessarily the only medium that hormones can pass through, local 
hormones may diffuse through extracellular fluid and some hormones, such as the 
insect hormones pheromones, are even transmitted via the atmosphere (Donascimento 
and Morgan, 1996). The term "target organ" is no longer accurate either; local 
hormones may stimulate the cell that synthesised them and plants produce hormones, 
known as alarmones, that can be secreted or used internally (Ozeretskovskaya et al., 
1994). Therefore, a broader and more accurate definition of a hormone is: a chemical 
substance that canies information between two or more cells, allowing the chemical co­
ordination of bodily functions.
1.2 Hormone-Target relationships
The three main systems of hormone action are the endocrine system, the paracrine 
system and the autocrine system. In the classical endocrine system, a hormone is 
made in one part of the body and it reaches its target in another part of the body via the 
bloodstream. When the hormone remains within the tissue where it is synthesised and 
reaches nearby cells by diffusion this is known as the paracrine system and if the 
hormone influences the cell that has secreted it, this is the autocrine system. All of 
these systems are open, there are no barriers and the selectivity of the target cell is 
determined by the presence or absence of receptors to the particular hormone.
Other systems have also been determined, including closed systems of hormone action. 
The first if theses is loiown as the crytocrine system, where a hormone is secreted into 
a closed environment. The cells involved here include sertoli cells and nurse cells 
(Fritz, 1994) or thymus nurse cell and T-lymphocytes (Brelinska and Waichol, 1997), 
and in both these cases an special intimacy exists between cells. The juxtacrine 
system involves membrane bound hoimone precursors, these may be cleaved to release
an active soluble peptide hormone or remain attached to the plasma membrane retaining 
their biological activity, affecting cells in close contact only. Finally, in the intracrine 
system a hormone is synthesised and bound to its receptor internally. This includes 
the endogenous generation of hormones in peripheral tissues from precursors 
synthesised in a classical endocrine tissue, for example, 75-100% of oestrogens in 
postmenopausal woman are generated in peripheral tissues from adrenal precursors 
(Labrie et al., 1995).
1.3 Principles of hormone action
The chemical structure of hormones is extremely diverse. The most abundant 
hormones are the peptide and protein hormones. These molecules can range in size 
from a simple tripeptide to complex glycoproteins with multiple subunits. Modified 
amino acids can also act as hormones, for example tyrosine is the amino acid precursor 
for the catecholamines and histiimne is the precursor for histamine. Lipids are another 
source of hoimones including steroid hormones, prostaglandins and insect pheromones 
(fatty acid derivatives). The nucleotides are also represented, these include some 
insect pheromones, plant hormones (cytokinins; Chernyadev, 1997), and 1- 
methyladenine has been identified as a hormone in starfish (Mita, 1992). Finally, 
some oligosaccharides hormones have been recently identified, including plant 
hormones derived from cell wall breakdown (Darvill et a l ,  1992); and an aggregation 
factor identified in sponges that appears to be a glycan (Mi se vie and Burger, 1990).
Despite the structural diversity of hormones, their mechanism of action generally 
depends on their solubility in water. Hydrophobic (or lipophillic) hormones, 
including steroid and thyroid hormones, are difficult to store within a cell as they can 
pass through the plasma membrane easily and therefore these hormones are synthesised 
for immediate use. Hydrophobic hormones are not water soluble, and require serum 
transport molecules to enable them to manoeuvre in the bloodstream. Serum transport 
molecules contain hydrophobic pockets and this protects the hormones, increasing their 
half-life. When hydrophobic hormones reach their target they diffuse through the 
plasma membrane and bind to cytoplasmic or nuclear receptors. Once activated the 
receptor-hormone complex elicits direct cellular effects (Evans and Bergeron, 1988). 
In contrast, hydrophilic hormones, mainly peptide and protein hormones, are stored 
within vesicles until needed, transported free in serum and as a result are eliminated 
rapidly from the circulation. Also, when hydrophilic hormones reach their target cell 
they interact with receptors at the cell surface, generating secondary signals to affect 
cellular processes, i.e. they induce cellular processes indirectly (Dohlman et a l,  1987).
1.4 Control of hormone activity
To enable co-ordination of tissues within the body the activity of all honnones must be 
very tightly regulated. To do this, hormonal regulation confonns to a limited number 
of mechanisms. The simplest mechanism is negative feedback, where rising levels of 
a particular hormone will shut off its synthesis to maintain the desired concentration. 
For example, the hypothalamus releases corticotrophin releasing hormone (CRH) 
which stimulates the anterior pituitary to release adrenocorticotrophic hormone (ACTH) 
which stimulates the adrenal gland to synthesise cortisol. Cortisol, in turn, will act on 
the anterior pituitary and hypothalamus to prevent further release of the stimulatory 
hormones and therefore reduce further cortisol production (Kemppainen and Behrend, 
1997). Positive feedback, where rising levels stimulate further production of the 
hormone, is less common and tends to occur only where there is a clear termination 
point, e.g. oxytocin is released to induce smooth muscle contraction in the uterus 
during the birth process, the uterus will contract harder and continue to stimulate 
oxytocin secretion until the foetus is expelled (Neumann et a l ,  1996). The last type 
of feedback is known as cycle-dependant feedback and is dependant on other 
physiological parameters, e.g. oestrogen normally has a negative feedback on the 
hypothalamus, however during mid-cycle this changes to a positive feedback and 
oestrogen levels will rise until they trigger a surge of luteinizing hormone which leads 
to ovulation (Millier, 1985).
1.5 Steroid hormones
The structure of steroid hormones coiTesponds to that of perhydrocyclopenetenphenan- 
threne, with 4 rings of C-atoms (3 cyclohexane and 1 cyclopentane) forming the basic 
molecular skeleton. Adjoining pairs of rings each share 2 carbon atoms at the ring 
junctions and almost all natural steroids usually possess 2 methyl groups at "angular" 
or "bridgehead" positions where 2 rings meet (Fig. 1.1). The diversity of biological 
effects of steroid hormones depends on the nature of the modification of this basic 
structure. Modifications can include the unsaturation of C-C bonds within the rings or 
the attachment of hydroxyl, ketone or other groups to specific C-atoms (examples in 
Fig. 1.3).
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Fig. 1.1 A: Steroid molecular structure 
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Steroid hormones are hydrophobic molecules and can therefore diffuse through the 
plasma membrane of cells and exert their effects at nuclear receptor sites (Evans and 
Bergeron, 1988). One consequence of this is that there is a lag time of 30-60 
minutes, sometimes longer, between the time of exposure of the target cell and the 
onset of a biological response. The mechanism of steroid hormone action is described 
in Fig. 1.2.
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Fig. 1.2 Mechanism of steroid hormone action. Free steroid hormone is in equilibrium with steroid 
bound to serum transport molecules (1), the free steroid can diffuse across the plasma membrane of the 
target cell (2). Steroid hormone receptors are associated with chaperones, which maintain the receptors 
in an inactive but ligand-friendly conformation (3). Binding to the steroid-hormone receptor occurs in 
the cytoplasm or the nucleus (4). The receptor-hormone complex binds to a hormone responsive 
element in the promoter region of a specific gene, this induces transcription of that gene (5 f The 
mature RNA leaves the nucleus, translation and post-translational modification (PTM) follows and the 
final gene-product is obtained (6). The protein will modify the cell function according to the nature of 
the specific hormone action (7). S=steroid hormone, B=serum transport molecule, R=steroid-hormone 
receptor, C=chaperone.
Steroid receptor proteins consist of several domains; a DNA binding domain, a nuclear 
localisation signal, a ligand binding domain and several transcriptional activator 
functions (Beato et al., 1995). Steroid hormone receptors regulate transcription of 
specific genes by induction or suppression by binding to palindromic DNA sequences 
known as hormone responsive elements. After binding to the DNA it is thought that 
the receptor interacts with components of the basal transcriptional machinery and with 
sequence-specific transcription factors. Unligated steroid hormone receptors are 
associated with chaperones which maintain the receptors in an inactive but ligand 
friendly conformation. The specificity of a single cell for a particular hormone arises 
because each cell can contain separate receptor proteins that are specific for different 
steroid hormones.
1.6 Major classes of steroid hormones
There are 5 major classes of steroid hormones; the mineralocorticoids, the 
glucocorticoids, the androgens, the progestogens and the oestrogens.
M ineralocorticoids:
The mineralocorticoids regulate the water and electrolyte balance in the body, in 
particular the kidney, the gastrointestinal tract, the salivary glands and the sweat glands. 
The main mineralocorticoid is aldosterone and its primary site of action is the distal 
tubule and the collecting ducts of the kidney, where it increases sodium reabsorbtion 
and excretion of potassium and hydrogen ions. Aldosterone increases the blood 
pressure, partly by increasing the plasma volume and partly by increasing the 
sensitivity of the arteriolar muscle to vasoconstrictor agents (Moms, 1981).
G lucocortico ids :
Glucocorticoids maintain critical biological processes at times of stress. The principal 
action of cortisol, the main glucocorticoid, is to increase the amount of glucose 
available for energy metabolism. The hormone causes both a decrease in the uptake 
and utilisation of glucose and an increase in gluconeogenesis. There is decreased 
protein synthesis and increased protein breakdown, particularly in muscle, this 
increases the availability of amino acids to be deaminated for de novo glucose 
production. In addition to this, cortisol also has powerful anti-inflammatory and 
immunosuppressive effects. It affects all types of inflammatory reactions whether 
caused by invading pathogens, by chemical or physical damage or inappropriate 
immune responses. Cortisol can also act as a mineralocorticoid, due to its ability to 
stimulate the mineralocorticoid receptor (MR). The type I MR actually has the same 
affinity for cortisol and aldosterone, however the renal receptor is protected from
cortisol by the dehydrogenase activity of IIB-HSD, which converts cortisol into the 
inactive glucocorticoid cortisone, allowing aldosterone free access to the receptor to 
regulate sodium homeostasis. (Walker and Edwards, 1991).
Androgens:
The androgens are the principal male hormones, the androgen testosterone is 
responsible for the initiation and maintenance of spematogenesis, the formation of the 
male phenotype during sexual differentiation (development of the male internal genitalia 
- epididymis, vas deferens, seminal vesicles and ejaculatory ducts) and the promotion 
of sexual maturation during puberty. Testosterone can be converted by 5a-reductase 
11 into the more potent androgen 5a-dihydrotestosterone (Russell and Wilson, 1994). 
This binds with much greater affinity to the androgen receptor, amplifies androgen 
activity and promotes male differentiation, including the development of the external 
genitalia (penis and scrotum) and the prostate gland (Wilson, 1978).
Progestogens:
These hormones are of utmost importance in the ovary. Progesterone is the principal 
product of the coipus luteura and is required for implantation of the fertilised ovum and 
maintenance of pregnancy. It also inhibits uterine contractions, increases the viscosity 
of ceiwical mucous, promotes development of the breast and increases basal body 
temperature. 17-hydroxyprogesterone is also secreted by the corpus luteum but has 
little known biological effect (Kliolkute et a l,  1995).
Oestrogens:
Like the progestogens, the oestrogens are extremely important in the development, 
growth and physiology of the female reproductive tract. The principal and most potent 
oestrogen is oestrodiol-1713, which is synthesised in the ovary. This hormone 
promotes development of female secondary sexual characteristics, thickening of the 
vaginal mucosa, thinning of the cervical mucosa and the development of the ductal 
system in the breast (Hillier, 1985).
1.7 The major pathways of steroid hormone biosynthesis
Steroid hormone biosynthesis takes place in a wide variety of tissues throughout the 
body. It is now known that it does not only take place in the classical endocrine 
tissues, such as the adrenal gland, the gonads and the placenta during pregnancy 
(Labriegf al., 1992), but also in peripheral tissues like the skin (Dumont et a l,  1992), 
the breast (Lachance et al., 1990), the liver (Zhao et al., 1991), the Iddney (Devine et
al., 1986) and even the brain (Martel et al., 1994). The peripheral tissues tend to 
synthesise sex steroids from precursors released from the adrenal gland and this 
process has been given the term intracrinology (Labrie et al., 1995). Through 
intracrinology, locally produced sex steroids may exert their action within the same 
cells that the final steps of their synthesis took place in without the need to be released 
into the extracellular compartment and the general circulation.
Adrenal Glands:
The adrenal glands are actually two glands in one; the outer layer of an adrenal gland is 
the adrenal cortex, which can synthesise steroids, and the centre layer, the adrenal 
medulla synthesises catecholamines (Kemppainen and Behrend, 1997). Each part of 
the adrenal has a distinct blood supply. The adrenal cortex can be further subdivided 
into three zones; the zona glomerulosa, containing ball-like clusters of cells and found 
below the adrenal capsule, the zona fasticulata, the middle layer containing cells in 
column-like pattern, and the zona reticularis, the innermost layer with cells in a netlike 
arrangements. Each zone also represents a functional division as the 
mineralocorticoids are synthesised from the zona glomerulosa, and the sex steroids and 
the glucocorticoids are synthesised in the zona fasticulata and the zona reticularis. The 
main reason for the functional zonation is the differential expression of the 
steroidogenesis enzymes.
The first enzymatic stage in the synthesise of all steroid hormones is the action of 
P450scc on cholesterol (Fig. 1.3). This enzyme cleaves the side chain of cholesterol 
to form pregnenolone. This is the rate-limiting enzymatic stage of the process, 
however the true rate-limiting step is the movement of cholesterol from the outer 
mitochondrial membrane to the inner membrane. This translocation is acutely 
regulated by the trophic hormones. It was noted from early studies that hormone 
production from cells stimulated to synthesise steroids was blocked by inhibiting 
protein synthesis (Davis et al, 1968). This suggested that a newly synthesised, 
hormone sensitive protein functioned to transfer the cholesterol molecule. There have 
been several proteins postulated to undertake this role (Stocco and Clark, 1997), one of 
these is a 30kDa protein studied by Pon et al. (1986), Pon and Onnejohnson (1986) 
and Stocco and Clark (1996a and b); this protein was named the steroidogenic acute 
regulatory protein (StAR). Although much evidence suggests that this protein is 
involved in cholesterol transfer, the mechanism of the translocation is still unknown. 
Stocco and Clarke (1997) have proposed a model whereby StAR may act in the transfer 
of cholesterol to P450scc. They suggest that a 37kDa precursor of StAR is 
synthesised in the cytosol in response to hormonal stimulation. This protein is then 
targeted to the mitochondria and during the processing of this molecule to form the
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Figure 1.3. Steroid biosynthetic pathways in the three functionally distinct zones of the adrenal cortex. 
Aldosterone and cortisol are the principal mineralocorticoid and glucocorticoid secreted by the zona 
glomerulosa and reticularis . Precursor sex steroids, DHEA, DHEA-S and androstenedione are secreted 
mainly from the zona reticularis. Reproduced by kind permission from Martin McBride.
30kDa StAR protein, "contact sites" are made between the outer and inner 
mitochondrial membranes. While the protein is being processed, cholesterol is 
somehow transfeiTcd from the outer to the inner membrane towards P450scc. Little is 
known about this mechanism, but it is possible that the formation of a protein complex 
or the physical contact between the membranes creates a hydrophobic core through 
which cholesterol could pass through. Once the mature protein has been synthesised 
the membranes separate and further cholesterol transfer is prevented.
Once synthesised from cholesterol by P450scc pregnenolone has three options; it can 
proceed down the mineralocorticoid pathway, it can be 17-hydroxylated and follow the 
glucocorticoid pathway or it can undergo 17-hydroxylation and cleavage of the C17-20 
bond leading to sex hormone production (Fig. 1.3). This is where the functional 
zonation and the specificity of enzyme expression becomes significant. 3B-HSD is the 
next enzyme in the pathway and is expressed in all three zones of the adrenal cortex, 
however P450cl7 is only expressed in the zona fastieulata and the zona reticularis 
(Sasano et ah, 1989). In the zona glomerulosa, pregnenolone is not diverted along 
the A5 pathway but converted into progesterone by 3B-HSD and onto aldosterone. 
Within the zona fasticulata and the zona reticularis, pregnenolone is converted into 17- 
hydroxy pregnenolone and either progresses to cortisol or is cleaved at the C l7-20 bond 
and converted to DHEA which is released and converted into sex hormones in the 
periphery.
Developmental changes can determine the flow of steroids from glucocorticoid to 
androgen pathways, e.g. puberty, which changes the adrenal cortex capacity for 
synthesising steroids. Mechanisms which regulate these changes include the 
dependence of C17-2Ü cleavage activity on concentrations of P450 reductase which can 
be altered in different steroidogenic tissues (reviewed by M iller et a l ,  1997), the 
regulation of 3B-HSD and 17a-hydroxylase activities (Bird et al., 1996, see section 
1.8.1) and the levels of the substrates and products available (Hanukoglu, 1992).
Progesterone and 17-hydroxy lated progesterone are converted into deoxycorticosterone 
and ll-deoxycortiso l by P450c21 in the pathways of mineralocorticoid and 
glucocorticoid respectively. P450c21 is expressed in all three zones of the adrenal 
cortex (Sasano et al., 1988). From here, deoxyeorticosterone is catalysed to 
corticosterone, then 18-hydroxycorticosterone which is hydroxylated to produce 
aldosterone and 11-deoxycortisol is converted into cortisol. Two different but closely 
related enzymes act to complete the aldosterone and the cortisol synthesis. The genes 
C Y P llB l and CYP11B2 are located in tandem and encode two enzymes which are 
93% identical. C Y P llB l is expressed in the zona fasiculata and the zona reticularis
and encodes P 4 5 0 c ll which catalyses ll-deoxycortisol to cortisone, whereas 
CYP11B2 is expressed only in the zona glomerulosa and encodes P450cl8 which 
performs the last three catalytic steps in aldosterone production, llB-hydroxylation, 18- 
hydroxylation and 18-methyl oxidation (White and Pascoe, 1992).
Gonads:
The majority of the sex hormones are produced by the testis in the male and the ovaries 
in the females. Although, the knowledge surrounding the importance of peripheral 
conversion from adrenal precursors is increasing, and it has been estimated that 30- 
50% of total androgens in man and possible more oestrogens in woman are synthesised 
in peripheral intracrine tissues from the adrenal precursors DHEA and DHEA-sulphate 
(Labrie et al., 1997). However, the testes and the ovaries are still the major tissues 
involved in sex hormone synthesis.
Testosterone synthesis in males is undertaken in the Leydig cells of the testis. 
Cholesterol is converted to androstenedione by P450scc, P450cl7 and 3B-HSD and is 
then catalysed to testosterone by the action of 17B-HSD. Multiple isoforms of 17B- 
HSD exist (Andersson and Moghrabi, 1997), type 3 17B-HSD is expressed in the testis 
and promotes the conversion of androstenedione into testosterone. Testosterone can 
be further converted into the more potent androgen 5a- dihydrotestosterone by 5a- 
reductase II (Fig. 1.4)
In the ovary, the synthesis of progesterone and androstenedione is identical to that in 
the Leydig cells in the testis and is undertaken in the theca interna cells. Granulosa 
cells are the major site of oestrogen production in females. P450arom is expressed in 
these cells and converts androstendione into oestrone and testosterone (via 17B-HSD) 
into oestradiol (Fig. 1.5).
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Figure 1.4. Ley dig cell steroidogenesis.
Testosterone is the major androgenic steroid hormone secreted by Leydig cells. Leydig cells do 
not metabolise 17-OH progesterone efficiently. The potent androgenic hormone 5a-D H T is only 
secreted in small amounts; the major sites of formation and action of Sa-DHT are in peripheral 
tissues (extraadrenal and extragonadal). Reproduced with kind permission from Martin 
McBride.
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Figure 1.5. Principal pathways of steroid hormone biosynthesis in the human ovary. Each cell type of 
the ovary contains the complete enzyme complement for the formation of oestradiol from cholesterol; 
however the concentrations of various enzymes differ amoung the cell types, and consequently 
hormones are synthesised in thecal and granulosa compartments as indicated . As in Leydig cells 
ovarian cell types do not metabolise 17-OH progesterone efficiently.
Reproduced with kind permission from Martin McBride
Placenta and human foetal adrenal:
During pregnancy, the placenta must act together with the human foetal adrenal gland to 
provide the necessary hormones required to maintain the pregnancy and allow the 
foetus to develop normally. The corpus luteum supplies the progesterone requirement 
for the first 6 weeks of pregnancy until the placental progesterone synthesis takes over 
as the primary source after 12 weeks. The placenta does not express P450cl7,
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therefore no conversion of C21 to C19 steroids can occur. This is overcome by using 
DHEA-sulphate (DHEA-S) of foetal and maternal adrenal origin as the oestrogen 
precursor. DHEA-S is converted to 16a-DHEA-S in the foetal liver and then it travels 
to the placenta where it has the capacity to produce androstenedione, 16-OH 
androstcncdione and testosterone. The high amount of aromatase activity in the 
placenta means that oestrone, oestriol and oestradiol can be produced from the above 
substrates respectively (Fig. 1.6; Siteri and MacDonald, 1967).
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Figure 1.6. Biosynthesis of progesterone and oestrogens (oestrone, oestradiol and oestriol) from the 
fetal-placental unit. Placental 3B-HSD enzyme activity is required for the maintenance of pregnancy 
and normal development of the fetus. Reproduced with kind permission from Martin McBride.
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1.8 315-hydroxysteroid dehydrogenase
3B-hydroxysteroid dehydrogenase (3B-HSD) is an enzyme important in the synthesis of 
all classes of steroid hormones - the mineralocorticoids, the glucocorticoids and the sex 
hormones. 3B-HSD converts 3B-hydroxy-A^-steroids into the corresponding A^-3- 
ketosteroids, firstly by 3B-hydroxysteroid dehydrogenation and then 5-ene-4-ene 
isomérisation. For example, pregnenolone is converted into progesterone, via 5- 
pregnene-3,20-dione (Fig. 1.7A). 3B-HSD also converts 17-hydroxypregnenolone 
into 17-hydroxyprogesterone and d ihydroepiandrosterone (DHEA) into 
androstenedione. The prefened cofactor for these reactions is NAD+.
In addition to this activity, 3B-HSD is responsible for the interconversion of 3-keto-5a- 
ketosteroids into 3B-hydroxysteroids, utilising NADH/NAD+ as cofactor, i.e. the 
interconversion of 5a-dihydrotestosterone and 5a-androstane-3B,17B-diol and 
androstanedione and epiandrostanedione (Fig. 1.7B).
A
CH. CH, CH.
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5-pregnenolone 5-pregnene-3, 20-dioiie 4-progesterone
B
H
NADH
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P H
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Fig. 1.7 Enzymatic reactions catalysed by 3B-HSD.
A: Two step catalytic reaction converting pregnenolone into progesterone. The first step is 
the dehydrogenase reaction using NAD+ as cofactor,folio wed by the isomérisation of 
A5 to A4.
B: Interconversion of 3-keto-5a-ketosteroids into 3B~hydroxysteroids using NADH/NAD+ 
cofactor.
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1.8.1 Molecular biology of 3B-hydroxysteroid dehydrogenase
Characterisation o f  the human type I  and type II 3Ji-HSD:
Evidence for a critical role for 3B-HSD in steroidogenesis was first revealed in the early 
1960s. Bongiovanni (1961) described an unusual steroid pattern in congenital adrenal 
hyperplasia which he determined was caused by a deficiency of 3B-HSD. The 3B- 
hydroxysteroid dehydrogenase-isomerase system was purified by Ford et a/.(1974) 
using sheep adrenal cortical microsomes, whilst the activity of human placental 3B- 
HSD was described by Ferre et a/.(1975). Rabe et «/.(1982) achevied the partial 
chai'acterisation of the placental 3B-HSD from mitochondria and Ishiiohba et a/.(1986) 
purified the testicular 3 B-hydroxy steroid dehydrogenase/isomerase. More recently, 
Thomas et aZ.(1988) reported the copurification of the dehydrogenase and isomerases 
activities from human placental microsomes and described the kinetics of substrate 
utilisation and product inhibition. Thomas et «/.(1989) extended his study to human 
placental mitochondrial 3B-HSD and compared the properties of the enzymes from the 
microsomes and the mitochondria. Both enzymes migrated identically on SDS-PAGE 
producing a single band of protein at approximately 42kDa. Kinetic data showed that 
NAD+ was the desired cofactor for the substrates pregnenolone and DHEA, with 
NADP+ utilised 90% less efficiently. Within this report, Thomas published a 29 amino 
acid sequence that corresponded to the amino terminus of the microsomal and 
mitochondrial 3B-HSD.
Polyclonal antibodies were raised to placental 3B-HSD and used to screen Xgtl 1 
expression libraries to isolate cDNA clones corresponding to 3B-HSD (Luu-The et a l ,  
1989; Lorence et al. 1990a). They isolated clones that contained an open reading 
frame of 372 amino acids with the first 29 amino acids corresponding to the sequence 
obtained by Thomas et a/.(1989). In addition, the calculated molecular weight of this 
peptide was 42,216 (Luu-The et al., 1989) and 42,120 (Lorence et a l ,  1990a), which 
also corresponds to the estimated molecular mass of 42kDa by Thomas et al. (1989). 
Lorence et al. (1990a) inserted the cDNA into a modified CMV expression vector and 
expressed it in COS cells (non-steroidogenic monkey kidney tumour cells). The 
expression protein catalysed the conversion of pregnenolone, 17-hydroxypregnenolone 
and DHEA into progesterone, 17-hydroxyprogesterone and androstenedione 
respectively. The reverse reaction was not observed. Cell homogenates of 
transfected COS cells also oxidised 5a-androstane-3B ,17B -diol into 5 a -  
dihydrotestosterone when supplied with NAD+ and, upon addition of NADH, reduced 
5a-dihydrotestosterone to 5a-androstane-3B,17B-diol. Therefore, it was established 
that a single polypeptide could catalyse both the dehydrogenation and isomérisation 
steps and could oxidise 4 major substrates, pregnenolone, 17-hydroxypregnenolone,
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DHEA and androstane-3B,17B-diol. However, Southern analysis of human genomic 
DNA hybridised with 3B-HSD sequences suggested that there was more than one 
isoform of 3B-HSD, as additional restriction fragments to those predicted were 
observed (Lachance et a l, 1990; Lorence et a l, 1990a).
It was known that the adrenal glands and the testis contained immunoreactive 3B-HSD 
protein (Doody et al., 1990; Milewich et a l,  1991) and with the detection of multiple 
fragments from the Southern analysis of human genomic DNA it was suspected that 
there was more than one 3B-HSD present in humans. In addition, Gibb et a/.(1985) 
described different catalytic constants for the human ovarian and human placental 3B- 
HSDs. Rheaume et al. (1991) screened a human adrenal cDNA library with the 
placental 3B-HSD cDNA. They isolated a cDNA with 93% similarity to type I and 
containing an open reading frame of 371 amino acids, this was designated 3B-HSD 
type II. They inserted both the type I and the type II cDNAs into expression vectors 
to compare the reaction kinetics. Type I possessed a 36-HSD activity higher than type 
II with respective Km values of 0.24|liM and I.2|tM  for pregnenolone and 0.18pM and 
1.6|aM for DHEA, while the specific activity (Vmax) was equal for both when 
standardised for the amount of protein translated. In addition, type I had a higher 
oxidoreductase activity using DHT as substrate in the presence of NADH, with Km 
values of 0.26pM and 2.7|liM for type I and II respectively. In fact, the relative 
enzyme activity (Vmax/Km) of type I is 5.9, 4.5 and 2.8-fold higher than type II using 
pregnenolone, DHEA and DHT as substrates respectively.
Gene structure o f  the human type I  and II 3f-HSD:
The gene for 3B-HSD type I (HSD3B1) was characterised first. The type I cDNA was 
used as a probe to screen a human EMBL 3 genomic library to isolate the genomic copy 
of type I 3B-HSD (Lorence et al ., 1990b; Lachance et al., 1990). The gene spans 
approximately 8 kb of DNA and contains 3 exons with sequence identical to that of the 
cDNA (Fig. 1.7). Examination of the nucleotide sequence revealed a putative TATA 
element (TATAT A A) 26 bp upstream of the exon 2 sequence. Primer extension 
analysis using poly (A)+ RNA from the placenta and the corpus luteum indicated that 
the RNA initiated upstream from the TATA box and that there was an untranslated exon 
5' to the first coding exon containing 59 bp. Therefore, HSD3B1 actually contained 4 
exons and 3 introns. The first exon contains 59bp and is untranslated, the second 
exon contains 232bp and encodes some 5' untranslated, residues 1-48 and the first 
nucleotide of residue 49. Exon 3 encodes the second and third nucleotides of residue 
49, residues 50-103 and the first nucleotide of residue 104. The last exon contains 
1218bp and encodes the second and third nucleotides of residue 104, residues 105-372
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and the whole of the 3' untranslated. The introns separating the exons contain 129, 
3383 and 2162bp respectively. A putative CAAT binding sequence is located 57 
nucleotides upstream from the TATA box.
The type II gene (HSD3B2) was isolated from an EMBL-3 human genomic library by 
Lachance et a l  (1991). HSD3B2 contains 4 exons and 3 introns included within a 
total length of 7,88Ibp. Intron/exon junctions were elucidated by comparison of the 
cDNA, and they are in agreement with type I. The exons contain 57, 231, 165 and 
l,214bp respectively and aie separated by introns of 128, 3,383 and 2,162 bp. One 
nucleotide is missing in the 5' untranslated region, as well as four nucleotides in the 3' 
untranslated compared to HSD3B1. Nucleotide changes at positions -2 and +2 results 
in the shift of the translational start codon and the loss of one amino acid in type II, 
compared to type I. This accounts for the difference of one amino acid between type I 
and II and knocks the residue numbers at the ends of exons out by one. The 
nucleotide sequence of the type II exons have 77.4, 91.8, 94 and 91% similarity with 
the corresponding exons of type I with 84, 80.3 and 73.9% similarity for the introns.
Primer extension analysis indicated that the transcription start site is 270 bp upstream 
from the ATG codon, this is the same position as type I. 1251 bp of the upstream 
region of type II was sequenced by Lachance to examine the promoter region. TATA 
elements were detected 28 and 140 nucleotides upstream from the transcription start site 
and a putative reverse CAAT motif (ATTGG) was located 178bp from start. The 
difference in TATA and CAAT boxes between type I and type II might suggest that 
type II has different RNA polymerase binding sites from type I. PISD3B2 also 
contains a TATA-rich repetitive sequence of 179bp within intron 3 that is absent in type 
I. Secondary structure analysis of this sequence suggests that it contains 6 hairpin 
loops which may be involved in transcription termination.
Schematic representation of the structure of HSD3B1 and HSD3B2 are found in Fig. 
1.8, and the full sequence of the genes can be found in appendix i.
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Fig. 1.8 Intron/ exon structure and partial restriction map of the 3B-HSD genes (not to scale). Exons 
are represented by boxes numbered I, II, III and IV. Open boxes represent 5' and 3' untranslated 
sequences, Introns are labelled A, B and C. Common restriction sites, and the translational initiator 
and stop codons aie indicated. Reproduced with kind permission from Martin McBride.
Chromosomal localisation o f  HSD3B1 and HSD3B2:
Using human-hamster somatic cell hybrids, Lorence et al (1990b) localised HSD3B1 to 
chromosome 1. These experiments also predicted that related genes or pseudogenes 
were also present on chromosome 1. Berube et al. (1989) mapped the genes to 
chromosome lp l3  and in 1991, Morrison et a /.(1991) refined the localisation by 
fluorescent in situ hybridisation (FISH) to chromosome lp l3 .1 . HSD3B1 and 
HSD3B2 are contained within a 290kb SacII fragment from human genomic DNA as 
determined by pulse field gel electrophoresis (Morissette et at., 1995). Morissette 
and co-workers also reported that the HSD3B loci was closely linked to the Genethon 
markers D1S514 and the centromeric D1Z5 locus.
Regulation o f  expression:
Mason et a/.(1993) examined the regulation of type I 3B-HSD in the human placenta. 
3B-HSD type I has extremely high levels of expression in the placenta, principally from 
the multinucleated syncytotrophoblasts. Gibb et «/.(1985) associated 3B-FISD activity 
to the chorion laeve and this was confirmed by Northern and Western analysis, which 
indicated that it was due to type I 3B-HSD not type II (Mason et al., 1993). Mason et 
<3/.(1993) also suggested that the enzyme activities from the above tissues (trophoblasts 
and chorion leave) were regulated by different mechanisms. In culture, human 
cytotrophoblast cells initially did not produce 3B-HSD, although after 48 hours 3B- 
HSD production started to increase and continued for up to 6 days. Cyclohexamide,
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an inhibitor of protein synthesis, prevented this increase which suggested that the 
expression of 3B-HSD required protein synthesis and that it is not a primary response 
gene. Also, the addition of various cyclic AMP agonists did not alter the already high 
increases of 3B-HSD. In contrast, after 24 hours in culture the 3B-HSD activity of 
chorion leave cells declined in a time-dependant manner, although similar to 3B-HSD 
activity in the cytotrophoblast cells cyclic AMP agonists showed no effect at all. It has 
been stated that syncytotrophoblasts differentiate from uninuclear cytotrophoblasts 
(Kliman et a l,  1986), this process is cAMP-promoted and it is possible that this 
differentiation may be defined by 3B-HSD, as 3B-HSD is characteristic of this stage of 
differentiation. Whereas, the villous cytotrophoblasts initially lacked 3B-HSD 
activity, the chorion laeve cells (cytotrophoblasts) already expressed 3B-HSD. These 
data suggest that the chorion laeve contains a discrete population of steroidogenieally 
active uninucleai' cytotrophoblasts that do not readily differentiate into syncytium, since 
there was no change in the levels of 3B-HSD under a variety of culture conditions.
Beaudoin et «/.(1997a) looked at the regulation of 3B-HSD type I during syncytium 
formation by progesterone and oetradiol. 3B-HSD type I and P450scc reached their 
maximum steady state mRNA levels and 3B-HSD specific activity at a time when 
syncytium formation occurs in vitro. By incubating these cells with progesterone or 
oestradiol, the adundance of the 3B-HSD mRNA increased but the amount of 3B-HSD 
protein stayed the same. This suggests that 3B-HSD steady state mRNA levels in 
placenta could be under post-translation regulation. These observations suggest a 
complex relationship in mechanisms that regulate transcription, mRNA processing and 
3B-HSD type I gene transduction due to the regulation by steroids on 3B-HSD mRNA 
levels. This may involve progesterone or oestradiol affecting the level of gene 
transcription and/or mRNA abundance or stabilisation, rather than affecting the rate of 
3B-HSD protein synthesis.
Beaudoin et «/.(1997b) also examined the regulation of 3B-HSD by calcium in human 
choriocarcinoma cells. In this instance, they found that with 3B-HSD stimulated by 
cAMP agonists calcium depleted 3B-HSD mRNA levels in a dose dependant manner. 
With PMA-stimulated 3B-HSD calcium had no effect. In addition, the use of 
thapsigargin (TG, a cell permeable lactone that releases calcium by inhibiting ER 
calcium-ATPase) indicated the presence of TG sensitive and TG insensitive calcium 
ATPases that regulate 3B-HSD mRNA levels. This data shows the complexity of 
calcium contribution to the protein kinase A and C pathways in the regulation of 3B- 
HSD.
19
At the level of the gene, Guerin et «/.(1995) found that the removal of intron I of the 
type I gene strongly impaired the transcriptional activity directed by the 313 type I basal 
promoter, although not cell-specific, as it affected 313-HSD activity in placental and 
adrenal cells similarly. DNAse I and DMS méthylation interference footprinting 
detected a 37kDa nuclear protein bound to a site within intron I, designated the 3131-A 
element. By increasing the protein concentration involved in binding, they reported 
another 3 nuclear proteins binding to this site, one of which was identified as the 
transcription factor Spl. Examination of the DNA sequence revealed the presence of a 
potential Spl binding site that overlapped 3131-A. The overlap between these two 
binding sites may indicate additional levels of control depending on a particular cell 
concentration of the nuclear proteins. 313-HSD type II does not have the same 
sequence over the 3131-A site as type I, although the site of Spl binding is identical (see 
Fig. 1.9). This may indicate that the 37kDa protein does not bind to type II and this 
may facilitate the binding of Spl or other Spl family members.
GT box3131-A
HSD3B1 1491 '
HSD3B2 1357
Fig. 1.9 Alignment between 313-HSD type I and type II intron I indicating the positions of the 3131-A 
element and the GT box. The coordinates are from the respective genomic sequences and the dots 
represent gaps in the nucleotide alignment.
The regulation of 313-HSD type II in the adrenal cortex is extremely important because 
of the developmental changes in the activity/expression of 313-HSD. In the foetus, the 
foetal zone of the adrenal produces large amounts of DHEA and very little cortisol. 
This suggests a block in 313-HSD activity or expression. After partuition, cortisol is 
the major adrenal steroid and this block in 313 activity/expression must be overcome. 
At adrenarche, the adrenal cortex starts to secrete large quantities of C19 steroid again 
and therefore there must be another alteration of regulation of 313-HSD in respect to the 
other enyzmes involved in steroidogenesis (Mason et a l, 1997).
In the foetal adrenal, Doody et «/.(1990) established that 36-HSD was not expressed, 
and that the massive secretion of hydroxy steroids was not because of an inhibition of 
36-HSD activity. The reason for the lack of expression in the foetal adrenal when the 
foetal testis express 36-HSD is not known at this time, although it has been shown that 
ACTH can induce 36-HSD from foetal adrenal cells in vitro via the protein kinase A 
pathway (Navilie et al., 1991).
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Bird et «/.(1996) examined the differential control of expression of P450cl7 and 36- 
HSD in human adrenocortical (H295R) cells. Stimulation of the protein kinase A 
pathway of signal transduction in H295R cells increased the levels of DHEA and 
androstenedione produced as well as the levels of 36-HSD and P450cl7 transcripts. 
The levels of 36-HSD mRNA were increased also by activating the protein kinase C 
pathway however, the P450cl7 mRNA levels were markedly attenuated. This 
differential response of these two enzymes to the protein kinase C pathway may be 
critical in the orchestration of adrenal steroidogenesis.
At the gene level of 36-HSD type II, Leers-Sucheta et «/.(1997) looked at the type II 
promoter region to identify specific areas that confer basal and phorbol ester induced 
regulation of transcription in adrenal cortical cells. Phorbol esters (PMA) induces the 
protein kinase C pathway in adrenocortical cells mimicking the effect of angiotensin II 
which regulates the production of aldosterone in these cells. To examine the type II 
promoter, deletion constructs were made with 5' deletions of 1251bps fused to the 
chloroamphenicol acetyltransferase (CAT) reporter gene. These were transfected into 
H295R cells and treated with or without PMA. CAT assay data indicated that the 
region between -101 and I52bp was necessary for the PMA induction. A putative 
SF-1 (Ad4BP) site was detected within this region (-61 to -56bp) by sequence 
homology. Steroidogenic factor (SF-1) is an essential transcription factor involved in 
cAMP transactivation of cytochrome P450 hydroxylases (Morohashi et al., 1995) and it 
is essential for adrenal and gonadal development and sexual differentiation (Luo et al., 
1994). The -101 36-HSD-CAT construct was transfected into non-steroidogenic cells 
with an expression vector for SF-1 and CAT activity increased 49-fold, confirming the 
functionality and essentiality of this SF-1 site. Unexpectedly, CAT activity increased 
540-fold over basal when the transfected cells were treated with PMA, indicating a 
synergistic activation of type II by PMA and SF-1. Mutation analysis of the SF-1 site 
abolished SF-1 induced CAT activity and the synergistic activation by PMA. The 
interaction of SF-1 with the putative element was confirmed by gel shift assays and the 
presence of SF-1 transcripts in the H295R cells was proved by Northern analysis. 
These data show that SF-1 is involved in the regulation of type II 36-HSD in adrenal 
cortical cells and this was the first study to show regulation of a non-cytochrome P450 
steroidogenic enzyme promoter by SF-1. It is interesting to note that the human type I 
36-HSD promoter does not contain a SF-1 site. This is consistent with the expression 
of type I in tissues like the placenta which does not express SF-1 and suggests that 
other transcriptional factors may be important in 36-HSD type I regulation of 
expression.
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1.8.2 Tissue distribution and subcellular localisation of 3B-HSD 
Tissue distribution:
36-HSD is found in the classical steroidogenic tissues, namely the placenta, adrenal 
cortex, ovary and testis (Labrie et al,, 1992). However, 36-HSD activity has also 
been identified in several peripheral tissues including the sldn (Dumont et a i, 1992), 
adipose tissue (Labrie et al., 1991), breast (Lachance et al., 1990), lung (Martel et al., 
1994), prostate (Abalain et a l,  1989), liver (Zhao et al,, 1991), kidney (Devine et al., 
1986) and brain (Martel et a l,  1994; Sanne and Krueger, 1995).
Rheaume et «/.(1991) used the ribonuclease protection assay to show that 36-HSD type 
I was found in the placenta, the skin and the breast whereas type II was identified in the 
adrenal, the ovaries and the testis. Although from longer exposures type I was also 
detected in the ovaries and the testis, and a small amount of type II was found in the 
breast. No type I was seen at all in the adrenal and no type II was found in the 
placenta. This data has since been confirmed by RT-PCR in our laboratory where 36- 
HSD type II was identified at low concentrations in the placenta (Sandra Burridge, 
personal communication).
The widespread distribution of 36-HSD suggests that this enzyme plays an important 
role in the peripheral conversion of adrenal precursor sex steroids into active sex 
steroids. This extragonadal conversion of sex steroids is particularly important in 
humans and some primates where the adrenal glands secrete large amounts of 
precursors of sex steroids such as DHEA and DHEA-sulphate.
Subcellular localisation o f  3fi-HSD:
36-HSD is a NAD+-dependant membrane bound enzyme. Lorence et al. (1990) 
showed that the cytosolic fraction of COS cell homogenates transfected with type I had 
no demonstrable activity, while the particulate fraction retained 36-activity. This is 
consistent with 36-HSD membrane-bound localisation. 36-HSD activity had been 
located in both the microsomes and the mitochondria. Studies on 36-HSD from each 
of these organelles revealed that it is the same protein involved (FeiTe et al, 1974; 
Thomas et al., 1989). The enzymes had similar kinetic profiles with respect to 
substrate utilisation, product inhibition and cofactor specificity and similar biophysical 
properties including molecular weight, subunit composition, pH optimum, temperature 
optimum, stability in storage and solution and the effects of cation inhibitors. 
Although, Cherradi et «/.(1993) stated that the Km values for DHEA and DHT as 
substrates for both enzymes were similar (1.6 and 2.5 respectively) but the Km for 
DHEA for the mitochondrial enzyme was much lower than the Km for DHT (4.5
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compared with 38). In addition, Cherradi et «/.(1992) reported that the bovine 
microsomal enzyme prefeiTcd 17-hydroxypregnenolone as a substrate. These data 
suggest that the microsomal and mitochondrial enzymes are not completely identical. 
The differences could be due to structural differences, different localisation in the 
organelles (and hence spatial or availability of substrate constraints) or differential 
regulation of the enzymes.
Alvarez et «/.(1994) studied the topology of placental 36-HSD in the microsomal 
membrane. Their methods involved immunoblotting and surface specific proteolysis. 
Inactivation of activity by proteinase treatment indicated that the crucial domains of the 
protein are located on the cytosolic side of the endoplasmic reticulum membrane. 
Sauer et al.{199A) also examined this by comparing the access to the active sites of the 
cofactor and the microsomal inhibitor merasyl, a nonpenetrant organic mercurial anion. 
Microsomal activity required exogenous NAD+ and was inhibited by merasyl, 
suggesting that the active site faced the cytoplasm. Merasyl had no effect on the 
mitochondrial 36-HSD unless the permeability of the inner membrane was disrupted. 
This suggests that in the mitochondria 36-HSD is located within the mitochondria and 
that the active sites face the matrix space.
These observations are supported by Cherradi et al.{1993) who found that the 
microsomal 36-activity was abolished when exogenous NAD+ was removed, whereas 
the activity in the mitochondrial fraction was still 40% of the activity measured with 
excess NAD+. This suggested that the mitochondrial enzyme utilises the 
intramitochondrial NAD+ available within the organelle and that the catalytic site was 
accessible from the matrix space. To confirm these observations, bovine adrenal 
mitochondria were separated into 3 fractions -the outer membrane (OM), the 
intermembrane space (IMS) and the inner membrane (IM)- and deduced that the 36 
activity was localised to the inner membrane and the intermembrane contact sites. 
This study was extended, when it was shown that the 36-activity was copurified with 
P450scc, suggesting a tight association between these proteins (CheiTadi et ah, 1994). 
They also reveal that the 36-activity was higher in the contact sites, than the IM. This 
work is consistent with the theory of cholesterol transport in the early stages of 
steroidogenesis which involves the recently identified StAR protein (Stocco and Clark, 
1997). This allows cholesterol to be made available to the enzymes involved in 
steroid synthesis.
More recently, Cherradi et al.{l991) examined the effects of calcium on 36-HSD as 
well as the StAR protein and P450scc. The presence of 36-activity in the IM was
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confirmed by preparing mitoblasts from bovine glomerulosa cells and mouse Leydig 
cells. A strong 36 signal was detected in the mitoplasts confirming that 36 is present 
within the mitochondria. Immunogold staining of adrenal fasiculata cells was studied 
as well. From this, is was observed that 36 antigenic sites were abundant in the 
mitochondria of these cells. These experiments also confirmed an earlier statement 
from Cherradi that 60% of 36-HSD was present in the microsomes. The apparent 
density of immunoreactive 36 is 56% higher than that of the mitochondria and the 
enrichment was even higher in stacking of smooth endoplasmic reticulum. The 
intramitochondrial pattern of 36 localisation was also examined using high power 
photomicrographs. The P450scc enzyme antigenic sites were localised exclusively to 
the crista membranes penetrating into the matrix space whereas 36-HSD was found in 
all compartments examined, although 60% was found in the crista membranes. This 
distribution also differed slightly from the StAR protein which was confined to the 
intermembrane space. Thus, it is almost certain that 36-HSD is localised inside 
mitochondria facing the mitochondrial matrix and within the contact sites in the 
intermembrane space. Although, the N-terminus of 36-HSD does not contain a 
mitochondrial targetting sequence, it has been shown in other genes that the targeting 
information can be contained internally or at the C-terminus (Court et aL, 1996; Folsch 
et al., 1996).
It is not known why there are two localised sites for 36-HSD activiy within the cell, 
one possible reason may be that 36-HSD acts in distinct steroidogenic units 
(Liebermann et a l ,  1984) with different regulatory controls. This is supported by 
CheiTadi et al(1991) who has shown tight association and similar localisation for the 
StAR protein, P450scc and 36-HSD. It must be stated here that despite the evidence 
presented above, some researchers believe that 36-HSD is a microsomal enzyme and 
the activity present in mitochondrial fractions is from microsomal contamination (Morel 
et al., 1997). Although Cherradi et al.{199A) estimated that the microsomal 
contamination of the mitochondrial fraction was less than 5%, and Pozzi et a l  (1996) 
demonstrated mitochondrial localisation of 36-HSD in the toad.
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1.8.3 Structure-function relationships of 3B-HSD
Two approaches have been undertaken to help understand the structure-function 
relationship of 36-HSD. The first of these is by examining the protein structure by 
affinity alkylation of type I 36-HSD and comparison of the amino acid sequences of all 
identified maimnalian 36-HSDs and the second is by the identification and examining 
the functional consequences of type II mutations found in patients with 36-HSD 
deficiency.
Studies o f  the 3fi-HSD protein:
Luuthe et «/.(1991) provided evidence, using differential inhibition, that there were two 
distinct active sites present in 36-HSD - one site for dehydrogenase activity and another 
for the isomerase activity. The conversion of dihydroepiandrosterone (DHEA) into 
androstenedione proceeds via the intermediate 5-androstene-3,17-dione, the ability to 
obtain tritiated intermediate gave them the opportunity to investigate differential 
inhibition of the dehydrogenase and isomerase activities using specific inhibitors. 
They found that N,N-dimethyl-4-methyl-3-oxo-4-aza-5a-andristane-176-carboxy- 
amide (4-MA) inhibited the dehydrogenase site competitively and specifically, whereas 
trilostane inhibited the isomerase activity non-competitively. This indicated that the 
activities belong on separate sites of the protein. He also speculated that because 36- 
HSD did not transform 3a-steroids, then the binding for the dehydrogenase site must 
be near to the position 3 on the steroid and that the site for the isomerase activity binds 
to the flattened B or A ring, since a compound without a flattened A or B ring did not 
bind to the isomerase activity.
Studies have been undertaken to discover where in the amino acid sequence the active 
sites may be. Thomas et «/.(1993) identified peptides and amino acids associated with 
substrate binding in type I 36-HSD. This group employed 2a-brom o[2 '-14c] 
acetoprogesterone, an active site-directed alkylator of type I 36-HSD, to affinity 
radio lab el the purified enzyme with or without protection by the substrate, 
pregnenolone. Trypic peptides of unprotected and substrate-protected radioalklyated 
were isolated and two of these were protected by the substrate. The primary affinity 
radioalklated peptide of 36-HSD is the Arg-250 trypic peptide containing radiolabelled 
His262 (251G Q F Y Y IS D D T P H Q S Y D N L N Y T L S K 274). The presence of 
pregnenolone substantially reduces the radioalkylation of the histidine residue. 
Histidine is the residue responsible for the hydride ion transfer during catalysis by 
lactate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase, and His 
residues have been identified in the active sites of bacterial 3a,206-HSD, foetal lamb 
36,20a-H SD  and human placental 176,20a-HSD. The second peptide Lys-175
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(175]t g GTLYTCALR^^^) contains radiolabelled Cysl83 which is protected by 
pregnenolone from radioalklyation to the same extent as His262 in the Arg-250 peptide. 
This equal protection suggests that these amino acids are both located in the substrate 
binding region and are located near one another in the tertiary structure of the protein. 
There is significant homology of the peptides in all identified mammalian forms of 36- 
HSD. 88% homology is detected in the amino acids of the Arg250 peptide between 
isofomis, with the His262 residue present in the same position throughout, and there is 
100% homology of the Lysl75 peptide (except for a single substitution in human type 
II) with Cysl83 positioned identically in all forms.
Thomas et «/.(1992) reported that different protein conformations were responsible for 
the 2 enzyme activities on 36-HSD, rather than the dehydrogenase and isomerase 
activities being catalysed at separate sites on the protein. This disputed what Luu-The 
had postulated in 1991. Thomas used a secosteroid, that acted as a site-directed 
alkylator of steroid A-isomerase activity, to evaluate the relationship between the two 
activities. They found that the isomerase site did not exist at low concentrations of the 
secosteroid but appeared as the concentration of secosteroid was increased, from this 
information they proposed that the dehydrogenase site underwent a conformation 
change to expose the isomerase site. They also predicted that NADH, the product 
from the dehydrogenation reaction induced this conformational change. Therefore, 
the protein starts that reaction sequence as a dehydrogenase, the products of this 
reaction (namely NADH) promote a change in protein conformation that triggers the 
isomérisation. Further studies have shown that the peptides involved in the 
inactivation by the secosteroid, and therefore the localisation of the isomerase site, are 
the same as the peptides identified in their study of the substrate binding site using 5a- 
BAP, i.e. Arg251-Phe274 with tritiated His-262 and Lysl75-A rgl86 with tritiated 
Cys-183 (Thomas et al., 1997; Thomas et al., 1996). This information supports the 
hypothesis that 36-HSD catalyses the two-step reaction at a single region mediated by a 
NADH-induced confoimational change around the bound substrate.
Rutherfurd et «/.(1991a) obtained 86% of the amino acid sequence of the bovine 
adrenal 36-HSD and found approximately 46% homology when comparing their 
sequence with the steroid binding region of bacterial isomerases. The conserved 
amino acids included K216, F271, D241, P242, F252 and Y253. These are found 
around the same region predicted by Thomas et al. (1996, 1997) and provide 
supporting evidence for the position of the active site.
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Thomas and collègues have also examined the 36-HSD protein to find the location of 
the cofactor binding site. NAD+ is the cofactor used in the dehydrogenase activity 
and it has also been shown to be a potent allosteric activator of the steroid isomerase 
activity. Thomas et «/.(1991) used the affinity labelling cofactor analogue 5'-[p- 
(fluorosulphonyl)-benzoyl] adenosine (FSA) to study the nucleotide binding sites of 
type I 36-HSD. It was known that FSA inhibits both activities of 36-HSD in rat 
adrenal and rat testis, therefore Thomas used FSA to examine the cofactor binding in 
the human placental isoform. Their data suggested that there was a single cofactor 
binding region which services both enzyme activities (the enzyme exhibited equal 
affinity for FSA as either an inhibitor of 36 or as an activator of isomerase activity, 
pregnenolone protected both activities from FSA and FSA inactivated both activities 
similarly). Rutherfurd et «/.(1991a) proposed the localisation of the NAD+ binding 
site on the basis of primary structure and comparisons with other nucleotide binding 
proteins. Some common features of NAD-h-binding domains include a "glycine-rich" 
sequence, GXGXXG, which maintains the appropriate structure for nucleotide 
binding, and the presence of a ADP-binding 6a6-fold containing specific amino acid 
identifiers (Wierenga et «/., 1986). The segment of residues 5-36 contains a glycine- 
rich sequence and a high score for a 6a6  fold predicts that this region may fold into 
such a unit, therefore Rutherfurd et «/.(1991a) proposed that this may at least be part of 
the cofactor binding site in type I 36-HSD. The same team also analysed NAD+ 
binding to type I 36-HSD using FSA inactivation (Rutherfurd et «/., 1991b). They 
reported that specific disulphide bonds were formed in 36-HSD due to FSA causing the 
inactivation of 36-HSD activity, the disulphide bridge was found to be between the 
cysteine residues in peptides 274-282 and 18-26 (Cys20 and Cys278). From this 
information Rutherford proposed that this putative cofactor binding region was in close 
proximity to a potential membrane anchor in 36-PISD (Trp284-Trp309). This study 
does not reveal an essential role for these residues (these can be substituted without loss 
of function), however it does reveal that these cysteine molecules are close to one 
another in the tertiary structure of the protein. To expand on this, Thomas et «/.(1993) 
speculated from the above information that the cofactor bound in the amino terminal 
may be close to substrate bound at the Arg250 peptide during the 36 reaction. All 
amino acids predicted to be important in both the substrate and cofactor binding are 
represented in Fig. 1.10.
In addition to the above, the question of cofactor specificity sheds more light on this. 
In the rat, mouse and hamster 36-HSD families there has been an isoform identified that 
can interconvert 3-ketosteroids (e.g. dihydrotestosterone) into 3-hydroxysteroids (e.g. 
androstane-36,176-diol) only, these enzymes are known as ketosteroid reductases (see 
section 1.7.4). These enzymes have a cofactor specificity for NADPH/NADP+.
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Within the region suspected of cofactor binding there is a residue that is conserved in all 
36-HSD isoforms except the ketosteroid reductase members, this residue is an aspartic 
acid (Asp35 in type II). Wierenga stated that one of the amino acids important in the 
6a6 fold in the co-factor binding sites of NAD+-requiring dehydrogenases was an 
acidic amino acid and it has been established that aspartic acid interacts better with 
NAD+ compared with NADP+ because a coulombic repulsion occurs between this 
residue and the 2'-phosphate on NADP+ (Nakanislii et al., 1997; Wierenga et al., 
1986). The absence of the aspartic acid in the ketosteroid reductase enzymes (these 
contain an aromatic residue in its place) allows NADPH and not NADH to interact. 
This supports the evidence above that this amino terminal region is the cofactor binding 
site in 36-HSD.
1 50
■k *
MTGWSCLVTG AGGFLGQRII RLLVKEKELK EIRVLDKAFG PELREEFSKL
51 100
■k
QNKTKLTVLE GDILDEPFLK RACQDVSVII HTACIIDVFG VTHRESIMW
101 150
■k
NVKGTQLLLE ACVQASVPVF lYTSSIEVAG PNSYKEIIQN GHEEEPLENT
151 200
WPAPYPHSKK LAEKAVLAAN GWNLKNGGTL "^ALRPMYI YGEGSRFLSA 
201  250
S^T VNPVYVGNVA WAHILALRALSaNEALNFTNG ILSSVGK: QDPKKAPSIR
251 300
CQFYYISDDT l^SYDNLNY TLSKEFGLRL DSRWSFPLSL MYWIGFLLEI 
301 350
■k
VSFLLRPIYT YRPPFNRHIV TLSNSVFTFS YKKAQRDLAY KPLYSWEEAK
351  373
*  *
QKTVEWVGSL VDRHKETLKS KTQ
Fig. 1.10 Amino acid sequence of 3B-HSD type I indicating the residues involved in the substrate and 
cofactor binding sites. Residues underlined represent the cofactor binding site, residues overlined 
represent the peptides identified in substrate binding studies (dehydrogenase and isomerase sites) with 
tritiated residues circled. Residues within boxes are homologous with another isomerase enzymes 
(Thomas et a i ,  1992, 1993, 1996 and 1997, Rutherfurd et a l ,  1991a and b).
28
3fi-HSD deficiency:
36-HSD deficiency is characterised by varying degrees of salt wasting, male 
pseudohermaphroditism and mild virilisation in females. To date, all mutations 
responsible for the disorder have been identified in 36-HSD type II, no deleterious 
mutations have been detected in type I. This is consistent with type II expression in 
the adrenal glands and the gonads and type I in the peripheral tissues.
24 mutations have been identified in 36-HSD type II (Morel et al., 1997), the nonsense 
and frameshift mutations introducing a premature stop codon are all associated with the 
classical salt-wasting form (Fig. 1,11 A). The locations of these mutations suggest 
that more than the first 318 amino acids out of 371 are essential for 36-HSD activity. 
There have been a number of missense mutations identified some of which coiTespond 
to the regions described above for substrate and cofactor binding (Fig. 1.1 IB) The 
mutations Y253N (Simard et al., 1993), Y254D (Sanchez et al., 1994) and T259R 
(Tajima et al., 1995) are all found within the Ai‘g250 peptide identified by Thomas et al. 
(1993) and these mutations result in severe salt-wasting form of 36 deficiency. A 
further mutation, G15D, results in the severe salt-wasting form and this is found within 
the "glycine-rich" segment important for cofactor binding (Rheaume et al., 1995). 
The activity of this mutant enzyme was established in vitro along with another mutant 
G15A, in which the glycine has been replaced with alanine (the second smallest amino 
acid after glycine). There was no detectable activity with G15D in intact cells, 
although relatively high 36-HSD activity was found with G15A. However in 
homogenates, both mutants had a decreased enzymatic activity compared with type II. 
This may suggest that the G15D mutation alters the intracellular localisation of 36-HSD 
or that in vivo its association with intact membranes modifies its efficient confonnation.
Other mutations may be involved in the attachment of 36-HSD to the membrane. Two 
segments have been predicted to be transmembrane domains within 36-HSD. the first is 
from residues 283-306, this is conserved throughout the 36 family and is reasonably 
hydrophobic. The second is from residues 75-91 and is identical in all members 
except bovine, rat II and mouse V, The nonsense and frameshift mutations predict a 
truncated protein without the C-terminal domain, except 318delC and these result in a 
severe salt-wasting form of 36 deficiency as expected. In contrast, A82T mutation is 
located within the second fragment and is associated with a non salt-wasting form 
(Mendonca et a l, 1994).
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186-InsC-187 
stop at 203 Y308X
273delAA 
stop at 279W171X
318delC 
stop at 279E135X R249X
Residues 5-36 
NAD+ binding site
t f
Lys-175 Arg-251
Substrate binding sites
B
Salt-wasting forms P186L
L205PE142K Y253N
L108WG15D T259R
Î L h A245PA82S
NIOOS G129R As above
L173R
As above
Non-salt-wasting forms
Fig. 1.11 A: Diagram of HSD3B2 showing the location of the nonsense and frameshift mutations. 
B: Diagram of HSD3B2 showing the location of the missense mutations.
Diagonal lines represent untranslated regions, small dots represent the location of the 
cofactor binding site and large dots represent the putative substrate binding sites. Both 
diagrams have been modified from Morel et al (1997).
1.8.4 Rodent 3B-HSD gene families
Multiple 3B-HSD cDNAs have been isolated in rat, mouse and hamster and the genes 
have been identified by roman numerals according to the order in which they have been 
isolated. Table 1 summarises some of the characteristics of these rodent 36-HSD
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isoforms. The rodent isoforms fall into two functionally distinct groups, NAD+- 
dependant dehydrogenase/isomerases and NADPH-dependant ketosteroid reductases 
(Abbaszade et a l,  1995; Delaunoit et a l, 1992). The ketosteroid reductase enzymes 
include mouse IV and V, rat III and hamster III and catalyse the conversion of 
ketosteroids into 36-hydroxysteroids, i.e. dihydrotestosterone into androstane-36,176- 
diol and androstane-3,17-dione (A-dione) into epiandrosterone. It is proposed that 
these isoforms are involved in the inactivation of active steroid hormones such as the 
potent androgen DHT. Payne et aL{\991) stated that mouse V has a lower Km than 
mouse IV for DHT and because mouse V is expressed in the male liver with type IV in 
the kidney, she suggests that mouse V is involved in DHT activation but mouse IV may 
have a preference for another ketosteroid substrate. This substrate may be 
dihydroaldosterone, a metabolite of aldosterone in the rat kidney.
The ketosteroid reductase enzymes are dependant on NADPH cofactor and the presence 
of a hydrophobic residue at residue 36 is predicted to be responsible for this specificity. 
The NAD+-dehydrogenase/isomerase isoforms of 36-HSD all contain an aspartic acid 
at residue 36 and it is proposed that this residue interacts more favourably with NAD+ 
than NADPH because a coulombic repulsion occurs between the aspartic acid and the 
2'-phosphate on NADPH (Wierenga et a l, 1986). Thus, the absence of the aspartic 
residue and its replacement with a hydrophobic residue favours the NADPH specificity.
It is interesting to note that the 36-HSD gene family is well-conserved across evolution. 
Simard et a l  (1993) stated that from 11 different 36-HSD protein sequences (mouse I, 
II and III, rat I, II, III and IV, human I and II, bovine and macaque) 50% of the amino 
acids are identical and conservative changes were found at 46 positions which gives an 
overall similarity of 62.4%. As well as this, the nucleotide sequences of the different 
mammalian isoforms have homologies ranging from 70% and above, the ketosteroid 
reductase enzymes are more similar to each other than to the dehydrogenase 
isomerases.
The mouse gene family have been found to be closely linked within a 3.5cM region of 
mouse chromosome 3 (Bain et a l ,  1993). This region is syntenic with the 
centromeric region of human chromosome 1, where the human 36-HSD genes are 
located (Bain et a l, 1993; Moiiison et a l,  1991). The mouse genes are grouped in a 
region not larger than 1400kb, determined by analysis of yeast artificial chromosomes 
containing the mouse 36-HSD gene family. However, additional analysis of mouse 
genomic DNA by pulse field gel electrophoresis indicates that all members of the mouse 
family are contained within a 400kb fragment (Clarke et a l, 1996),
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ISOFORM CLASSIFICATION
Rat I
Rat II 
Rat III 
Rat IV 
Mouse I
Mouse II 
Mouse III 
Mouse IV 
Mouse V 
Mouse VI
Hamster I
Hamster II
Hamster III
A
A
B
A
A
A
A
B
B
A
A
A
B
TISSUES EXPRESSED REF
Adrenal glands, gonads, 1
kidneys
Adrenal glands, fat 2
Male liver 3
Placenta, skin 4
Adrenal glands, gonads, 5,6,7
neonatal liver
Kidney, liver 5,6
Liver, kidney 5,6
Kidney 6
Male liver 8,7
Placenta, skin, maternal 8*
decidua, giant trophoblasts, 
testis
Adrenal glands, male kidney 9 
Kidney, male liver 9
Kidney 9
Table 1.1 Classification of rodent 3B-HSD gene families.
A=NAD+-dependant dehydrogenase/isomerase, B= NADPH-dependant ketosteroid reductase 
(1 - Simard et a l ,  1991, 2 - Zhao et al., 1991, 3 - de Launoit et al., 1992, 4 - Simard et 
al., 1993, 5 - Bain et a l ,  1991, 6 - Clarke et at., 1993, 7 - Park et at., 1996, 8 - 
Abbaszade et al., 1996, 8* - Abbaszade, unpublished observations, 9 - Rogerson et a l,  
1997)
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I.9 Background and aims of project
As described in section 1.8.1, there are two isoforms of 36-HSD expressed in humans, 
known as type I and type II. These enzymes are products of two distinct genes, 
HSD3B1 and HSD3B2, which have been localised to human chromosome Ip lS .l 
(Lorence et a l ,  1990a; 1990b, M orrison et a l ,  1991). However, several 
observations were made that suggested more than 2 isofoims of 36-HSD existed in the 
human genome. Southern analysis of human genomic DNA digested with a range of 
restriction enzymes and hybridised with 36-HSD sequences resulted in more restriction 
fragments than predicted from HSD3B1 and HSD3B2 (Lachance et a l,  1990). This 
could indicate the existance of other functional 36-HSD genes, pseudogenes or 36- 
related sequences. Also, during mutation screening experiments in our laboratory 
novel 36-HSD sequences were discovered (Russell et a l, 1993). Exon-specific 36- 
HSD PCR amplifications were analysed by denaturing gradient gel electrophoresis 
(DGGE) and it was noted that some products migrated differently from type I and type
II. These products were cloned, sequenced and novel exonic sequences were detected. 
This evidence led our laboratory to screen two Agem ll human genomic libraries for 
sequences similar to the known type I and II 36-genes (McBride et a l,  1995, McBride, 
1996).
One library was created from DNA of a member of a family affected with a dominant 
form of hirsutism (McBride et a l,  1995), the other library contained DNA from an 
unrelated normal individual. These were screened with ^^P-labelled 36-HSD type I 
cDNA. From a total of 1.4x10^ plaques, 57 positive plaques hybridised reproducibly 
through to the secondary stage of screening. The DNA from these clones was used as 
template for PCR amplification with primers designed to amplify exon 4b from 36 type 
I. The products were analysed by DGGE and classified according to their mobility 
which was different from type I exon 4b. In particular, two phage clones were 
analysed from this screen, clones 19(4) and 24(4), and it was demonstrated that these 
contained 36-HSD sequences similar but not identical to type I or type II (McBride, 
1996). For some clones no amplification product was obtained for exon 4b so exon 3 
primers were designed and amplification of exon 3 was attempted. Again, the products 
obtained were analysed by DGGE and several interesting phage clones were identified 
from these experiments, including clones designated clone 2(7) and 8(3).
The aim of this project was to extend the studies above and investigate the extent of the 
36-HSD gene family. The primary aims were threefold: Firstly, to characterise two of 
the phage clones identified from the library screens and demonstrate whether they 
contain putative new members of the 36-HSD gene family (Chapter 3). Secondly, to
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establish a genomic contig across the 36-HSD gene family using yeast artificial 
chromsomes (YACs) and bacterial artificial chromosomes (BACs) genomic clones and 
create a detailed restriction map of the gene family (Chapter 4) and thirdly, to develop 
hybrid selection experiments to attempt to identify further expressed sequences at the 
36-HSD locus (Chapter 5).
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CHAPTER 2
M aterials and Methods
2.1 BACTERIAL STRAINS
Strain
Nova-Blue
Genotype Source/Ref,
endA 1, hsdR 17, (r "k, m" k), supE 44, thi -1 Novagen
recA 1, gyrA 96, re/A 1, lac[ V~ proAB, lacNZAM15 
TnlO {tet 0]
E l 647 ER1648, recD1014 Biolabs
DS941 rec F143, pro A7, str 31, thr 1, leu 6, tsx 88 
mit 12, his 4, arg E3, lac Iq, lac ZDM15, gcd k2 
aro 14, supE 44, 5
D.Shen'att
DH5a F-, y80dlacZDM15, D(lacZYA-argF), U169, 
deoR, reclA , endA l, hsdRn{i:}^\m]^'^), phoA, 
supE44-, 1", hi-1, gyrA96, relA l.
Gibco BRL
2.2 B A CTERIA L M EDIA
L broth lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 950ml 
H2O
L-agar lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 15g bacto- 
agar, 950ml H2O
2xYT 1.6% (w/v) bacto-tryptone, 1% (w/v) bacto-yeast extract, 0.5% 
(w/v)NaCl pH7.5
NZCYM lOg NZamine, 5g NaCl, 5g Bacto-yeast extract, Ig casamino 
acids, 2g MgS04, 1.5% Bacto-agar up to I litre
BBL agai' lOg trypticase peptone (BBL), 5g sodium citrate, 1.5 % Bacto- 
agai- up to 1 litre
BBL Top agai’ lOg tryptic ase peptone, 5g NaCl, 6g Bacto-agar up to 1 litre
BBL Top agarose As above but with 0.7% agarose
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2.3 MANIPULATION OF BACTERIOPHAGE 
2.3.1 Preparation of Plating Bacteria (ER1647)
20mls L-broth medium containing 15qg/ml tetracyclin (Sigma) was innoculated with a 
single colony of ER1647 cells and incubated overnight at 37°C. 2mls of this overnight 
culture was used to innoculate lOOmls L-broth containing tetracyclin as above, and 
grown at 37°C for approximately 3 hours until the G.D.^oo ”  0.5. The culture was 
then centrifuged at 4,000g for 5 minutes, the supernatant was removed and the cells 
were resuspended in lOmM MgSO^ until the O.D.^oo = 2.0.
2.3.2 Plating Bacteriophage
NZCYM plates containing I5|Lig/ml tetracyclin were poured and dried at 42°C for 
approximately 1 hour. Tenfold solutions of high titre phage stock (see below) were 
made, lOOjil of each dilution was mixed with lOOjil ER1647 cells and incubated at 
37°C for 20 minutes. Meanwhile, the top agarose was melted and after 20 minutes 
3mls of top agarose was added to each phage/cell mix and quickly poured over 
NZCYM plates. The plates were incubated at 37°C overnight.
2.3.3 Plaque Lifts
Before starting, the phage plates were placed in the fridge for 30 minutes to harden the 
top agarose and nylon transfer membrane (Micron Separations Inc.) was cut to the size 
of the plates. Once the plates had been chilled the membrane was carefully placed on 
top of the plates avoiding air bubbles. The filters were labelled and orientated by 
stabbing holes in the membrane through to the agar, these were left on the plates for at 
least 1 minute before transferring to denaturing solution (1.5M NaCl, 0.5M NaOH, pH 
7.4) for 30 seconds, neutralising solution (0.5M Tris, 1.5M NaCl) for 2 minutes and 
20xSCC (3M NaCl, 0.3M Tri-sodium citrate, pH 7.0) for a minimum of 10 minutes. 
The membranes were then blotted onto 3mm paper and the transfeiTed DNA crosslinked 
to the membrane by exposure to UV radiation or baked at 80°C for 2 hours.
2.3.4 Making high titre phage stocks
Phage were plated as above to produce confluent lysis of the plating bacteria. l-2mls 
of phage buffer was added and left for approximately 15 minutes to allow the 
bacteriophage to diffuse out of the agar. The buffer, containing the phage, was 
removed from the plate using a pipette and stored at 4°C.
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2.3.5 Phage lysis
Dilutions (l/lOpl, l/5pl and Ipl) of high titre phage stock were added to 1ml ER1647 
plating cells and incubated at 37®C for 20 minutes. lOOmIs NZCYM, preheated to 
37°C, was added and placed on a shaker at 37°C for 5-6 hours until cell lysis was 
observed. The media was turbid after 2-3 hours incubation and cleared upon cell lysis. 
The lysate was centrifuged at 4,00Qg for 10 minutes to remove the cell debris, the 
supernatant was transfeiTed to a sterile tube and stored at 4°C.
2.3.6 Purification of Lambda DNA
Wizard Lambda Preps Purification System (Promega). Used as manufacturers 
recommendations.
2.3.7 Plating phage onto BBL plates
BBL plates contain agar not agarose and so phage can be plated out and used directly in 
the polymerase chain reaction without interference. BBL plates were poured and dried 
as NZCYM plates, lOOpl top BBL was mixed with lOOpl ER1647 plating cells and 
poured over the plates. Once set, lOpl spots of phage were dropped onto the plate and 
the plates were facing upwards left overnight at 42°C. Plugs were removed the next 
day and used directly as template in PCR reactions.
2.4 PURIFICATION OF PLASMID DNA
2.4.1 Isolation of plasmid DNA
Wizard minipreps DNA purification systems (Promega) or Qiagen Plasmid Midi-kit 
(Qiagen). Both kits used as manufacturers recommendations.
2.4.2 Sm all-scale isolation of plasmid DNA by phenol/chloroform  
extraction
1.5-3mls of an overnight culture of E.Coli transformed with the plasmid DNA was 
centrifuged at maximum speed. The pellet was resuspended in 200pl PI solution 
(50mM Tris-HCl (pH 8.0), lOmM EDTA), then 300pl P2 solution (2Q0mM NaCl, 1% 
SDS) was added gently, followed by 300pl chilled P3 solution (3.CM potassium 
acetate, pH 5.5), the solution was mixed gently but throughly. It was centrifuged at 
maximum speed for 10 minutes and the supernatant was transferred into a fresh
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eppendorf. 2pl RNAseA (20mg/ml) was added to the supernantent and it was 
incubated at 37°C for 20 minutes. An equal volume of phenol/chloroform (1:1 ratio) 
was added, mixed well ,then centrifuged at maximum speed for 1 minute. The 
aqueous layer was removed and an equal volume of chloroform alone was added to it, it 
was mixed and centrifuged as before for 1 minute. The aqueous layer was transfeiTed 
into a fresh eppendorf, 2xvolume of 100% ethanol and 1/10 volume of sodium acetate 
(3M, pH5.4) was added and the mixture was placed at -20°C for 30 minutes. The 
DNA was centrifuged at maximum speed for 15 minutes, the pellet was washed with 
70% ethanol, dried at 42°C for 10 minutes and resuspended in 20ql sterile water. 
This prep, gives a yield of 5-15jig DNA depending on the volume of culture used, the 
copy number of the plasmid and the bacterial strain used.
2.4.3 Large-scale isolation of plasmid DNA by phenol/chloroform  
extraction
25-lOOmls overnight culture of E.Coli was centrifuged at 4,000g for 15 minutes. The 
supernatant was removed and the cells resuspended in 4mls PI (solutions as above). 
4mls P2 was gently added and the mixture left at room temperature for 5 minutes, 4mls 
of chilled P3 was then added and the mixture placed on ice for 15 minutes. It was 
then centrifuged at 4°C for 30 minutes at >30,000g. The supernatant was removed and 
an equal volume of phenol/chloroform was added (ratio 1:1), it was mixed well and 
centrifuged at >20,000g for 10 minutes. The aqueous layer was removed and ethanol 
precipitated with 2xvolume ethanol and sodium acetate as above. The pellet was 
washed with 70% ethanol, dried and resuspended in 500-1000 |t1 sterile water, 
depending on the size of the pellet. The DNA was further treated with RNaseA (2jil 
20mg/ml for 20 minutes at 37°C, as above), phenol/chloroform extracted and ethanol 
precipitated, finally resuspending the pellet in 250ql sterile water. This prep, gives a 
yield of 50-200jXg DNA again dependant on factors above.
2.5 MANIPULATION OF PLASMID DNA
2.5.1 Restriction digests
IjTg DNA, 2|Li1 lOx REACT buffer (Gibco BRL), 5-10 units restriction enzyme (Gibco 
BRL) were mixed carefully and dH20 was added to a final volume of 20jil. The 
reaction mixes were placed at 37°C for 1-2 hours.
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2.5.2 Agarose gel elecrophoresis
Unless otherwise indicated, all agarose gels were run in TBE buffer (89mM Tris, 
89mM Boric acid, 2mM EDTA). Ethidium bromide was added to each gel at a 
concentration of 0.5pg/ml. The sample loading buffer consisted of 0.25% 
bromophenoi blue, 40% (w/v) sucrose in water (6xbuffer). The size marker included 
was the Ikb ladder from Gibco-BRL unless stated.
2.5.3 Purification of DNA from agarose gel slices
DNA fragments were recovered from agarose gel slices using Spin~X centrifuge filter 
units (Costar). Briefly, a gel slice containing the fragment of DNA was placed in a 
costar column, placed at -70°C for 10 minutes, 37°C for 5 minutes then centrifuged at 
maximum speed for 10 minutes. The eluant containing the purified DNA.
2.5.4 pTTBlue T-vector cloning of PCR products
Taq DNA polymerase leaves single 3' A-nucleotide overhangs on their reaction 
products, these products can be ligated directly into a vector containing compatible 
single T-nucleotide overhangs. pT7Blue vector (Novagen) has been constructed for 
this purpose. For a standard reaction the ligation mix contained 2.0ql x5 ligase buffer 
(200mM Tris-HCl pH7.6, 50mM Mg CI2), 0.5pl lOmM ATP, l.Opl T-vector 
(50ng/|Lil), 2-3 Weiss units T4 DNA ligase, 0.2pmol amplififed product and sterile 
distilled water to a final volume of lOjil. This was mixed gently and incubated at 16°C 
overnight.
2.5.5 Transformation of plasmid DNA into Novablue competent cells
20pl of Novablue competent cells (Novagen) was aliquoted into pre-chilled eppendorfs, 
Ip l of above ligation reaction was added and the tubes were placed on ice for 30 
minutes. After 30 minutes, the tubes were heated to 42°C for 40 seconds, then placed 
on ice for 2 minutes. 80jil of room temperature SOC medium was added to each tube 
and they were incubated at 37°C for 1 hour. 50pl of each transformation was then 
spread onto LB agar plates containing 50jig/ml ampicillin and 15qg/ml tetracyclin. For 
blue/white selection of colonies, 35pl of 50mg/rnl X-gal (Gibco BRL) in dimethyl 
formamide and 20pl lOOmM IPTG (Gibco BRL) were pre-spread on the plates and 
allowed to soak in. The plates were inverted and incubated at 37°C overnight.
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2.5.6 Transformation of plasmid DNA into DH5a competent cells
The other strain of competent cells used to transform plasmid DNA were D H 5a 
competent cells (ams Biotechnology). 4pl of the above ligation reactions were added 
to 20\x\ of competent cells and incubated on ice for 30 minutes. The transformation 
mixture was heat shocked at 42°C for 1 minute, 1ml of LB medium was added and the 
cells were grown at 37°C for 1 hour. The cells were centrifuged at maximum speed 
for 3 minutes and the pellet was resuspended in lOOpl LB medium. 50pl of this was 
spread on LB agar plates containing ampicillin (50mg/ml) only. Blue/white selection 
was accomplished as above. The plates were inverted and incubated overnight at 37°C.
2.5.7 Ligation of lambda phage DNA digests with pUC cloning vector
Ipg lambda phage DNA was digested with a restriction endonuclease (as above), at the 
same time Ipg of pUC 18 (Genbank accession number A02710) was digested with the 
same enzyme. Both digests were purified by a microcon 30 filter (Amicon) to remove 
the restriction enzyme and allow buffer exchange to the ligation buffer. A molar ratio 
of 2:1 insert:vector was combined in a reaction tube containing Ipl lOxligation buffer 
(300mM Tris-HCl (pH 7.6), lOOmM MgC12, lOQmM DTT, lOmM ATP) , l\x\ lOmM 
ATP, 1-2 units of T4 DNA ligase (Promega) with a final volume of lOjLtl made up with 
sterile water. The reaction was incubated at 16°C overnight. The recombinant 
clones were transfoimed into competent cells as above.
2.5.8 Selection of recombinant clones (single colony gel)
Single colonies were picked into 3-5mls LB medium containing the appropriate 
antibiotic selection and grown overnight at 37°C. 1.5mls of each culture was 
transferred into an eppendorf and centrifuged at maximum speed for 30 seconds, the 
supernatant was carefully removed. The pellets were resuspended in 100pi single 
colony loading buffer (2.5% ficoll, 1.25% SDS, bromophenoi blue, made up to final 
volume with TBE) and the cells were left to lyse for at least 20 minutes. The reactions 
were then centrifuged at maximum speed for 30 minutes and ~35pl of each supernatant 
was carefully loaded onto a 1% agarose gel. The gel was ran as described above and 
then photographed. Supercoiled DNA was visible at the top of the gel and it could be 
easily deteimined which clones contained inserts.
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2.6 POLYMERASE CHAIN REACTION (PCR)
Unless indicated, PCRs were carried out in a Hybaid "Omnigene" for 30-35 cycles of:
(i) 9 P C  for 30 seconds
(ii) annealing temperature for 30 seconds
(iii) 72°C for 30 seconds
The reaction mixture contained amplification buffer (50mM KCl, lOmM Tris-HCl (pH 
9.0), 0.1% Triton X-100, 15mM M gC h), 0.2mM of each dNTP, IpM  of each 
oligonucleotide primer, 0.5-1 unit Taq DNA polymerase (Gibco-BRL) and 10-50ng of 
DNA template, final volume 50pl made up with sterile distilled water.
2.6.1 Synthesis of oligonucleotides
Oligonucleotides were either synthesised using an Applied Biosystems 392 
oligonucleotide synthesiser into ammonium hydroxide or synthesised by Gibco BRL 
custom oligos.
2.6.2 Primer Sequences 
HSD3B1 primers
Name (Exon) 5' coord. Sequence 3'coord.
A (Ex.l) 1354 AGTGCATAA AGCTTC AG 1370
B (Ex.2) 1545 TAACCATTTGAC ATCTC 1561
C (Ex.2) 1585 CCT AGA ATC AGATCTGC 1601
*D (Ex.2) 1787 TCTCTC AATTCTGGTCCG 1764
AAG GCC
E (Ex.2) 1855 CCA CAT ACA TGC AGT GT 1839
(Ex.3) 5655 GGT TAG TGG ACT GGA CA 5671
G (Ex.3) 5682 TTG AGG TCT TGT TCT GG 5698
H (Ex.3) 5881 CCA CCT TGC TGC ATC TC 5865
I (Ex. 3) 6268 GTG ACT ACA GTG GCA CC 6252
J (Ex.4) 7955 CGT GGT TGG CAC CTC TT 7971
»K (Ex.4) 8031 GAG GCC TGT GTC CA/GG C 8047
L (Ex.4) 8159 GGC CAT GTG TTT TCC AG 8142
= M (Ex.4) 8217 ACC CGT TAG CCG CCA G 8202
N (Ex.4) 8239 CCC TGT ACA CTT GTG CC 8255
O (Ex.4) 8400 CAC ATT CTG GCC TTG AG 8416
P (Ex.4) 8466 AGT AGA ACT GTC CTC GG 8450
Q (Ex.4) 8511 ATT AAG GTT ATC ATA GC 8494
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R (Ex.4) 8881 GGA GCT TGA TGA CAT CT
=^S (Ex.2) 1671 TCC TGC TCC TGT CAC AAG G
* indicates type II primer also.
8865
1689
HSD3B2 primers
Name 5'coord. Sequence 3'coord.
T (E x .l) 1219 AGA GCA TAA AGC TCC AG 1235
U (Ex.2) 1522 ATG GGC TGG AGC TGC CTT GTG AC 1544
V (Ex.2) 1720 CCA CAC CCA TGC AGA GT 1704
W (Ex.3) 5515 AGC TCC AGA ACA GGA CC 5531
X (Ex.3) 5695 CCC CAG GCT ACT GTA CC 5680
Y (Ex.3) 5714 CCA ACT TGT TTT ATC TC 5698
Z (Ex.4) 7849 TGT GGT TGC AGC TCC TT 7865
AA (Ex.4) 8741 GCA CAT CTC TGT CAT CC 8725
BB (Ex.4) 8774 GAG TTT GAT GAC ATT T 8758
Gene-specific primers (HSD3BI co-ordinates)
Name 5'coord. Sequence 3'coord.
HSD3B1 1388 AGG TGA GAA GTA CGT CC 1404
HSD3B2 1388 AGG CAG TAA GGA CTT GG 1404
y4 5' 8600 AAT AGT GAG CTT CCT GCC G 8618
y4 3’ 8846 CAC ATC TCT GTC ATC CTT CG 8827
y l 5' 5662 CCT GAC CTG TGT TCT TG 5678
y l 3' 5788 AGA GGC GGT GTG GAT GAC T 5770
y2 5' 1391 TGA CCA GCA CCC TGA CTA C 1409
y2 3' 1836 AAG CTG GAG CCA CAC A AC T 1818
y5 5' 1615 CTG TTT CCT GGA GTG TCT TGT 1635
y5 3' 1796 GAA AAT TCC TTC CTC AAT TCC 1776
y3 5' 8221 CAC TGA AAA ATA GCG TAT 8238
y3 3' 8344 CTT GAC AGG ATC CCA TTG TAA 8322
Conserved oligonucleotides (HSD3BI coordinates)
Name 5'coord. Sequence 3'coord.
Exon 2 5' 1585 CCT AGA ATC AGA TCT GC 1601
Exon 2 3' 1671 TCC TGC TCC TGT CAC AAG G 1689
Exon 4 5' 8031 GAG GCC TGT GTC CA/GG C 8047
Exon 4 3' 8741 GCA CAT CTC TGT CAT CC 8725
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Cloning vector primers
Name Sequence
M13-40 GTT TTC CCA GTC ACG ACG TTG TA
M13-50 TTG TGA GCG GAT AAC AAT TTC
T7 TAA TAC GAC TCA CTA TAG GG
U19 GTT TTC CAG TCA CGA CGT T
Somatic cell hybrid primers (HSD3BI coordinates)
Name 
SCH 5' 
SCH 3'
5'coord.
8031
8890
Sequence 3'coord.
GAG GCC TGT GTC CA/GG C 8047
CAG GAG GGT GGC GCT TGA TGA 8867
CAT
Y AC primers
Name Sequence
93096 TTC CTC ATG TCA TCA AAA CCT G
93097 TCA GAA TCA GCT ACT GAG ATT TGG
GAPDH primers
Name 5'coord.
5 ’ 78
3 ’ 1051
Sequence
CGG AGT CA A CGG ATT TGG 
CAT GTG GGC CAT GAG GT
3'coord.
95
1035
2.6.3 Primer precipitation from ammonium hydroxide stocks
lOOpl oligo stock were mixed with 300pl 100%ethanol and lOpl sodium acetate (3M, 
pH5.2), placed at -70°C for 15 minutes and then centrifuged at 4°C for 30 minutes at 
maximum speed. The supernatant was removed, lOOpI 70% ethanol was added and 
the mixture was centrifuged at 4°C for 15 minutes at maximum speed. The 70% 
ethanol was removed and the pellet was dried at 42°C for 10 minutes, then resuspended 
in lOOpl sterile water.
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2.7 SOUTHERN BLOTTING
2.7.1 Bidirectional southern blotting
DNA to be blotted was electrophoresed on IxTBE agarose gels as above. The gel was 
photographed beside a size marker (usually a ruler) to allow sizing of bands later on. 
The gels were first depurinated in dilute HCl acid (0.25M) for 20 minutes to increase 
the efficiency of transfer of big fragments, then washed in denaturing solution (1.5M 
NaCl, 0.5M NaOH), 2x15 minutes, and followed by neutralising solution (0.5M Tris, 
1.5M NaCl, pH 7.4), 2x20 minutes. A sandwich arrangement was set up on the 
bench as follows: 
weight 
glass plate
2 inch pile of flat paper towels
3 sheets of 3mm paper 
nylon transfer membrane 
gel
nylon transfer membrane 
3 sheets 3mm paper 
2 inch pile of paper towels 
This was left for 6 hours to overnight. The DNA was crossed linked to the filters by 
exposure to UV light. The filters were stored at room temperature until required.
2.7.2 Unidirectional southern blotting
This was canied out as above except the blots were set up as follows: 
weight 
glass plate
2 inch pile paper towels
3 sheets 3 mm paper 
nylon transfer membrane 
gel
3mm paper whicker into 20xSSC
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2.8 PREPARATION AND HYBRIDISATION OF RADIOLABELLED 
PROBES
2.8.1 Random priming of DNA
20ng of DNA was labelled with a-^^P-dCTP (3000Ci/mmol; Amersham) by the random 
primer method, using a Ready-To-Go DNA labelling kit (Pharmacia). The reaction 
mixture consisted of 20ng DNA in 46pi water, 4pi a-^^P-dCTP (lOpCi/pl), reaction 
mix (dATP, dCTP, dGTP, dTTP, FPLC p u re^  Klenow fragment 4-8units) and 
random oligodeoxyribonucleotides (primarily 9-mers), the final volume was 50pl. The 
DNA was heated to 95°C for 3 minutes before being added to the above mix, once 
added the reaction mix was incubated at 37°C for 45 minutes.
2.8.2 Hybridisation of random-prime probes
For all hybridisations hybaid bottles and hybridisation oven were used. The 
membranes to be probed were placed in MO mis pre-hybridisation solution (5xSSC, 
5xDeinhardts, 0.2% SDS, lOpg/ml heiTing sperm) at 65°C for at least 30 minutes. 
The labelled DNA (above) was heated to 95°C to denature and added to the membranes 
and pre-hybridisation solution, this was left overnight at 65®C. The next day the 
membranes were transfened from the solution containing the probe into wash buffer 
(IxSSC, 0.1% SDS) and placed at 65°C for 30 minutes, this was repeated twice. The 
membranes were then placed in bags, sealed and put in an autoradiograph cassette with 
X-ray film (Fuji Medical X-ray film). The film was developed after 1-2 days.
2.8.3 Preparation of oligo probes
lOpmoles of oligo were placed in a reaction mix containing 2.0pl lOxkinase buffer 
(700mM Tris-FICl (pH 7.6), lOOmM MgC12, 50mM DTT), 3.0pl g-32p-dATP 
(lOpCi/pl, DuPont), l-2units of polynucleotide kinase (Promega) with a final volume 
of 20pi made up with sterile water. The reaction was then incubated at 37°C for 45 
minutes.
2.8.4 Hybridisation of oligo probes
As with random-prime probes (above) a Hybaid hybridisation oven and bottles were 
used. The membrane to be probed was placed in -40mls pre-hybridisation buffer 
(6xSSC, O.OIM sodium phosphate, ImM EDTA, 0.5% SDS, lOOpg/ml herring sperm 
(denatured), 0.1% non-fat dried milk) at 42°C for at least 45 minutes. The labelled
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oligo (above) was added to the solution and it was incubated at 42®C overnight. 42°C 
was the hybridisation temperature used for oligos between 20 and 25 nucleotides long. 
The next day, the membranes were rinsed with wash buffer (6xSSC, 0.1%SDS) for 10 
minutes at room temperature followed by 2 washes at 42°C. The membranes were 
sealed into bags and exposed to X-ray film overnight.
2.8.5 Gene-specific oligo probe sequences
Name 5'coord. Sequence 3'coord.
HSD3B1 1390 GTG AGA AGT ACG TCC ACT CT 1409
HSD3B2 1387 GAG GCA GTA AGG ACT TGG ACT 1407
HSD3Byl 1423 TAA CCA TTT AAT TAA TGG TGA A 1439
HSD3By2 1540 GTG TAT AAA TAT CTG ATC TC 1559
HSD3By3 8315 GGC CCC ATT ACA ATG GGA TC 8336
HSD3By5 1623 TGG AGT GTG TTG TCT GCT ACT 1643
2.9 DIDIEOXY SEQUENCING
2.9.1 Sequencing plasmid DNA
Double-stranded plasmid DNA sequencing was performed with the Sequenase Kit, 
USB Version 2 (Amersham) or Sequenase Quick-Denature Plasmid Kit (Amersham). 
Both kits were used as manufacturers recommendations.
2.9.2 Sequencing PCR products
Direct PCR sequencing was earned out using Sequenase PCR sequencing Kit (USB, 
Amersham). Used as manufacturers recommendations.
2.9.3 Automatic sequencing
Automatic sequencing was performed using ABI automatic sequencer. Protocols used 
as manufacturers recommendations.
2.10 SYNTHESIS OF FIRST-STRAND CDNA FOR RT-PCR
Total prostate, placental, testicular and ovarian RNA was bought from Cion tech and 
used as template in the reaction (reprecipitated as manufacturers recommendations).
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The first-strand cDNA reaction was accomplished using the first-strand cDNA 
synthesis kit from Clontech. Oligo dT was used as the primer.
2.11 YAC PROTOCOLS
2.11.1 Making YAC plugs
10ml culture (containing the appropriate media and supplements) was innoculated and 
incubated at 30°C overnight. The yeast cells were harvested at ISOOrpm for 5 minutes 
at room temperature. The pellet was resuspended in 0.5ml YRB (1.2M sorbitol, 
lOmM Tris, 20mM EDTA, pH 7.5) containing 14mM B-mercaptoethanol and 50 units 
of lyticase. 95% spheroblasting was observed under the microscope after 80 minutes 
at 37°C, then 0.5mls of 1% low melting point agarose in YRB was added. The 
agarose solution was mixed, poured into taped plug fonuer and placed on ice until set. 
Once set the plugs were removed into 20mls YLB (1% lithium dodecyl sulphate, 
lOOmM EDTA, lOmM Tris-HCl; filter sterilised), left at RT for 1 hour and then 
incubated overnight at 50°C. Thereafter, the plugs were placed in 20mls fresh YLB 
and stored at room temperature for up to one year.
2.11.2 Pre-treatment of YAC plugs for sizing
A whole plug from each YAC to be sized was put into an eppendorf containing TE 
(lOmM Tris-HCl, pH7.5, ImM EDTA). This was left for 2 hours to overnight at 4°C 
changing the TE at least twice. Approximately one hour before the YAC plugs were 
loaded onto the gel, the plugs were pre-equilibriated in 0.5xTAE.
2.11.3 Digestions of YAC plugs
For partial digestions running uncut and four time-points for each enzyme, three YAC 
plugs were cut in half, incubated in several changes of TE and left overnight at 4°C. 
The next day the plugs were incubated in 500|il Ixrestriction buffer at 4°C for 1 hour. 
Fresh buffer was then diluted to give "complete" digestion buffer, 200pl was used for 
each plug and it was diluted in the following proportions: lOOpl lOxbuffer, lOjul 1% 
gelatin, 2.5jLil IM  spermidine, 887.5 q l  sterile water. 100ml of the above buffer was 
added to each plug for 20 minutes at 4°C, the buffer was removed and lOOpl fresh 
buffer containing the restriction enzyme (see below) was added. At each time-point (5, 
10, 20, 40 and 60 minutes) the reactions were stopped by adding lOOjil ice-cold EDTA. 
This was left for 10 minutes then the plugs were equilibriated in 0.5xTAE with three
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changes over 30 minutes. The plugs were then ready to be loaded onto a pulse-field 
gel.
Amount of enzyme added per plug for complete digestion in one hour:
4.5pl SacII 
3.75jil Xhol 
7.5|xl Notl 
2.5|Li1 Smal
2.11.4 Pulsed field gel electrophoresis (PFGE) for YACS
Pulsed field gels were ran on a CHEF-DR II PFGE system (Biorad). 1.25% Seakem 
GTG (Flowgen) gels in 0.5xTAE were used for sizing YACS and resolving YAC 
digests, no ethidium bromide was added to the gel. YAC plugs were pre-treated as 
above and then cut in half with a single-edged razor-blade. The gel slots were flooded 
with 0.5xTAE and a half plug was slid into a slot using a microspatula for guidance. 
Lambda and yeast chromosome size markers (Gibco BRL) were loaded at either side of 
the gel. The slots were sealed with 1.25% Seakem GTG and once the agarose was set 
it was placed in the gel support in the CHEF. The running conditions used for the 
YACs (average insert size of 300kb) were 20-80 seconds for 20 hours at 200V at 14°C. 
The gels were suitable for southern blotting and hybridisation of radiolabelled probes as 
described above.
2.12 BAG PROTOCOLS
2.12.1 Isolation of BAG DNA
The isolation of high quantités and high quality BAC DNA was achieved using a 
modified Qiagen protocol. A 5ml culture containing 12.5mg/ml chloramphenicol was 
innoculated with a single colony and grown at 37°C overnight, 0.5mls of this was used 
to innoculate a 100ml culture which was incubated at 31^C overnight also. The next 
day the culture was split into 2x50mls and centrifuged at 5K for 15 minutes. The 
Qiagen midi plasmid kit protocol was used with the following additions: 
lOmls of PI, P2 and P3 were added to ensure complete lysis 
The cleared lysates were pooled onto a single column 
The DNA was eluted from the column by adding 5 aliquots of 1ml elution 
buffer pre-heated to 65°C.
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The DNA was resuspended in 200p.l sterile water, a typical yield from this prep, was 
20-30jig DNA. Once the DNA was resuspended, to prevent shearing of the BAC 
DNA, it was only ever pipetted after the ends of the pipette tips had been cut off.
2.12.2 Digesting BAC DNA
With respect to restriction digesting, BAC DNA was treated as any other plasmid DNA 
(see above). One difference, however, was that the digests were electrophoresed on a 
0.7% IxTBE agarose gel, rather than a 1% gel. This provided better resolution for the 
bigger fragments obtained.
2.12.3 Pulsed field gel electrophoresis (PFGE) for BAC DNA
BAC DNA was resolved on pulsed field gel electrophoresis much the same as the YAC 
DNA (see above). The main differences were that BAC digests were loaded directly 
into the slots (no need to make plugs), a 1% agarose gel for PFGE running (Sigma) 
was used and the running conditions varied. The running conditions for resolving 
BAC DNA were:
l-50kb fragments - 0.1-2.5 switch, 6volts/cm, 8 hours 
5-lOOkb fragments - 0.2-6.0 switch, 6volts/cm, 12 hours 
50-400kb fragments - 30-30 switch, 6volts/cm, 16 hours 
These gels were suitable for southern blotting and hybridisation of radiolabelled probes 
as described above.
2.13 HYBRID SELECTION PROTOCOLS
2.13.1 Isolating total RNA from placenta
Total RNA was isolated from placental tissue using TRI REAGENT (Sigma 
Biosciences). 250pg of total placental RNA was obtained from 300mg tissue. The kit 
was used as the manufactuers recommendations.
2.13.2 Isolating mRNA from total RNA
mRNA (poly Ah-) RNA was isolated from total RNA using the FastTrack 2.0 mRNA 
Isolation Kit from Invitrogen. From 400pg total RNA a yield of 8qg mRNA was 
obtained. The kit was used as the manufacturers recommendations.
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2.13.3 Synthesis of double-stranded blunt-ended cDNA
Double-stranded blunt-ended cDNA ready for ligating to linkers was synthesised using 
The Copy Kiy cDNA Synthesis System from Invitrogen. 2.8qg of double-stranded 
cDNA was produced from 5.5p,g mRNA using a 50:50 mix of random primers and 
oligo dT primer. The kit was used as the manufaeturers reeommendations.
2.13.4 Ligation of oligonucleotide linkers to double-stranded cDNA
5' phosphorylated oligos were synthesised by Gibco-BRL, the sequence of the oligos 
were:
Oligo 1 - 5’ TAG TCC GAA TTC AAG CAA GAG CAC A 3'
Oligo 2 - 5' CTC TTG CTT GAA TTC GGA CTA 3'
The oligos were annealed by heating equimolar amounts of each oligo at 70°C for 10
minutes, to break the secondary structure, then placing the eppendorf into a beaker of
water at 65°C and allowing it to cool to room temperature. This permits the oligos to 
come together gently forming duplex kinase linkers. Before ligating the linkers onto 
the ends of the cDNA, the cDNA was digested with Alul, producing blunt-end 
fragments ~250bp in length. 0.1-0.5qg cDNA was then placed in a reaction mix with 
l-2qg linkers, Iq l lOmM ATP, 2|li1 blunt-end ligation buffer (0.66M Tris-Cl (pH 7.6), 
50mM MgCl2, 50mM dithiothreitol, lOmM hexaminocobalt chloride, 5mM spermidine- 
HCl), 1-2 units T4 DNA ligase made up to a final volume of 20jil with sterile water. 
This was incubated overnight at 16°C. The unincorporated linkers were separated 
from the linkered cDNA by running the ligation mix on a 2% low melting point (LMP) 
agarose gel for only 0.5-1cm. Bromophenoi blue was not included in the loading 
buffer as that prevented visualisation of the linkered bands. A gel slice was cut out just 
above the band of unincorporated linkers. PCR reactions were set up directly from the 
gel slice, by melting the agarose and transfeixing an aliquot into pre-heated water, lOql 
of the LMP agarose was used as template in a 1ml reaction. The shortest oligo was 
used as the PCR primer. lOql of the PCR was electrophoresed on a 1% agarose gel 
and a smear was observed at ~500bp. The rest of the PCR was purified by Microcon 
30 (Amicon), to remove the primer and the nucleotides.
2.13.5 Biotinylation of BAC DNA
Iqg of BAC DNA was biotinylated using Nick Translation kit by Gibco-Brl. The kit 
was used as the manufacturers recommendations with the following modifications:
- a mixture of 0.18M dTTP/0.02M BiodUTP (Boeringer Mannheim) was used.
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- various dilutions of DNAse I were used.
- the reaction was stopped with Ijil 0.5M EDTA, 0.5ql 10% SDS and heated to 
70°C for 10 minutes.
12.5|il of the reaction was loaded onto a 1% agarose gel looking for a smear ranging 
from 200bp to 2kb. The rest of the DNA was ethanol precipitated and resuspended in 
20|l11 water.
2.13.6 Blocking cDNA
Before hybridisation the DNA must be pre-blocked with COT-1 DNA to reduce the 
chances of selecting repeated sequences. 2qg of PCR amplified linkered cDNA and 
2qg human COT-1 DNA were made up to lOp-1 volume with water, heated to 95°C to 
denature and lOql 2xhybridisation buffer was added (1.5mM NaCl, 40mM NaP04, pH 
7.4, lOmM EDTA, lOxDenharts, 1.2% SDS). Parafin oil was placed on the top and 
the mix was incubated at 65°C for 4 hours.
4.13.7 Selection and analysis of retained cDNA
lOOng of biotinylated BAC was denatured and added to 20 |li1 blocked cDNA, 5ql 
2xhybridisation buffer was also added. This was incubated at 65°C for at least 54 
hours, usually 64 hours. lOOql streptavidin beads (Dynal) were washed 3 times with 
lOOql 2xbinding buffer (lOmM Tris-HCl, ImM EDTA, 2M NaCl), the hybridisation 
mix was diluted to lOOql volume with water and added to the beads resuspended in 
lOOql 2xbinding buffer. The beads were incubated with the beads for 15 minutes at 
room temperature, with rotation. The beads were then washed twice with 500|xl 
IxSSC, 0.1% SDS at room temperature, then three times with 500|xl O.lxSSC, 0.1% 
SDS at 65°C. To elute the DNA, the beads were incubated with 50ql lOOmM NaOH 
for 10 minutes at room temperature and neutralised with 50ql IM  Tris, pH 7.4. The 
DNA was desalted with microcon 30 filter (Amicon) and resuspended in lOOql water.
Ijil of eluted cDNA was used as template in 50ql PCR reaction, with Iq l starting 
library as control. The PCR product was electrophoresed on 1.5% agarose gel and 
then purified by Microcon 30 filter. 2|ig of eluted cDNA was reblocked with COT-1 
DNA and hybridised with lOOng biotinylated BAC DNA as before. The hybridisation 
mix was incubated with the beads, washed, eluted and then re-amplified. This eluted 
cDNA was the second cycle of selection and was cloned into T-vector.
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Recombinants clones were screened by PCR and hybridised to a variety of probes 
including the BAC used in the experiment, COT-1 DNA and a gene present on the 
BAC. "Interesting" clones were sequenced.
4.14 DATABASE SEARCHES
Sequence analysis and database searches, using the Pasta and Tfasta programs (Pearson 
and Lipman 1988), were as implemented in the Wisconsin GCG package release 9.0.
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CHAPTER 3
Characterisation and sequencing of new members of the
3B-HSD gene family
3.1 INTRODUCTION
Although only two isoforms of 3B-HSD have been described in humans, Southern 
analysis of human genomic DNA and the identification of novel 3B-HSD sequences 
during mutation screening experiments suggested that more than two existed (section 
1.9). This information prompted Martin McBride to screen two À gem ll human 
genomic libraries for sequences similar to 36-HSD type I and type II. These screens 
identified phage clones 2(7) and 8(3) which gave exon 3 amplification products that 
migrated differently in denaturing gradient gel electrophoresis (DGGE) from 3B-HSD 
type I and type II. These fragments were cloned and novel exon 3 sequence was 
obtained (McBride et al, 1996). To determine wheither these phage clones contained 
putative new members of the 3B-HSD gene family, they were characterised and the 
coding regions sequenced.
3.2 RESULTS
3.2.1 Purification of clone 2(7)
Lambda clone 2(7) was plated onto NZCYM medium containing ER1647 cells, the 
resulting plaques were immobilised onto nylon filters and hybridised with 3B-HSD 
typel full-length cDNA. Plugs were picked from positive plaques and the resultant 
phages were replated. This was repeated until every plaque on a plate yielded a 
positive signal and high titre stocks of pure clone 2(7) phage were made.
3.2.2 Does clone 2(7) contain full-length 3B-HSD gene sequence?
To determine wheither clone 2(7) contained the entire 3B-HSD coding sequence, the 
filters of 2(7) plaques prepared above were probed with HSD3B exon 2 and exon 4b 
amplification products from genomic DNA. Hybridisation was observed with the 
HSD3B exon 2 probe but not the exon 4b probe (Fig. 3.1). This indicated that clone 
2(7) may not contain the entire coding sequence of a 3B-HSD gene, ending prematurely 
before exon 4b.
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Exon 2 probe Exon 4b probe
Fig. 3.1 Clone 2(7) plaques lifts hybridised with HSD3B exon 2 and exon 4b probe.
3.2.3 PCR amplification of clone 2(7) exons
A range of primers were available to amplify specific 36-HSD type I and type II exons 
and different combinations were chosen to attempt to amplify homologous exons from 
clone 2(7) (Fig. 3.2; primer sequences can be found in section 2.6.2).
A
Exon 1 Exon 2 
A E C U
Exon 3 
F GW
Exon 4a Exon 4b
K O
D E
V
R
AA
B
1,6kb— 500bp—-
1.6kb500bp
1 2 3 4 5 10 111213 14
1.6kb— 500bp—
500bp—
6 7 8 9 1516 1718
L anel- G & Y 
Lane2 - F & Y 
LaneS- A & E 
Lane4- C & E 
Lane5- U & V
Laneô - O & R 
Lane? - K & R 
Lane 8 - K & AA 
Lane9- -ve
Lane 10 - G & Y Lanel5 - B & E
Lane 11 - F & Y Lane 16 - C & E
Lane 12 - W & Y Lanel? - U & V
Lane13 - G & I Lanel8 - G & Y
Lane14 - C & D
Fig. 3.2 A:
B:
Diagram of HSD3B1 indicating the type I and type II primers screened for their ability 
to amplify homologous exons in clone 2(7). Open boxes represent untranslated regions 
of HSD3B1 whereas filled boxes represent the translated regions.
Agarose gel of PCR amplification products obtained using clone 2(7) DNA as template 
in the reaction. Primer pairs used as indicated.
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Amplifications of the expected size (compared to type I and II) were obtained from:
(i) Lane 6, O and R
(ii) Lane 13, G and I
(iii) Lane 14, C and D
(iv) Lane 17, U and V
Exon 4b, expected size 480bp 
Exon 3, expected size 590bp 
Exon 2, expected size 205bp 
Exon 2, expected size 200bp
Amplification products were observed in lanes I, 2, 3, 5, 7, 8, 10 and I I ,  however the 
fragment sizes indicated were larger than expected from comparisons with type I and II 
sequence. This suggested that these were spurious amplification products obtained due 
to sequence divergence between clone 2(7) and type I and II, and therefore these were 
not analysed any further.
The PCR products from (i), (ii) and (iii) were cloned into T-vector and single colony 
gels determined which recombinants contained inserts. No recombinants with inserts 
were identified for exon 2. Clones 1-6, containing exon 3, and clones 7-11, 
apparently containing exon 4b, were tested by PCR using exon 3 and exon 4b primers 
(Fig. 3.3A). A strong PCR product was obtained for exon 3, but the exon 4b 
products were very faint. Clones 4, 6, 7 and 9 were digested with restriction enzymes 
H indi and Smal to examine the length of the insert cloned (Fig. 3.3B).
B
Exon 4b 
Clone no. 1 2 3 4 5 6
Exon 3 
Clone no. 7 8 9 1011 Clone no. 4 6 7 9
3kb —
Ikb — Ikb—
—  faint 
products
500bp — 500bp—
Fig. 3.3 A: PCR amplification o f T-vector clones using primer pair 0 -R  (exon 4B , clones 1-6) and 
primer pair G-1 (exon 3, clones 7-11).
B: Restriction digest o f positive recombinants clones with H in d i and Smal to 
excise the insert from vector. These restriction digests confirmed the insert 
size.
Clones 4 and 7 contained inserts of 460bp and 580bp, respectively, the expected size 
for exon 4b and exon 3 amplification products. The inserts were sequenced using 
vector PCR primers T7 and U19. Sequence homologous to HSD3B exon 3 was 
obtained from clone 7. Surprisingly, sequence from clone 4 was homologous to
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HSD3B exon 4a and not exon 4b as expected (Fig. 3.4). This suggested that the 
conditions used for amplification were not stringent enough, allowing primers to anneal 
to exon 4a sequence. This would occur if, as suggested from the plaque screening, an 
exon 4b homologue is not present in clone 2(7). It was not possible to examine clone 
2(7) sequence for putative primer sequences because the PCR product sequence from 
clone 4 contained intron sequence and the intron sequence was not available over the 
predicted primer site region.
C l o n e 4 5 6 GTGGTTGCAGCTCCTTTGGGATATTTCTTGACACTGTCATCATGCTCTTC 
1 1 1 1 1 1 1 1 I I I  11 1 1 1 1 1 II 1 1 1 1 1 II II 1 1 1 1 1 1 1 1 1
1 0 5
3 E - t y p e l 7 9 5 6
1 1 1 1 1 1 1 1 1 1 1 1 I M 1 M II 1 1 1 1 1 II II 1 1 1 1 1 1 1 1 1
GTGGTTGGCACCTCTTAGGGATATATCCTGACAGTGACAATATGCTCTTC 8 0 0 5
C l o n e 4 1 0 6 GTGGGCAGGTACCCGGCT. GAGTTGGAGGCCTGTGTCCAAGCCAGTGTGC 
I I I  1 1 1 1 1 II 1 1 I I I  I I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1
1 5 4
3 E - t y p e l 8 0 0 6
III 1 1 II 1 II 1 1 III III 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ATGGACAGGTACCCAGCTCCTGTTAGAGGCCTGTGTCCAAGCTAGTGTGC 8 0 5 5
C l o n e 4 1 5 5 CAGTCTTCATCTACACCAG 1 7 3  
I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
3 E - t y p e l 8 0 5 6
I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
CAGTCTTCATCTACACCAG 8 0 7 4
Fig. 3.4 Sequence of amplification product from clone 2(7) using primers designed to HSD3B1 exon 
4b, aligned with sequence of HSD3B1 exon 4a. Co-ordinates shown are from HSD3B1 
(Genbank accession no. m38180).
3.2.4 Subcloning clone 2(7) into pUC18
The attempts to amplify HSD3B exon homologues from clone 2(7) yielded sequence 
for exon 3, but difficulties were found with cloning exon 4 and exon 2 product (exon 1 
and 2 amplifications were repeated several times without success). It was therefore 
decided to subclone clone 2(7) into pUC18 cloning vector. This would have the 
additional benefit of overcoming any complications due to Taq Polymerase-induced 
mutations and the need to sequence over primer sites.
High titre stocks of pure clone 2(7) stock were used to infect established cultures of 
Exoli, after cell lysis the cell debris was removed producing a clear lysate containing 
infectious phage. Phage DNA was isolated from the lysate using A, phage purification 
kit (Promega). The DNA was digested with a panel of restriction enzymes and 
hybridised with exon-specific probes to find suitable restriction bands for cloning (Fig. 
3.5). Ideally, bands should contain an entire exon and be small enough to allow 
trouble-free cloning and sequencing.
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B
1 2  3 4 5 6 7 1 2 3 4 5 6 7  1 2 3 4 5 6 7  1 2 3 4 5 6 7
1.6kb
6kb —
3kb—
1 6kb —
Exon 2 Exon 3 Exon 4
Fig. 3.5 A: Agarose gel showing restriction digests from clone 2(7) using a variety o f restriction 
enzymes.
(Lanel - BamHI, Lane2 - EcoRl, Lane3 - HindIII, Lane4 - SstI, LaneS - Xbal, Laneô - 
Kpnl, Lane7 - Sali)
B: Southern analysis o f restriction digests from panel A hybridised to HSD3B exon specific 
probes. Exon specific probes were synthesised from exon specific PCR amplification 
products with HSD3BI template and primer pairs C-D for exon 2, G-I for exon 3 and K- 
R for exon 4.
The results in Fig. 3.5 indicated that SstI was the best restriction enzyme to use to 
subclone the exons, as it yielded a band of approximately 3.3kb for exon 2 and either a 
singlet or doublet band of about 4.0kb for exons 3 and 4. As only 5 fragments are 
produced from SstI digest of clone 2(7) (Fig. 3.5A) it was possible to "shotgun" clone 
the entire digest into pUC18 and screen for the subclones of interest. Many 
recombinants were produced and those with inserts were tested by PCR using exon- 
specific primers pairs (Fig. 3.6).
Clone no.
Ikb
Exon 2 I Exon 3
+ 4 11 23 25 31 3236 - + 4 11 23 25 31 3236 Clone no.
Exon 4
+ 3 5 6 14 17 4 11 23253132
Fig. 3.6 Agarose gel o f exon-specific amplification o f SstI subclones o f clone 2(7). Primers used
were C-D for exon 2 (expected size 205bp), G-1 for exon 3 (expected size 590bp) and K-Q for 
exon 4 (expected size 490bp). + indicates the positive control reaction using H SD 3B 1
template, this controls for the efficiency o f the reaction as well as providing the expected 
PCR product size. - indicates the no template negative control reaction.
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Clone 11 (containing exon 2) and clone 25 (containing exons 3 and 4) were mapped 
and sequenced (Fig. 3.1 A  and B). Exon 2 and exon 3 amplification products were 
obtained from clone 23, this was unexpected as different sized SstI fragments for these 
exons were observed in Fig. 3.5. It is possible that this clone represents a fragment 
from a SstI partial digest, a SstI digest of clone 23 would confirm if this assumption is 
coiTect. Restriction analysis of subclone 25 was accomplished using a selection of 
restriction enzymes and single and double digests were attempted. pUC primers and 
HSD3B1 and 2 specific prim ers were used to obtain sequence (Fig. 3.7). The 
sequence obtained from the pUC primers provided the approximate end-points of the 
2(7) subcloned insert.
4350
HS
M13-40 I) Exon 2 Exon 1
Fig. 3.7 A: Schem atic diagram o f  2(7) subclone 11 indicating the position o f  the sequencing primers, 
approximate coordinates (boxed) are taken from equivalent sequence in H SD 3B 1 (S=SstI, 
E=EcoRI, H=HindIII).
8332
KS p  S S p ^
M13-40 L
Exon 4
E A G F
I
Exon 3
4350
RevEVK P SE P
Fig. 3.7 B Restriction map o f  2 (7 ) subclone 25 indicating the position o f  sequencing primers, 
approximate coordinates (boxed) are taken from equivalent sequence in H S D 3 B 1 
(Sp=SphI, S=SstI, E=EcoRI, A =A ccI, EV =E coR V , K=KpnI, F=PstI).
Clone 25 contained HSD3B sequence homologous to HSD3B1 from  base 4350 to 
8332. The sequence from 2(7) subclone 25 using vector primer M l3-40 indicated the 
end of HSD3B sequence within the phage clone. The phage genomic library was 
created using human genomic DNA partially cut with Sau3A with the sticky ends of the 
digest filled in with bases AG to prevent religation of inserts, and vector DNA partially 
cut with X hol with the digest ends filled  with bases TC. This resulted  in 
complementary pairing for insert and vector to create the library. This cloning site was 
adjacent to the SstI site which was utilised in subcloning clone 2(7) into the pUC 
vector. The sequence obtained from  clone 25 using prim er M l3-40 contained the 
Sau3A restriction site which arises only from the phage cloning and therefore it appears
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that 2(7) HSD3B sequence in the phage clone ends at HSD3B1 equivalent base 8332 
(Fig. 3.8).
Sequence obtained from pUC primer M l3-40 was :
Sau3A site from phage cloning
pUC sequence GTACCGAGCTC
SstI site
GATC K III I ' I. Hiitncin senomic DNA -CCATTGTT -  7J HSD3B exon 4
8332
Fig. 3.8 Diagram to indicate the sequence obtained from pUC primer M13-40 and show where the 
2(7) HSD3B insert ends within the phage vector.
This information confirms that an exon 4b homologue of HSD3B1 is not present in 
clone 2(7) since exon 4b sequence starts from approximately base 8400 in HSD3B1. 
However, coincidently an exon 4 PGR amplification product (primer pair K-R) from 
another phage clone identified from the library screen (clone 1(2)) produced sequence 
identical to clone 2(7) exon 4a sequence and extended into exon 4b sequence. 
Therefore, this clone completed the sequence necessary for clone 2(7) HSD3B exon 4 
(Fig. 3.9).
Clone 2(7) 
Clone 1(2)
8014 8332
Exon 4
8825
K N 0
-....................1
------ ------------------------------------------------------------------------------------ ►
Q R
Fig. 3.9 Schematic diagram to represent the sequencing of exon 4 from clone 2(7) and clone 1(2).
Primers used for clone 1(2) sequencing are indicated. Approximate coordinates (boxed) are 
taken from the equivalent sequence in HSD3B1.
A result of sequence divergence between clone 2(7) and 3B-HSD type I and II was that 
some of the HSD3B1 and 2 primers did not produce sequence from 2(7) subclone 11, 
in particular primers A and T (Fig. 3.1 A). Consequently, no sequence was obtained 
from subclone 11 homologous to exon 1 and the 5' end of exon 2. Therefore, to 
complete the sequencing of clone 2(7) a further exon 1 and 2 subclone was produced. 
A BamHI fragment from 2(7), approximately 900bp, containing exon 2 (Fig. 3.5) was 
subcloned into pUC and recombinants were screened by exon 2 specific PCR and
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BamHI digests (Fig. 3.10A and B). Clone D yielded a PCR product the correct size 
(205bp) and contained the appropriate size of insert (900bp) and this was used to obtain 
exon 1 and 5' exon 2 sequence (Fig. 3. IOC).
A B
Clone no. 4^  8  Ç D E F -  C o n e  no.
Ikb—
B C D E F Con.
Ikb—
2184
H B
M13-40 D Exon 2 Exon 1
Fig. 3.10 A: Agarose gel o f PCR amplification products obtained using recombinant clone template 
from clone 2(7) BamHI subcloning using exon 2 primer pair C-D, expected size 
205bp. + indicates positive control using HSD3B1 template, - indicates no 
template negative control.
B: Agarose gel o f BamHI restriction analysis o f recombinant clones from clone 2(7)
BamHI subcloning to determine insert size, expected insert size 900bp. Con. indicates 
control digest using DNA from a blue colony obtained during cloning. This clone 
does not contain an insert and indicates that blue/white selection was successful.
C: Schematic diagram of subclone D indicating which primers were used to obtain 
sequence, approximate coordinates (boxed) are taken from equivalent sequence in 
HSD3B1 (H=HindlIl, B=BamHI, E=EcoRI).
Therefore from subclones 11, 25, D and clone 1(2) the entire 36-HSD coding sequence 
from clone 2(7) was obtained (Fig. 3.11).
a) Exons 1 and 2 alignment
Type2TypelClone2-7
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GAGGCAGTAA GGACTTGGAC TCCTCTGTCC AGCTTTT-AA CAATCTAAGT. . . .TGAG. . .T..G.CC.. ..T...............-...........C. TGACC. .C..CCT... .A.............A..-.. T .......C.
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5 1 1 0 0
*
T y p e s T A C G g t ta g a g c t t t c t c c t t t t c t t t c a a c t a c t ------CC t g g c a g t t g t
T y p e l A . T ................... . a . . . t . . a . ......................... g . . . . . . . g . .
C l o n e s - 7 A . T ................... . . . a . t . . g . ......................... ^ ............. . . . . .  a . g^. .
1 0 1 1 5 0
* *
T y p e s g g g g t c a t g g a a t t t t t g t a a a a a a ------t g g g g t g g a g g a a a a t a a g g c a
T y p e l . . .  g . . . . c , .............a a - . . . . . .  g .............
C l o n e s - 7 . a . . a t . . . . ...................... c . .............a a a . . ................... a .  t . . . - .  a . . .
1 5 1 2 0 0
T y p e s t c t g - c t g a g t g t a t a a c c a t t t t a c c t c t t g t t t t t a g C CCTCTTCTGG
l y p e l ------- t g -------- .............C . A .  .
C l o n e s - 7 . . . .  t ^ j . . . . . . . . . . .  t  . . e . g . t . . . —. . . C . A —.
S OI S 5 0* *
T y p e s GTCACGCTAG AATCAGATCT GCTCTCCAGC ATCTTCTGTT TCCTGGCAAG
l y p e l ... C.. .  . _____c .............. ................T G . .
C l o n e s - 7 . A . . .C_____ . . . A ................ T . . .C............. ................AG.  .
2 5 1 3 0 0*
T y p e s TGGTTTCCTG CTACTTTGGA TTGGCCACGA TGGGCTGGAG CTGCCTTGTG
l y p e l . , . A ................ - .............A T G . C .........................
C l o n e s - 7 . . . . C . C . . . ................ATG. C A ......................
3 0 1 3 5 0
T y p e s ACAGGAGCAG GAGGGCTTCT GGGTCAGAGG ATCGTCCGCC TGTTGGTGGA
T y p e l .............T . . . . . . . A ................ . . . A ................ . C ......................
C l o n e s - 7 .............T . . . . . . . A . . T . . . . . .  . A .............
3 5 1 4 0 0* *
T y p e s AGAGAAGGAA CTGAAGGAGA TCAGGGCCTT GGACAAGGCC TTCAGACCAG
T y p e l G ...................... G ................T . . . . . . G ................
C l o n e s - 7 G . . . . C A . . G . . C C ................
4 0 1 4 3 0*
T y p e s AATTGAGAGA GGAATTTTCT A g t a a g t a a a
T y p e l
C l o n e s - 7 G . . T G A . G
b) Exon3 alignment
1 5 0*
T y p e s c c a a t g a c c t g a c c t g t g t t c a c a c a g A G C TCCAGAACAG GACCAAGCTG
T y p e l ...................... A . ......................... A
C l o n e s - 7 ...................... A .
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5 1 100
T y p e s  ACTGTACTTG AAGGAGACAT TCTGGATGAG CCATTCCTGA AAAGAGCCTG
T y p e l  . . A . . G . . G ............................................................................................................. G ........................
C l o n e s - 7  . .A .  .G .  . G ............................................................................................................. G ........................
101 1 5 0
T y p e s  CCAGGACGTC TCGGTCGTCA TCCACACCGC CTGTATCATT GATGTCTTTG
T y p e l  .................................................. A ..........................................................................................................C .
C l o n e s - 7  .......................... G ...............................................................................................................................C .
1 5 1 20 0
(G)
T y p e s  GTGTCACTCA CAGAGAGTCC ATCATGAATG TCAATGTGAA A G g t a c a g t a
T y p e l  ........................................................T ....................................................................................... t g . . .
C l o n e s - 7  . A .................................... C . . . . T ..................................................................................... g g . . .
201 2 3 0
T y p e s  g c c t g g g g a g  g a g a t a a a a c  a a g t t g g t t -
T y p e l  . g .......................................... g c . g .  . . . g .  . . g g -
C l o n e S - 7  .................n n n n  n n n n n n n n n n  n n n n n n n n n n
c) Exon 4 alignment
5 0
T y p e s  t c t t c g t g g g  cagG T AC C C A  GCTACTGTTG GAGGCCTGTG TCCAAGCCAG
T y p e l  .............a . . . a ..........................................C .............. A ........................................................T . .
C l o n e s - 7  . . . . t c ................. g ...................................C ..............................................................................T .C
5 1 100
(A)
T y p e s  TGTGCCAGTC TTCATCTACA CCAGTAGCAT AGAGGTAGCC GGGCCCAACTlYpel ..........................................................................................................
C l o n e s - 7  .....................................................................................C . C .  C C . . T ................................................
1 0 1  1 5 0
*  *
T y p e s  CCTACAAGGA AATCATCCAG AACGGCCACG AAGAAGAGCC TCTGGAAAAC
T y p e l  .........................................................................T ..............T ......................................................................
C l o n e s - 7  ................................................... T G . . . . T . C .  . . T ..............................CTT .............................
1 5 1 2 0 0
T y p e s  ACATGGCCCA CTCCATACCC GTACAGCAAA AAGCTTGCTG AGAAGGCTGT
T y p e l  .......................... C ............................ A C ...............................................................................................
C l o n e s - 7  ................. T .T G   T . .  A ........................................T ..................................................
201 S 5 0
T y p e s  GCTGGCGGCT AATGGGTGGA ATCTAAAAAA TGGTGATACC TTGTACACTT
T y p e l  A .................................. C ....................................G ..............C . . C . G C .  . . C ..............................
C l o n e s - 7  .................A ..............................................C . . . G .................................................................................
2 5 1 3 0 0
T y p e s  GTGCGTTAAG ACCCACATAT ATCTATGGGG AAGGAGGCCC ATTCCTTTCT
T y p e l  . . . . C . . . C ....................T G .............................................................A ................ A .......................
C l o n e s - 7  . . . . C ................................ T G .............................................................A .......................T .................
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3 0 1  3 5 0* *
T y p e s  GCCAGTATAA ATGAGGCCCT GAACAACAAT GGGATCCTGT CAAGTGTTGG
T y p e l  . . T ......................... C ...............................................................................................................................
C l o n e l - S   A .......................................................................................................................... G ..............C A .
3 5 1  4 0 0
"lY peS AAAGTTCTCT ACAGTCAACC CAGTCTATGT TGGCAACGTG GCCTGGGCCC
T V p e l  .......................... C . . T .  . T ...................................................................T ..........................................
C l o n e l - 2  C  C  C ...............................................................................................................
4 0 1  4 5 0
T y p e s  ACATTCTGGC CTTGAGGGCT CTGCGGGACC CCAAGAAGGC CCCAAGTGTC
T y p e l  .............................................................C . . .  . A ...................................................................... C A . .
C l o n e l - 2  ............................................................... - ..............................................................................................
4 5 1  5 0 0
(T ) *
T V P eS  CGAGGTCAAT TCTATTACAT CTCAGATGAC ACGCCTCACC AAAGCTATGA
T y p e l   A .  . G ................ C . . T ...........................................................................................................
C l o n e l - S  . T . . . A . . G .................C.  . T ............................................................................................T _____
5 0 1  5 5 0
T y p e s  TAACCTTAAT TACATCCTGA GCAAAGAGTT TGGCCTCCGC CTTGATTCCA
T y p e l  ............................................ C .....................................................................................................................
C l o n e l - 2  .................................................. T .......................................... C . . . . C . T ..........................................
5 5 1  6 0 0* *
l y p e S  GATGGAGCCT TCCTTTAACC CTGATGTACT GGATTGGCTT CCTGCTGGAA
T y p e l  ......................T ...........................T .................................T ......................................................................
C l o n e l - 2  . . . . A ...................... T . . . . T T ....................................................................................................G.
6 0 1  6 5 0* *
T y p e s  GTAGTGAGCT TCCTACTCAG CCCAATTTAC TCCTATCAAC CCCCCTTCAA
T y p e l  A ............................................................ G ........................  A ..................G . . . G .......................
C l o n e l - 2  A  C  G ..............  G . . . G . . . G .  A ................................G .................. G.
6 5 1  7 0 0
T y p e s  CCGCCACACA GTCACATTAT CAAATAGTGT GTTCACCTTC TCTTACAAGA
T y p e l  ......................T ..............................G ...........................C . . A .............................................. T . . . .
C l o n e l - S  . T ............................... G ..............G ...........................C A ......................................................................
7 0 1  7 5 0* *
T y p e s  AGGCTCAGCG AGATCTGGCG TATAAGCCAC TCTACAGCTG GGAGGAAGCC
T y p e l  ............................................T .....................................................................................................................
C l o n e l - 2  .........................................................A .......................................T ..........................................................
7 5 1  8 0 0
T y p e s  AAGCAGAAAA CCGTGGAGTG GGTTGGTTCC CTTGTGGACC GGCACAAGGA
T y p e l  ...................................G ...............................................................................................................................
C l o n e l - 2  ......................................A ....................A ..................................................................................................
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801 850
Types GACCCTGAAG TCCAAGACTC AGTGATTTAA GGATGACAGA GATGTGCATG
Typel . .A..................... TGA...........................
Clonel-S ..A....................... C .......NNNNNNNNN NNNNmiNNNN
851 900
Types TGGGTATTGT TAGGAAATGT CATCAAACTC CACCCACCTG GCTTCATACATypel ................G ...........G .........T ...... C .......
Clonel-S NlSnSINNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
Fig. 3.11 Sequence obtained from clones 2(7) and 1(2) aligned with homologous sequences from 3B- 
HSD type I and II. Triplet nucleotides underlined are translational stop and start codons. 
Dashes indicate gaps introduced for alignment. Bases corresponding to intron sequence in 
type I and II are shown in lower case.
3.2.5 Long range PCR to determine the size of HSD3B intron 
homologues in clone 2(7)
Clone 2(7) contains sequence homologous to HSD3B introns (intron sequence was 
observed from subclones 25, 11 and D), therefore long range PCR was performed to 
determine the length of the intron sequence present. PCR amplification was attempted 
over introns 11 (exon 2 to 3) and 111 (exons 3 to 4) using the long template PCR system 
(Boeringer Mannheim). Primers U and H were used for intron 11 and primers G and 
L for intron 111, and PCRs were extended at 68°C for 7 minutes (Fig. 3.12). Clone 
2(7) yielded amplification products of approximately 4kb for intron 11 and 
approximately 2.5kb for intron 111, which correspond well with HSD3B1 intron lengths 
of 4.2kb and 2.6kb for 11 and 111 respectively.
Intron II Intron III
5kb —  
3kb —
2kb —
:
Fig. 3.12 Agarose gel indicating long range PCR amplification o f intron II and III from clone 2(7). 
Primers U and H were used for intron II, G and L were used for intron III.
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3.2.6 Identification of clone 2(7) as a pseudogene
The 36-HSD coding sequence determined from clone 2(7) contained frameshft 
mutations resulting in premature stop codons. The first frameshift mutation is the 
deletion of A producing a stop codon in the predicted polypeptide sequence at residue 
42 found at the end of exon 2 (Fig. 3.13). No other significant open reading frames 
were found within the sequenced fragments. Therefore, it was concluded that clone 
2(7) was an unprocessed pseudogene and was thereafter designated 36-HSD\|/2.
Clone 2(7)
A C G T
G
G
C
C
T
T
C
A
G
A
C
C
Asp 35
G
A
36Arg
Pro37
Ser^ B
39Asp
Gln^ O
41Asp
ST0P42
HSD3B1
G J
G 
A 
C 
A 
A 
G 
G 
C 
C 
T 
T 
C 
A 
G 
A 
C 
C 
A 
G 
A 
A 
T 
T 
G 
A
Asp 35
Lys36
.37Ala
Phe38
39Arg
Pm40
Gly
Leu
41
42
Fig. 3.13 Clone 2(7) sequence indicating deletion o f A and compared with homologous H SD 3B 1
sequence. This delection caused a frameshift and produced a STOP codon at residue 42. 
Deletion is represented by *.
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3.2.7 Expression studies of clone 2(7)
Previously in the laboratory, Sandra Burridge detected RNA transcripts in the placenta 
from other pseudogenes identified in the X phage library screen. These transcripts 
were alternatively spliced. To examine the possibility that 36-HSD\{/2 may be 
expressed, primers specific to \|/2 were designed and RT-PCR from the placenta was 
attempted. The placenta was chosen as it is a major steroidogenic tissue and because 
the other 36-HSD pseudogene transcripts were found here. Term placenta was 
obtained from Queen Margaret's Maternity Hospital and RNA was isolated using 
RNAzol B. cDNA was synthesised using the cDNA synthesis kit from Clontech. 
RT-PCR was carried out using the \\f2 specific primers (2(7) 5' and 2(7) 3'; primer 
sequences can be found in section 2.6.2), type I primers (type I and D) were used as a 
positive control and the reactions were carried out at 45°C annealing. The gels was 
blotted and probed with full-length 36-HSD type I cDNA (Fig. 3.14).
1.6kb —
500bp—
1.6kb —
500bp—
Fig. 3.14 Gel electrophoresis o f RT-PCR products using HSD3Bvir2 specific PCR primers with
placental cDN A  as template. Hybridisation o f Southern blot with 3B-HSD typel cDNA. 
Lane 1 - placental cDNA, lane 2 - no reverse transcriptase control, lane 3 - no RNA  
control, lane 4 - no template PCR control, lane 5 - HSD3B\j/2 template, positive control.
A smear was observed for the RT-PCR using HSD3B\j/2 specific primers, although a 
distinct band of the expected size (450bp) was detected after hybridisation with type I 
cDNA (lane 1, Fig. 3.14). The amplification products found in lane 1 were cloned 
into T-vector, white colonies were screened for inserts by single colony gel and 
recombinants with inserts were screened by PCR using the \\f2 specific primers. 8 
recombinants positive for \|/2 specific PCR were sequenced and from these 36-HSD 
type I sequence only was detected. Therefore, no HSD3Bn/2 transcripts were detected 
from this experiment and it is likely that this pseudogene is not expressed.
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3.2.8 PCR amplification of clone 8(3)
Phage clone 8(3) was another clone discovered from the genomic library screens and 
novel exon 3 sequence was identified by DGGE analysis and sequencing. Martin 
McBride initiated sequencing of the coding region of this clone; myself and Tilda 
Gordon, an undergraduate student, completed the sequencing and subcloned 8(3) exon 
4 into pUC 18. The sequencing strategy used was the same as clone 2(7) with exon- 
specific PCR amplifications and subcloning exons into pUC18. Therefore, to begin 
with different combinations of typel and II exon-specific primers were chosen to 
attempt to amplify exon homologues from clone 8(3) (Fig. 3.15).
Exon 1 Exon 2 
T
A C U
Exon 3 
F G
Exon 4a Exon 4b
J K
D E H I L M P Q R
B
1 2 3 4 5 6 7 8 9 10 II 12 1314 15
â l i i i l É i l i l l
— 1.6kb
— 500bp
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
1 1  L i  I A
— l.okb
— SOObp
Lane 1 - A & D 
Lane 3 - T & D 
Lane 5 - C & D 
Lane 7 - U & D 
Lane 9 - C & E
Lane 11 - U & E 
Lane 13 - G & H 
Lane 15 - G & I 
Lane 17 - F & H 
Lane 19 - K & L
Lane 21 - K & M 
Lane 2 3 -  K & P  
Lane 25 - K & Q 
Lane 2 7 - K & R  
Lane 29 - J & L
Fig. 3.15 A: Diagram o f HSD3B1 indicating the type I and type II primers used to amplify the 
homologous exons in clone 8(3). Open boxes represent untranslated regions 
in HSD3B1 whereas filled boxes represent translated regions.
B: Agarose gel indicating the results from trial amplifications using clone 8(3) as 
template. Primers used as indicated, even lanes represent no template controls.
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Sequence was obtained from exons 1 and 2 (lanes 1, 3 and 7), exon 3 (lane 13) and 
exon 4 (lanes 19, 21, 23 and 27) products using direct PCR sequencing (Amersham). 
Direct PCR product sequencing eliminated the need to subclone the products into T- 
vector. The sequence obtained from the amplification product using primer pair K-R 
(lane 27) was unexpected. Using the primer R the sequence produced started 200bp 
from the primer site, even from sequencing reactions containing Mn^+ which produces 
sequence close to the primer sequence (Fig. 3.16). This was repeated several times 
with the same result. This suggested that primer R was not annealing to the correct 
sequence and that, similar to clone 2(7), clone 8(3) may not contain the entire coding 
sequence and may end prematurely before the stop codon.
C l o n e  8 ( 3 ) 1 4 6 CCCAAGAAGGCCCTAAGCATCCGAGGACAGTTCTAANATATCTCAGATGA 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 . 1 1 1 1 1 1 1 1 1 1 1 1 1 9 7
H SD 3B 1 8 4 3 0
1 1 M 1 11 M M M 1 1 M 1 M 1 1 1 M M M M 1 M • M 1 M M M 1 1 1 1
CCCAAGAAGGCCCCAAGCATCCGAGGACAGTTCTACTATATCTCAGATGA 8 4 7 9
C l o n e  8 ( 3 ) 9 6 CATGTCTTACCAAAGCTATGACTACCTTAGTTACACCCTGAACAAAGAAT II 1 II 1 1 11 1 1 1 1 1 1 1 1 1 1 1 1 11 1 1 1 M ! 1 1 1 1 t 1 1 1 1 1 1 1 1 4 7
H SD 3B 1 8 4 8 0
II 1 II 1 1 1 It 1 1 1 1 1 II 1 1 11 1 1 1 1 1 1 I 1 1 1 1 II 1 1 1 1 1 1 1 1
CACGCCTCACCAAAGCTATGATAACCTTAATTACACCCTGAGCAAAGAGT 8 5 2 9
C l o n e  8 ( 3 ) 4 6 T . TGCCTCTGCCTTGATTCCAGATGGAGCCTTCCTCTAGCCCTGAT 21 mil iiiiiiiiiiiMiiiiiii Mill II mini
TCGGCCTCCGCCTTGATTCCAGATGGAGCTTTCCTTTATCCCTGAT 8 5 7 5H SD 3B 1 8 5 3 0
Fig. 3.16 Sequence alignment of clone 8(3) sequence from primer R and HSD3B1 sequence.
Coordinates from HSD3B1, genbank accession no. m38180.
3.2.9 Subcloning exon 4 from clone 8(3)
To investigate the possibility that clone 8(3) did not containall of HSD3B exon 4 
sequence, exon 4 from clone 8(3) was subcloned into pUC18. Exon 1, 2 and 3 
sequence was obtained from sequencing PCR products. Clone 8(3) phage DNA was 
produced and digested with a panel of restriction enzymes, and then hybridised with an 
exon 4 specific probe to find a suitable restriction band for cloning (Fig. 3.17).
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B
1 2 3 4 5 6
— 5kb
— 2kb
— 500bp
1 2 3 4 5 6
— 5kb
— 500bp
Exon 4 probe
Fig. 3.17 A: Agarose gel indicating the digestion patterns o f clone 8(3) with a variety o f restriction 
enzymes. Lane I - BamHI, lane 2 - EcoRI, lane 3 - HIndlll, lane 4 - SstI, lane 5 - 
Xbal, lane 5 - Xbal, lane 6 - KpnI.
B: Southern analysis o f restriction digests shown in panel A hybridised to HSD3B exon 4 
probe.
The results from Fig. 3.16 suggested that Kpnl was the best restriction enzyme to use 
to subclone exon 4, since a fragment of an ideal size (~3.5kb) containing exon 4 was 
observed. The Kpnl digest was "shotgun" cloned into pUC18, recombinants with 
inserts were determined by a single colony gel and PCRs with exon 4 specific primer 
pair identified the clones containing the exon 4 fragment (Fig. 3.18).
1 2  3 4 5 6 7 8 9  1011 121314 15 161718 1920 2122 23 24
2kb—
500bp—
Fig. 3.18 Agarose gel showing e xon 4 specific amplifications o f Kpnl subclones o f clone 8(3),
primer pair used was K-Q, expected size 480bp. Lane 24 contains no template control.
Clone 19 was sequenced with pUC specific primers to determine the orientation of the 
insert (Fig. 3.19).
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97 8050
H K-K- K E
M13-50
M13-40 R Exon 4
Fig. 3.19 Schematic diagram of subclone 19 indicating the position of the sequencing primers, 
coordinates from HSD3B1 (K=KpnI, E=EcoRI, H=HindIII).
Fig. 3.19 indicates that pUC primer M13-50 produced sequence from 5' exon 4 and 
M13-40 did not produce sequence at all, therefore the precise endpoint of the subclone 
is unknown. Primer R was used once more to attempt to gain 3' exon 4 sequence. 
However as with PCR sequencing, the sequence obtained started 200bp from the 
primer and therefore clone 19 did not provide any further insights into why exon 4b 
could not be found. It is probable that clone 8(3) does not contain sequence 
homologous to HSD3B exon 4b, and therefore primer R eannot anneal to the correct 
sequence and instead produces spurious amplifications and sequence. Exon 4 could 
be subcloned further until the vector primers read into the 3’ end similar to HSD3B\|/2 
subclone 25 (Fig. 3.8) which would determine the end of the phage clone. To 
generate exon 4 sequence it would be possible to use genomic clones BAC 21 or BAC 
7 (see Chapter 4) as template for PCR, using an 5' exon 4 8(3) specific primer and 
primer R.
Direct sequencing of PCR amplification products from clone 8(3) and sequencing of 
exon 4 from clone 19 determined the sequence of the coding regions homologous to 
HSD3B except 3' 200bp of exon 4 (Fig. 3.20).
a) Exons 1 and 2 alignment
5 0
T y p e 2  GAGGCAGTAA GGACTTGGAC TCCTCTGTCC A G CTTTT-AA CAATCTAAGT
T y p e l   TGAG. . . T . . G . C C . .  . . T ............................................ - .................................. C.cione8-3 NNmnsnmmiN mmnmmimr tmmumiNN. .c .g  ca
5 1 100
i y p e 2  T A C G g t t a g a  g c t t t c t c c t  t t t c t t t c a a  c t a c t  c c  t g g c a g t t g t
T y p e l  A . T ...........................a .  . . t . . a .................................g    . .  . . . . . .  . g .  .
C l o n e 8 - 3  A . T .  . c ..............................t .  . a .  . . . t . . . t t t  . a .  . . a c c a  g .  .
70
1 0 1 1 5 0
*
T y p e 2 g g g g t c a t g g a a t t t t t g t a a a a a a ------t g g g g t g g a g g a a a a t a a g g c a
T y p e l . . . . a . . c a . . . .  g . . . . c .
C l o n e 8 - 3 * * * * * .............a — g a ...................... g .
1 5 1 2 0 0
*
T y p e 2 t c t g - c t g a g t g t a t a a c c a t t t t a c c t c t t g t t t t t a g C CCTCTTCTGG
T y p e l ------- t g . . . . . . . g . . a . . - .............C . A .  .
C l o n e s - 3 ------- t g -------- . . . g . . . a . - .............C . . . .
2 0 1 2 5 0
*
T y p e 2 GTCACGCTAG AATCAGATCT GCTCTCCAGC ATCTTCTGTT TCCTGGCAAG
T y p e l .............C . . . . ................TG.  .
C l o n e 8 - 3 .............C T . . . . T . . C ............. ......................C. C ................G.  .
2 5 1 3 0 0
*
T y p e 2 TGGTTTCCTG CTACTTTGGA TTGGCCACGA TGGGCTGGAG CTGCCTTGTG
T y p e l . . . A ................ - .............A T G . C .........................
C l o n e s - 3 G ......................... . .A .  . . M S - ......................... A . . T ...................
3 0 1 3 5 0
* (A )
T y p e 2 ACAGGAGCAG GAGGGCTTCT GGGTCAGAGG ATCGTCCGCC TGTTGGTGGA
T y p e l .............T . , .  . . . . A ................ . . . A ................ . C ......................
C l o n e 8 - 3 . . A N . T . . . .
3 5 1 4 0 0
*
T y p e 2 AGAGAAGGAA CTGAAGGAGA TCAGGGCCTT GGACAAGGCC TTCAGACCAG
I V p e l G ...................... G ................T . . . . . .G ................
C l o n e B - 3 G ...................... G . . . G ................
4 0 1 4 3 0*
T y p e 2 AATTGAGAGA GGAATTTTCT A g t a a g t a a a
T y p e l
C l o n e 8 ~ 3 . . .TNMNINISIN NNNNNNNNNN N n n n n n n n n n
b) Exon3 alignment
1 5 0*
T y p e 2 c c a a t g a c c t g a c c t g t g t t c a c a c a g A G C TCCAGAACAG GACCAAGCTG
T y p e l
C l o n e 8 “ 3 n n n n n n n N N N NNNNNNNNNN NNNNNNNNNN
5 1 1 0 0
*
I V p e 2 ACTGTACTTG AAGGAGACAT TCTGGATGAG CCATTCCTGA AAAGAGCCTG
T y p e l . .A .  . G . . G . . G ......................
C l o n e 8 - 3  N N N N T G T .G ................................................... A .
71
1 0 1 150
i y p e 2 CCAGGACGTC TCGGTCGTCA TCCACACCGC CTGTATCATT GATGTCTTTG
I V p e l ................A . . . ...................... C .
C l o n e 8 “ 3 ................... A .  . . T . . . . A . . . ................... T .  . . . C ................... . .c.............c.
151 2 0 0
T y p e 2 GTGTCACTCA CAGAGAGTCC ATCATGAATG TCAATGTGAA A G g t a c a g t a
T y p e l ......................... T .............t g . . .
C l o n e 8 - 3 . . . , C . . . . T ...................... A. C .........................
2 0 1 2 3 0
T y p e 2 g c c t g g g g a g g a g a t a a a a c a a g t t g g t t -
T y p e l ■ g ...................... .............g c . g . . . . g . . . g g -
C l o n e 8 - 3 t ......................... .............g c . g . . . . g . . . g - c
c )  E x o n  4  a l i g n m e n t
1 50
T y p e 2 t c t t c g t g g g cagG T A C C C A  GCTACTGTTG GAGGCCTGTG TCCAAGCCAG
T y p e l .............a . . . a . . . C .............A ................... T .  .
C l o n e 8 - 3 A . . T ................ . . - A ................ ...................T .  .
51 1 0 0
* (A ) *
T y p e 2 TGTGCCAGTC TTCATCTACA CCAGTAGCAT AGAGGTAGCC GGGCCCAACT
T y p e l
C l o n e 8 - 3 . A . - . . . . G. ................C.  . . . . . . C . T . . . . . . A . . . T . . A .........................
1 0 1 1 5 0
*
T y p e 2 CCTACAAGGA AATCATCCAG AACGGCCACG AAGAAGAGCC TCTGGAAAAC
T y p e l . , T .............T .
C l o n e 8 - 3 . . . G . . . TGA G ......................... . . T ................... . . T ................... . T ......................
151 2 0 0
T y p e 2 ACATGGCCCA CTCCATACCC GTACAGCAAA AAGCTTGCTG AGAAGGCTGT
T y p e l ......................... C A C ......................
C l o n e 8 - 3 . T ................TG A . . G ................
2 0 1 2 5 0
T y p e 2 GCTGGCGGCT AATGGGTGGA ATCTAAAAAA TGGTGATACC TTGTACACTT
T y p e l A ......................... . . C ................... . . . . G ............. C . . C . G C . . . C .........................
C l o n e 8 “ 3 ■ A . C A . . G ....................A . C .
2 5 1 3 0 0
T y p e 2  GTGCGTTAAG ACCCACATAT ATCTATGGGG AAGGAGGCCC ATTCCTTTCT
T y p e l  . . . .C .  . . C ....................T G .............................................................A ................ A .......................
C l o n e 8 - 3  . . . . C   C T . . .T G ................................A ....................... A _____T A .A ....................
72
301 35 0
T y p e 2  GCCAGTATAA ATGAGGCCCT GAACAACAAT GGGATCCTGT CAAGTGTTGG 
T y p e l
C l o n e 8 - 3
T y p e l
T y p e l
C l o n e 8 - 3
T y p e l
C l o n e 8 - 3
T y p e l
C l o n e 8 - 3
T y p e l
T y p e l
T y p e l
. . . . c . . c . . A T T — ............. ................... C A .
3 5 1 4 0 0
*
AAAGTTCTCT ACAGTCAACC CAGTCTATGT TGGCAACGTG GCCTGGGCCC
......................... C . . T . . T . . . . ................T .  . .
C > . . • . A . , C . . . - .............A ................T .  . -
4 0 1 4 5 0
ACATTCTGGC CTTGAGGGCT CTGCGGGACC CCAAGAAGGC CCCAAGTGTC
......................... C . . .  . A ............. ................C A . .
......................... T . . . . G T . T . C . . .  . A ............. . . T .  . .C A . .
4 5 1 5 0 0
CGAGGTCAAT TCTATTACAT CTCAGATGAC ACGCCTCACC AAAGCTATGA
.............A .  ,G . . . . . C . . T . .
5 0 1 5 5 0
*
TAACCTTAAT TACATCCTGA GCAAAGAGTT TGGCCTCCGC CTTGATTCCA
C A ................G . . . . . C ............. A ................ A .  . . - .............T .  .
5 5 1 6 0 0
*
GATGGAGCCT TCCTTTAACC CTGATGTACT GGATTGGCTT CCTGCTGGAA
...................... T . ...................T .  .
6 0 1 6 5 0
GTAGTGAGCT TCCTACTCAG CCCAATTTAC TCCTATCAAC CCCCCTTCAA
A ......................... G .......................... A ................G . . . G ......................
A . C .............A . . . . . G ............. NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
6 5 1 7 0 0
CCGCCACACA GTCACATTAT CAAATAGTGT GTTCACCTTC TCTTACAAGA
...................... T . ...................... G . ................... C . . A ......................... .............T . . . .
m im im m iN M isMsnsnsiisnsiNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
7 0 1 7 5 0
AGGCTCAGCG AGATCTGGCG TATAAGCCAC TCTACAGCTG GGAGGAAGCC
MSINNNNNMSIN MSMsnsnsnsnsiNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
7 5 1 8 0 0
*
AAGCAGAAAA CCGTGGAGTG GGTTGGTTCC CTTGTGGACC GGCACAAGGA
. G ......................
ISnSINISINNNNI^ ÎSIM®INNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
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Type2 GACCCTGAAG TCCAAGACTC AGTGATTTAA GGATGACAGA GATGTGCATG
Typel . .A..................... TGA...........................
Clone8-3 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
851 900
Type2 TGGGTATTGT TAGGAAATGT CATCAAACTC CACCCACCTG GCTTCATACA
Typel ................G .......... G .........T ...... C .......Clone8-3 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
Fig. 3.20 Sequence obtained from clone 8(3) aligned with homologous sequences from 36-HSD type I 
and II. Triplet nucleotides underlined are translational stop and start codons. Dashes indicate gaps 
introduced for alignment. Bases corresponding to intron sequence in type I and II are shown in lower 
case.
3.2.10 Long range PCR to determine the size of HSD3B intron 
homologues in clone 8(3)
Clone 8(3) contains sequence homologous to HSD3B introns (intron sequence was 
obtained from PCRs using primers A, T, E and I), therefore long range PCR was 
performed to determine the lengths of the intron sequence present. PCRs were 
attempted exactly as for clone 2(7) (section 3.2.5). Clone 8(3) yielded amplification 
products of approximately 4kb for intron II and 2.5kb for intron III (Fig. 3.21), which 
corresponds well with HSD3B1 intron lengths of 4.2kb and 2.6kb for II and III 
respectively.
Intron II Intron III
5kb —
3kb —
2kb —
Fig. 3.21 Agarose gel o f long range PCR amplification o f intron II and III from clone 8(3). Primers 
U and H were used for intron II, G and L were used for intron III. + indicates clone 2(7) 
template added, - indicates no template negative contol.
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3.2.11 Identification of clone 8(3) as a pseudogene
The 3B-HSD coding sequence determined from clone 8(3) contained frameshft 
mutations resulting in premature stop codons. The first stop codon in the predicted 
polypeptide sequence is at residue 143 (nucleotide 108 in exon 4, Fig. 3.19). No other 
significant open reading frames were found within the sequenced fragments. 
Therefore, it was concluded that clone 8(3) was also an unprocessed pseudogene and it 
was thereafter designated 3B-HSD\|/3.
3.2.12 Searching for a human 3B-ketosteroid reductase (KSR) enzyme
The members of the 3B-HSD gene families in rodents fall into two functionally distinct 
groups. Rat I, II and IV, mouse I, II, III and VI and hamster I and II function as 
NAD+ dependant dehydrogenases/isomerases whereas rat III, mouse II and IV and 
hamster III function as NADPH dependant 3-ketosteroid reductases (KSR; section
1.8.4). These enzymes convert 5-keto-5a-androstanes into 3B-hydroxysteroids, for 
example, dihydrotestosterone into 5a-androstane-3B,17B-diol. Human 3B-HSD type
I and II cDNA have KSR activity when expressed in tissue culture cells (Lorence et a l , 
1990a, Rheaume et a l ,  1991). The prefered cofactor for this is NADH, compared to 
NADPH, the reducing agent favoured by the rodent KSRs. KSR activity has been 
observed in human tissues, in particular, the prostate gland (Abalain et a l,  1989, Tunn 
et a l ,  1990, Trapp et a l ,  1992 and Amet et a l ,  1992). In the human prostate 
dihydrotestosterone (DHT) is removed by reduction to 5a-androstane-3B,17B-diol and 
5a-androstane-3a,17B-diol by 3B-HSD and 3a-HSD respectively. Trapp et al 
(1990) showed that the KSR activity in the prostate had a three-fold preference for 
NADPH than NADH, consistent with the KSR enzymes in the rodent and not the KSR 
activity of human type I and II 3B-HSD.
To investigate the KSR activity found in the human prostate RT-PCR was utilised to 
establish what isoform of human 3B-HSD (if any) was present in this tissue. Prostate 
cDNA was synthesised from RNA purchased from Clontech and RT-PCR was earned 
out using 5' primers specific to 3B-HSD type I (type I with AA; section 2.6.2) and type
II (type II with AA; section 2.6.2). Placental and testis cDNA were used as positive 
controls in these experiments. The RT-PCR amplification products were 
electrophoresed on an agarose gel, blotted and hybridised with full-length 3B-HSD type 
I cDNA (Fig. 3.22). Fig. 3.22 indicates that a product of the expected size (1.3kb) 
was obtained from the prostate gland using type II specific primers (lane 1, type II),
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while no 36-HSD type I transcripts were detected. The type II products were cloned 
into T-vector and sequenced to confirm that the sequence was 36-HSD type II.
1
Type I Type II
I 2 3 4 5 6 I 2 3 4 5 6
T yp el Type II
I 2 3  4 5 6 1  2 3 4 5 6
I.6kb — 1.6kb — I
500bp— 500bp—
Fig. 3.22 Agarose gel o f RT-PCR amplification products from the prostate gland using 36-
HSD type I and II specific primers and hybridisation with 36-HSD type I cDNA. Lane 1 - 
prostate cD N A , lane 2 - no template control, lane 3 - placental cD N A  for type I and testis 
cDN A  for type II, lane 4 - no template control, lane 5 - no RNA control, lane 6 - no RT 
control.
Therefore, the human prostate gland expresses type II 36-HSD and this enzymes does 
possess KSR enzyme activity. However, it is still unclear as to whether this isoform 
alone is responsible for the KSR activity detected in the human prostate and the 
possibility of a specific KSR enzyme in humans cannot be disregarded.
3.3 CONCLUSIONS
This chapter has described the characterisation and sequence analysis of two new 
members of the 36-HSD gene family, HSD3B\j/2 and 3. Both genes contain 
frameshift mutations which result in premature stop codons in the predicted polypeptide 
sequence (HSD3B\|/2 at residue 42 and HSD3B\i/3 at residue 143) and therefore we 
concluded that these genes are unprocessed pseudogenes.
The screen of 2 genomic libraries identified 5 new genes in total; HSD3Bt|/I and 4 
were sequenced Martin McBride, HSD3B\j/2 and 3 by myself and HSD3B\|/5 by Nicola 
Craig. Each gene contains frameshift mutations which result in premature stop codons 
in their predicted polypeptides and therefore all represent unproccessed pseudogenes. 
The sequence alignment of the identified 36-HSD genes is shown in appendix ii.
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CHAPTER 4
Physical mapping of the 3B-HSD gene family
4.1 INTRODUCTION
To date, the 36-HSD gene family in humans contains 7 members; 2 functional HSD3B 
genes and 5 non-functional pseudogenes (Chapter 3). All of these genes have been 
loealised to chromosome Ip 13 by fluorescent in situ hybridisation (FISH) by Norma 
Monison from the Dept, of Medical Genetics, Yorkhill hospital (Morrison et al, 1995, 
personnal communication). To analyse the gene family further, it was decided to 
order the genes at chromosome Ip 13 by mapping each sequence to clones from a Y AC 
and BAC genomic library. It was possible that the construction of the 36-HSD gene 
map would provide the answers to the following questions concerning the gene family: 
(i) Have the mutations identified in HSD3B2 and associated with 36-HSD deficiency 
originated by gene conversion from another 36 sequence? (ii) How are the 36-HSD 
genes related to one another with respect to the expansion of the gene family? (iii) Are 
the functional 36 genes (type I and II) physically close to one another in the genome 
and could they have shared promoter sequences?
Dr. Jenny Varley at the Paterson Institute of Cancer Research, Manchester screened a 
human genomic YAC library by PCR using primers specific for HSD3B1. 3 Y AC 
clones containing 36-HSD sequences were identified. In Dr. Varley's laboratory I 
screened a human BAC library for clones containing 36-HSD gene family members. 
The resulting YAC and BAC clones were used to construct a contig over the 36-HSD 
gene cluster. This was investigated by restriction analysis to provide the orientation of 
the genes with respect to each other, in particular HSD3B1 and HSD3B2, and to 
establish the physical distances between the genes.
4.2 RESULTS 
4.2.1 Designing and testing gene-specific PCR primer pairs and oligo 
probes.
In order to generate a contig across the 36-HSD gene cluster, gene-specific PCR primer 
pairs and gene-specific oligonucleotide hybridisation probes were designed for each 
member of the family. To ensure specificity, the PCR primers were designed with at 
least 2 consecutive base pair differences at the 3' end of the primer. For the same 
reason, gene-specific oligonucleotide probes were designed with at least four base pair 
differences located at the centre of the oligonucleotide. As discussed in Chapter three, 
at the nucleotide level, the members of the gene family are very closely related and it 
was necessary to search the 5' untranslated region to find sufficient base pair 
differences. From this area, gene-specific PCR primers were successfully designed
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for HSD3B1, 2, \\f2 and \j/5 and oligonucleotide probes were designed for HSD3B 1, 
2, \|/1, \j/2 and \j/5. However, the 5' untranslated region did not yield PCR primer 
sites for HSD3B\i/l, \j/3 and \|/4. Consequently, gene-specific primers were designed 
to HSD3B\j/l exon 3 and to exon 4 of HSD3B\j/3 and HSD3B\|/4. A specific 
oligonucleotide probe for HSD3B\|/3 was designed in exon 4 and no region was 
identified within known sequence to create a specific probe for HSD3B\|/4 (Fig 4.1 A 
and B and the sequence of the oligonucleotides can be found in section 2.6.2 and
2.8.5). Gene-specific PCR primer pairs were tested for specificity using human 
genomic DNA as template and the resulting products were sequenced (Fig. 4.1C). 
Initially, the type II primer pair did not amplify from genomic DNA, however this was 
successful when repeated (Fig. 4 .ID).
I
II Con.
\j/2 \i/5 Vl Con. i|/3 Vj/4
V|/5 V|/2 
Con.
vi \|/3 \|/4 Con.
B
I
II Vl \|/2 \|/5 Con. Con. V3
D
Ikb—  
500bp—
II -ve
Ikb 
500bp■
Fig. 4.1 A: Schematic diagram o f HSD3B indicating the approximate positions o f  the gene-specific 
primers (Con - conserved primer). Not to scale.
B: Schematic diagram of HSD3B indicating the approximate positions o f the gene-specific 
oligonucleotide probes (Con - conserved primer). Not to scale.
C: Agarose gel o f test PCRs using gene-specific primers with human genomic DNA  
template. These products were sequenced to confirm specificity.
D: Agarose gel o f test PCR using type II specific primers with human genomic DNA  
template.
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The gene-specific hybridisation probes were tested against the seven members of the 
HSD3B gene family immobilised on nylon membrane. The original phage clone that 
genes HSD3Bvj/l-5 were identified from were used as control DNA, as well as 
HSD3B1 and 2 full length RT-PCR products from the placenta and testis respectively 
(see section 3.2.12). Unfortunately, the HSD3\|/1 specific probe did not anneal to 
HSD3B\|/1 DNA, and the HSD3Bt{/3 probe was not specific for HSD3B\|t3 DNA. 
Therefore, only probes specific for HSD3B1, 2, \[f2 and \jf5 were used in subsequent 
experiments (Fig. 4.2).
I II i|/l V|/4 vj/2 \|/5 vii3
12kb
Ikb
B
I II \|/I V|/4 \|/2 \|/5 i)/3
Exon 2 conserved
I II v|/l \|/4 \|/2 \j/5 \|/3
I2kb —
Typel
I II \|/1 ij/4 \j/2 \j/5 i|/3
I2kb —
Ikb —
Typell
I II \|/1 \|/4 \|/2 \|/5 i|/3
12kb —
HSD3BX1/2
I II \|/1 i|/4 \jr2 V}/5 \|/3
12kb —  1
Ikb —
H S D 3 B #
Fig. 4.2 A: 1% agarose gel containing uncut control DNA to test the gene-specific oligonucleotide 
hybridisation probes. Type I and type II control DNA were full-length RT-PCR 
products, see section 3 .2 .11. The phage clone used to identify each pseudogene was 
used for \|/I - \|/5.
B: Southern analysis o f panel A hybridised with oligonucleotide probe to a conserved region 
o f exon 2 in all 7 family members.
C: Southern analysis o f panel A hybridised with gene-specific oligonucleotide probes for 
H SD 3BI, 2, \\f2 and \}/5.
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4.2.2 Screen of human YAC library for HSD3B genomic clones.
The YAC library screen was undertaken by Bill Brintnell in Dr. Jenny Varley's 
laboratory, Manchester. A human YAC library (Zeneca) was screened by PCR with 
primers to 3B-HSD (primers 93096 and 93097; section 2.6.2). Three clones were 
purified: 9GF11, 32EG4, and IG D ll, with genomic inserts of 250, 200, and 220 kb, 
respectively. YAC DNA from these clones was donated to our laboratory in Glasgow, 
where each clone was screened with gene-specific PCR primer pairs and a preliminary 
YAC map was constructed. The PCRs were repeated at least three times and the 
resulting products were sequenced to check specificity. The PCR products obtained 
and the YAC map generated is shown in Fig. 4.3. The map contains 2 sets of genes 
within which the order cannot be deduced, one set contains II and \|/2 and the other I, 
H/I, \j/3 and \|/4. It has been established that \j/5 is found at the far left side of the cluster 
shown, this gene is present on YAC 9GF11 but not YAC 32EG4. The size of the gap 
between the 2 sets of unordered genes has not been determined.
B
\|/5 v|/4 V|/3 I Vj/l \|/2 II
500bp 9GF1I l|/5 [\|/4 \j/3 I \|/1] [\|/2 II]
9GF11
500bp—
500bp—
32EG4
IG D II
32EG4
IG D ll
Fig. 4.3 A: Agarose gel o f PCR products from Y AC clones 9G F11, 32EG4 and IG D I1 screened using 
gene-specific primer pairs (Fig. 4 .1 A).
B: A preliminary genomic map constructed from the YAC PCR results shown in A.
4.2.3 Screen of human BAC library for HSD3B genomic clones.
A human BAC library (Research Genetics Inc.) was screened with primers to sequence 
that is fully conserved between the seven members of the gene family (primer pairs C-S 
and K-AA). The BAC library was provided on 192 384-well microtitre plates. Each 
plate was pooled to produce 192 subpools which were further pooled into 24
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superpools. To screen the BAC library, the superpools were screened first, which 
provided an address of the subpool to screen next, and in turn, gave the address of the 
plate to be screened. The plate was screened by pooling the rows together and the 
columns together which led to a row letter and column number address of the positive 
clone. A representative clone identified from the BAC library screen is shown in Fig. 
4.4.
800bp —
R/C:
SOObp —  
200 bp —
A B C D E F G H I  J K L M N O P l
2 3 4 5 () 7 X '> 10 II 12 1 0 4  15 1(117 IX
B
Sub.: A B C D E F G H
SOObp
SOObp
200bp
SOObp
200bp
IV202I 22 23 24-vc «# '
Fig. 4.4 Agarose gels indicating the BAC library screen strategy and the identification o f clone L-2 
A: Agarose gel o f PCR screen o f superpools (Sp) 1-9 o f BAC library, using primer pair K- 
AA. Expected product length 830bp.
B: Agarose gel o f PCR screen o f subpools (Sub) A-H from superpool 1, using primer pair K- 
AA. Expected product length 830bp.
C: Agarose gel o f PCR screen o f rows and columns (R/C) from plate 7 which corresponds to 
subpool G, primer pair used C-S. Expected product length 160bp. Clone L-2 is 
identified and is shown by *.
32 BAC clones were identified from the library screen. These were tested with the 
gene-specific primers and 9 of the 32 were shown to contain the 7 members of the gene 
family. These BACs were used to construct a BAC map (Fig. 4.5). The BAC PCRs 
were repeated at least 3 times and the products were sequenced to ensure specificity. 
The BAC PCR data allows the genes within the 2 sets of unordered genes from the YAC 
PCR data to be ordered (Fig. 4.3B). The only genes that cannot be ordered from the 
BAC map are \j/4 and \j/5.
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SOObp -----
SOObp ■
SOObp —
SOObp -----
SOObp ■
BAC 31
BAC 21
BAC 7
BAC 27
BAC 29
V|/5 \ |/4 \ |/3  I (j/I \|/2  II 
5 0 0 b p — I  BAC 24
500bp
500bp —
500bp ■ '
BAC 22
BAC 1
BAC 30
B
[\|/5 \i/4 ] n/3 I \j/l \|/2 II
31
21
27
29
24
22
1
30
Fig. 4.5 A: Agarose gels o f the PCR products from 9 BACs positive with gene-specific primer pairs. 
Gene-specifc primer pairs as indicated on Fig. 4.1 A, except PCR amplification for 
HSD3B\j/l using BAC clone 7 template. The PCR primer pair used in this 
amplification was 5’ \j/l specific with primer I.
B; A genomic map constructed from the BAC PCR results shown in A.
From the other 23 BACs identified, 16 resulted from contamination of the library at 
source and represented the same clone. The remaining 7 were rescreened with the 
conserved PCR primers. Some failed to reamplify, which was not unexpected as some 
of the initial PCR products were extremely faint but were investigated to ensure that 
nothing was missed. Amplification products were obtained from 3 clones but attempts
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to sequence them were unsuccessful. From the gene-specific PCR screen of the BAC 
clones, the main objective of these experiments was achieved, as a genomic contig was 
constructed (Fig. 4.5) and because the above observations did not provide any evidence 
of any other HSD3B genes, these clones were not investigated further.
The BAC data provided the order of all the genes except \j/4 and \j/5, but the Y AC data 
revealed that HSD3B\j/5 was present at the left end of the cluster. Therefore, a 
combination of the Y AC and BAC PCR results provided a genomic contig indicating the 
gene order of the 7 identified members of the 3B-HSD gene family (Fig. 4.6).
\|/5 “ \|/4 ” \|/3 ” I “ \|/1 - \|/2 ” II
9GF11
32EG4
31
21
27
29
24
IG D ll
YACs
22
1
30
BACs
Fig. 4.6 Order of the 3B-FISD gene family at human chromosome ip  13, deduced from the Y AC and
BAC contigs. Size of Y AC clone genomic inserts are 250kb, 200kb and 220kb for 9GF11, 
32EG4 and IG D ll respectively, therefore the maximum size of the contig is 470kb.
4.2.4 Confirmation of the gene-order across the human 3fi-HSD gene 
cluster
To confirm the gene order obtained above, the DNA from BAC clones 31, 21, 7, 29, 1 
and 30 was isolated. These 6 clones were chosen because together they span the cluster 
and contain all 7 genes, and the remaining 3 BAC clones are contained within one or 
more of them (Fig. 4.6). BAC clone DNA was purified using a modified protocol 
from Qiagen. BAC DNA was manipulated as plasmid DNA, although to prevent 
shearing of the large BAC molecule the ends were removed from pipette tips. Each 
BAC clone was digested with BamHI, Hindlll and EcoRV and electrophoresed on a
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0.7% agarose gel. The gels were blotted as described (section 2.7) with an additional 
wash with 0.25M HCl to depurinate the larger fragments for ease of transfer. The 
membranes were probed with the conserved exon 2 oligonucleotide and conserved exon 
4 oligonucleotide (Fig. 4. IB).
The Hindlll digest probed with conserved exon 2 oligonucleotide yielded a clear pattern 
which was further investigated.(Fig. 4.7A). From this blot, the number of exon 2 
bands present on each BAC and also what gene each band represents could be 
identified. BAC 30 only contains HSD3B2 (PCR data. Fig. 4.5A), therefore the band 
observed in this digest must represent HSD3B2 exon 2. This fragment is present in the 
BAC 1 digest and BAC 1 also contains HSD3Bt|/2 and HSD3B\|/1 (PCR data. Fig. 
4.5A). HSD3B\|/1 is present in BACs 1, 29 and 7 and therefore HSD3Bi|/l exon 2 can 
be identified as the 600bp fragment which is common to each of these BACs. 
HSD3Bt|/2 is present on BACs 1 and 7, therefore it is deduced that the 2.8kb fragment 
represents HSD3Bi|/2 exon 2. Moreover, HSD3B1 is found on BACs 29 and 7, 
therefore if the 600bp fragment from BAC 29 is HSD3B\|/1 exon 2 then the 700bp 
fragment must be HSD3B1 exon 2. This can also be seen in BAC 1. To confirm these 
deductions, the membrane was stripped of the conserved exon 2 oligonucleotide and 
reprobed with HSD3B\)/2 and HSD3B1 specific oligonucleotides, which were designed 
to exon 2 in both these genes. These hybridisations confirmed that HSD3B\|/2 exon 2 
was present on the 2.8kb fragment and that HSD3B1 exon 2 was on the 700bp 
fragment. (Fig. 4.7B).
BAC 31 contains HSD3B\j/4 and \|/5 and it appears as if the fragments resolve at the 
same size, which is not surprising considering their sequence similarity. BAC 21 
contains these 2 genes also and the 5kb fragment can be observed. BAC 21 also 
contains HSD3Bt|/3 which may be represented by the fragment at 700bp or the 5kb 
fragment. The 700bp Hindlll fragment (indicated as * on Fig. 4.7A) was subcloned 
into pUC 18 and sequenced to determine if it contained HSD3B\|/3 exon 2. The 
sequence of the 700bp band was found to be HSD3B\)/3 exon 2. This indicated that 
HSD3B\|/3 exon 2 Hindlll fragment is the same size as the HSD3B1 fragment (seen in 
BACs 7 and 29) leaving the question, what does the 5kb fragment in BAC 7 contain? 
This fragment (indicated + on Fig. 4.7A) was also subcloned into pUC and sequenced. 
The sequence obtained from band + was HSD3B\]/4 exon 2. This confirms the earlier 
deduction that HSD3B\|/4 is present on the 5kb fragment from BACs 31 and 21, and it 
reveals some information on the orientation of the genes within the cluster which will be 
discussed further in section 4.3.7.
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Fig. 4.7 A: Agarose gel o f Hind III restriction digests o f BACs 3 1 , 2 1 , 7 ,  29, 1 and 30 and Southern 
blot hybridised with exon 2 conserved probe. * and + indicate bands that have been 
subcloned and sequenced.
B: Southern analysis o f H indlll digests hybridised with HSD3B1 and HSD3B\}/2 specific 
probes.
The PCR data indicated that BAC 21 contained the HSD3B genes HSD3B\|/3, 4 and 5 
and that BAC 31 contained HSD3B\j/4 and \{/5 (Fig. 4.5). The Hindlll digest for BAC 
21 probed with conserved exon 2 oligonucleotide only revealed two bands, one at 
700bp containing HSD3B\j/3 exon 2 and the other at 5kb containing HSD3Bi|/4 and \j/5 
exon 2 and the BAC 31 digest revealed one band at 5kb containing HSD3B\|/4 and \j/5 
exon 2 (Fig. 4.7A). From this data HSD3B\|/4 and 5 could not be separated. To 
confirm that \i/4 and t{/5 were both present at this end of the cluster, BAC 21 was 
digested with a number of restriction digests and hybridised with the conserved exon 2 
and exon 4 oligonucleotides. Restriction enzymes Xbal and EcoRV produced 3 bands 
when hybridised with the conserved exon 2 oligonucleotide (Fig. 4.8A). This 
membrane was stripped and reprobed with the HSD3B\j/3 and HSD3Bq/5 gene-specific 
oligonucleotides (Fig. 4.8B), indicating which fragment each gene belonged to. This 
confirmed that the 3 genes were present on BAC 21, however HSD3B\j/4 and \|/5 could 
not be separated in BAC 31 (see Fig. 4.9, only one band can be detected from digests 
hybridised with either conserved exon 2 or exon 4 oligonucleotides).
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2kb—
»
Conserved exon 2 HSD3B\|/5 HSD3B\i/3
Fig. 4.8 A: Southern analysis o f Xbal and EcoRV restriction digests o f BAC 21 hybridised with 
conserved exon 2 oligonucleotide (X=Xbal, EV=EcoRV).
B: Southern analysis o f Xbal and EcoRV restriction digests o f BAC 21 hybridised with 
HSD3Bv|/5 and n/3 specific oligonucleotides (X=Xbal, EV=EcoRV).
4.2.5 Searching for unidentified 3B-HSD genes in the gene cluster
To determine if there were any unidentified 3B-HSD genes within the cluster, each BAC 
was digested with a panel of restriction enzymes and probed with the conserved exon 2 
and exon 4 oligonucleotide probes. These oligonucleotidess were designed to regions 
conserved in all 7 identified genes, with the aim that similar genes present in the contig 
would be detected. From the 6 BACs examined no additional bands were detected. 
Each BAC had the correct number of bands, or less, predicted from the Y AC and BAC 
contig (Fig. 4.9).
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Fig. 4.9 Restriction digests o f 6 BACS (left column) probed with exon 2 (central column) and exon 
4 (right column) conserved probes to indicate the number o f exons present in each BAC. 
Lanel - EcoRI; lane2 - Xbal; lane3 - Sail; lane4 - Kpnl; laneS - BamHI; lane6 - Hindlll, 
lane? - SstI; laneS - Notl; lane9 - EcoRV. * indicates partial digestions.
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4.2.6 Restriction analysis of YAC IG D ll
The YAC and BAC genomic contig suggests that YAC IGDl 1 contains HSD3B genes 
HSD3B\|/2 and 2. The size of this YAC clone is approximately 220kb (Jenny Varley, 
personnal communication) and it is situated at one end of the contig, therefore, it is 
conceivable that it may contain more than 2 36-HSD sequences. To investigate this 
possibility, YAC digests were resolved by PFGE and then probed with 36-HSD type I 
cDNA. Agarose plugs containing IG D ll were prepared and digested as described in 
section 2.11. The YAC was digested by four enzymes, Notl, Smal, Xbal and SacII, 
and the digestion reactions were stopped at various time points to create partial 
digestions. The running conditions for the digests on PFGE were 20-80 seconds for 
20 hours at 200V at 14°C. After electrophoresis the gel was blotted and hybridised 
with 36-HSD type 1 cDNA as before. The resulting blot (Fig. 4.10) indicated that 36- 
HSD sequences were detectable on YAC clone IGDl 1 by Southern analysis, however 
the limited restriction information obtained does not confirm that two 36-HSD genes are 
present on this clone. Additional restriction analysis and the use of gene-specific 
probes would be neccessary to verify this.
Notl Xhol SacII Smal Notl Xhol SacII Smal
5 10 20 40 60 5 10 2040 6 0 5 10 20 40 6 0 5 10 20 40 60 5 10 20 40 60 5 102040 60 5 10 20 4060 5 10 20 40 60
200kb —  
50kb —
Fig. 4.10 A: PFGE of YAC I G D l l  restriction digests. Four restriction enzymes were used (Notl, 
Xhol, SacII and Smal) and partials digests were accomplished at 5 time points (5, 10, 20, 
40 and 60 minutes). Size markers are lambda concatamers and yeast chromosome marker. 
B: Southern hybridisation o f PFGE (panel A) with 36-HSD type I cDNA.
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4.2.7 Defining the physical map of the 36-HSD gene cluster
To investigate the 3B-HSD contig further, restriction digests of the BAC clones were 
resolved by pulse field gel electrophoresis (PFGE). A detailed map was constructed 
using conserved oligonucleotide probes to HSD3B exon 2 and exon 4 and the BAC 
vector arms, T7 and SP6. The final map is presented in Fig, 4.11 and the data that 
supports it is analysed in the following two sections.
HSD3B\]/5 H S D 3 B #  H S D 3 B #  HSD3B1 HSD3B\i/1 HSD3B11/2 HSD3B2
-------
100kb 120kb
\ r r  X XX
110kb
E X X
170kb
21
9GF11 32EG4 1GD11
31
29
7 
22
30
Fig. 4.11 Genomic map of 36-HSD gene family at human chromosome lp l3 .1 , constructed by
restriction analysis of overlapping YAC (9GF11, 32EG4 and IG D ll)  and BAC clones (31, 
21, 7, 29, 22, 1 and 30). X=XhoI, E=EcoRV.
Exon 2 and exon 4 oligonucleotide probes conserved in all 7 members of the gene 
family (Fig. 4.1) and oligonucleotide probes to the BAC vector arms were hybridised 
to restriction fragments from each BAC to determine which exons (if any) were present 
at the ends of the genomic inserts. The pBeloBACl 1 vector restriction map is shown 
in Fig. 4.12. Xho I, EcoRV and Notl cut the BAC vector, releasing the vector arms 
with the ends of the insert. This infoimation was used to construct the majority of the 
genomic map. Each blot was handled and analysed with the utmost care, to ensure that 
all bands identified could be aligned correctly to fragments of the digest (section 2.7). 
Photo scanning and printing has reproduced the blots quite well, however, the original 
gels are available for inspection.
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cosN loxP LucZ
SaU Not!
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7.3kb ■* — Xhol
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EcoRV
Fig. 4.12 Restriction map of BAC vector - pBeloBAC 11.
R IG H T SIDE OF M AP:
This section is concerned with HSD3B genes HSD3B2, HSD3B\|/2, HSD3B\[/1 and 
HSD3B1. The data is reasonably complicated and therefore a brief summary of the 
results which provided the orientation of the genes or helped create the restriction map 
of the genomic contig is provided below for reference.
GENE: COMMENTS:
HSD3B2 The orientation of this gene was determined by restriction analysis of
BAC clones 30 and 1. An Xhol restiiction map was determined for 
BAC 30 and an EcoRV restriction site orientated HSD3B2 with respeet 
to the BAC vector arms (Fig. 4.12E).
HSD3B\]/2 This gene was not orientated due to the lack of infoimative restriction
sites within the gene itself. However, it was incorporated into an Xhol 
restriction map of BACs 30, 1 ,7  and 22 (Fig. 4.13D).
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GENE; COMMENTS:
HSD3B\|/1 Xhol restriction digests of BAC 29 determined the orientation of this
gene. An Xhol restriction site was present between exon 2 and 4 in 
HSD3B\i/l, and it was established that exon 2 was situated adjaeent to 
one of the BAC vector amis (Fig. 4.14B).
HSD3B1 HSD3B1 was orientated from the position of the breakpoint of BAC
clone 29. It was demonstrated that exon 2 but not exon 4 was present 
in the genomic insert of BAC 29 (Fig. 4.15B)
Orientation and restriction mapping o f HSD3B2:
HSD3B2 is found on BAC 30 and BAC I. Earlier gene-specific PCR data (Fig. 4.5) 
showed that BAC 30 contains only HSD3B2, and no additional bands were detected by 
hybridising BAC 30 restriction digests with conserved exon 2 and exon 4
oligonucleotide probes (Fig. 4.9). Further confirmation of this was obtained by
. !probing the same digests with the HSD3B2 specific oligonucleotide probe (Fig. j"■"I4.13A), which hybridised to the same fragments as the conserved exon 2 j
oligonucleotide probe. In addition, Fhndlll restriction digests of BAC clones 30 and 1 , ,|
showed that all BAC 30 Hindlll fragments were in common with BAC 1 H indlll |
restriction fragments, indicating that BAC 30 is internal to BAC 1 (Fig. 4.13B).
Xhol restriction fragments for BAC 30 and BAC 1 were resolved by pulse field gel 
electrophoresis (PFGE), blotted and hybridised with the conserved exon 2, conserved 
exon 4, T7 and SP6 oligonucleotide probes (Fig. 4.13C). A 50kb fragment from 
BAC 30 contained HSD3B2 exon 2, HSD3B2 exon 4 (no other HSD3B genes 
identified on this BAC) and SP6. EcoRV digests of BAC 30 and BAC 1, also probed 
with conserved exon 2, conserved exon 4, T7 and SP6 oligonucleotides, indicated that 
exon 4 and SP6 were contained on a 9.5kb fragment from BAC 30 (Fig. 4.13D). The 
EcoRV digest of BAC 30 produced 6 bands, including 4 bands clustered between 
approximately 9.5kb to 20kb. The eonserved exon 4 and the SP6 oligonucleotide both 
hybridised to the smallest band (9.5kb) within this cluster, determined by careful 
measurements during the blotting procedure (section 2.7). This information indicated 
that HSD3B2 exon 4 was closest the SP6 end of the vector within a 9.5kb fragment.
Xhol restriction digests of BAC 30 produced 3 fragments, 2 of which were in common 
with Xhol fragments from BAC 1. In partieular, both BAC clones had an Xhol 
fragment, approximately lO.Skb, which hybridised to the T7 oligonucleotide probe.
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This suggested that at the T7 end of the vector the genomic inserts of these two BAC 
clones were created at the same restriction site. The other common band was 
approximately 7.5kb, leaving a 50 kb fragment from BAC 30 which was equivalent to 
the 70kb fragment in BAC 1 (since BAC 30 is contained within BAC 1). This is 
confirmed by the hybridisation of the conserved exon 2 and exon 4 oligonucleotide 
probes to the 70 kb fragment from BAC 1. Other bands are observed from BAC 1 
using these oligonucleotide probes, these are important with respect to HSD3B\j/2 and 
HSD3B\j/l and are discussed further on. The Xhol restriction fragments for BAC 
clone 1 and 30 were used to generate a restriction map for BAC 30 and the left end of 
BAC 1 (Fig. 4.13E). The EcoRV data for BAC 30 provided an indication of the 
orientation of HSD3B2. The EcoRV site between HSD3B2 exon 2 and 4 is confirmed 
in BAC 1. The conserved exon 2 oligonucleotide hybridised to a 14kb fragment which 
is the same in BAC 30, and the conserved exon 4 oligonucleotide hybridised to a 16kb 
fragment (these bands are faint on the blot shown), which must correspond to HSD3B2 
exon 4 as it is the only band larger than 9.5kb.
A
1 2  3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9  1 2 3 4 5 6 7 8 9
lOkb —
2kb —
Probe: Exon 2
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Probe: HSD3B2
B 1 30
— lOkb
— 5kb
— 2kb
— 500bp
Hindlll
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Fig. 4.13 A: Agarose gel indicating restriction digests of BAC 30 and hybridised with exon 2
conserved oligo and HSD3B2 specific oligo. Lanel - EcoRI; lane2 - Xbal; lane3 - Sail; 
lane4 - Kpnl; laneS - BamHI; laneô - Hindlll; lane? - SstI; lane8 - Notl; lane9 - 
EcoRV.
B: Agarose gel showing Hind III restriction digests of BACs I and 30.
C: Xhol restriction digests of BACs 1 and 30, resolved by PFGE and hybridised with
conserved exon 2, conserved exon 4, T7 and Sp6 oligonucleotides.
D: EcoRV restriction digests of BACs I and 30, resolved by PFGE and hybridised with
conserved exon 2, conserved exon 4, T7 and Sp6 oligonucleotides.
E: Xhol and EcoRV restriction map showing the orientation of FISD3B2.
Orientation and restriction mapping ofHSD3B\j/2:
HSD3B\j/2 is the next gene in the cluster and gene-specific PCR data (Fig. 4.5) 
indicates that it is present on BAC clones 1, 22 and 7. Xhol restriction digests were 
resolved by PFGE and probed with conserved exon 2, conserved exon 4, T7, SP6 and 
HSD3B\|/2 specific oligonucleotides. HSD3B\]/2 was found within BACs 7, 22 and 1 
on fragments of 24kb, 30kb and 70kb respectively (Fig. 4.14A). The 24kb fragment 
from BAC 7 contained exon 2, exon 4 and the T7 vector end, the 30kb fragment from 
BAC 22 contained exon 2, exon 4 and the SP6 vector end and the 70kb fragment from 
BAC 1 contained only exon 2 and exon 4. Other fragments from BACs 1, 22 and 7 
hybridised with the conserved exon 2 and exon 4 probes; these have already been 
discussed in relation to HSD3B2 or will be discussed in relation to the other HSD3B 
genes.
The presence of exon 2 and exon 4 together on the same fragment indicated that 
HSD3B\|/2 does not contain an Xhol restriction site between these exons. Therefore, 
other restriction enzymes were used to attempt to digest the 24kb Xhol fragment from 
BAC 7 and the 30kb Xhol fragment from BAC 22. Ideally, the enzyme would digest 
between exons 2 and 4 without restricting between the gene and the BAC vector. 
Although several restriction enzymes were used in double digests with Xhol, none cut 
between the exons without cutting between the gene and the vector (Fig. 4.14B and C).
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It can be observed from Fig. 4.14B and C that none of the fragments containing the 
BAC vector arms hybridised to either the conserved exon 4 oligonucleotide or the 
conserved exon 2 oligonucleotide. There was not time to test other restriction 
enzymes. Therefore, although the orientation of HSD3B\|/2 was not determined, the 
gene was incorporated into the Xhol restriction map. The left end of BAC I had 
already been mapped in Fig. 4.13E. By examining the restriction fragments and the 
hybridisation patterns in common between BACs 1, 22 and 7 and analysis of genes 
further along the cluster, the restriction map of the genomic cluster can be extended to 
include HSD3B\|/2 (Fig. 4.14D).
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95
c  - BAC 22
1 2 3 4  1 2 3 4  1 2 3 4  1 2 3 4  1 2 3 4
50kb-
lOkb-
1 5kb —
Exon 2 Exon 4 T7
Oligonucleotide probes
Sp6
D HSD3B\i/2
T7
X
Sp6
hSp
BAC 7
BAC 22
6.0
HSD3B2
4 2 T7
I I ' BAC 1
X X  X
Sp6
EX
T7
,  BAC 30
70.0
5.5 9.5 14.0
7.5 105
Fig. 4.14 A: PFGE o f Xho I restriction digests o f BACS 7, 22 and 1, hybridised with exon 2, exon
4, T7 and Sp6 oligos by Southern analysis.
B: Agarose gel showing BAC 7 digested with panel o f restriction enzymes, hybridised with 
exon2, exon 4, T7 nd Sp6 oligos by Southern analysis. Lanel - XhoI/BstXI; lane2 - 
XhoFNdel; lane3 - XhoF SphI; lane4 - XhoFSstlI; lane5 - XhoFMluI; laneô - 
XhoI/HincII.
C; Agarose gel showing BAC 22 digested with a panel o f restriction enzymes, hybridised 
with exon2, exon 4, T7 and Sp6 oligos by Southern analysis. Lanel - Xhol; lane2 -
XhoFKpnl; lane3 - XhoFSphI; lane4 - Xhol/Pstl.
D: Xhol restriction map including the position o f HSD3Btj/2.
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Orientation and restriction mapping ofHSDSBlf/l:
From the gene-specific PCR data, this gene is found on BACs 1, 22, 29 and 7 (Fig.
4.5). Xhol restriction digests of these clones were probed with conserved exon 2, 
conserved exon 4, T7 and SP6 oligonucleotides (Fig. 4.15A). The conserved exon 4 
oligonucleotide hybridised to a L8kb fragment from each BAC. This indicated that 
these fragments contain HSD3Bi(/l exon 4, since this gene is the only HSD3B gene 
present on all 4 of these BAC clones. The orientation of HSD3B\i/l was determined 
from BAC 29 Xhol restriction digests and hybridisations. From the gene-specific 
PCR data (Fig. 4.5), BAC 29 contains 2 genes - FlSD3B\|f 1 and HSD3B1. Two 
exon 2 fragments are observed for BAC 29 (Fig. 4.15A), one at 12kb and the other at 
48kb. The T7 oligonucleotide hybridised to the 12 kb fragment also and the SP6 
oligonucleotide hybridised to the 48kb. From this information, it can be concluded 
that at either end of the BAC 29 genomic insert there is an exon 2 present and one of 
these must belong to HSD3Bt(fl and the other to HSD3B1. Within BACs 1, 22 and 
7 there is an Xhol fragment of 22kb which contains an exon 2. Since HSD3B\j/2 
belongs to the left end of BACs 7 and 22 (Fig. 4.14D) and HSD3B\)/1 is the only other 
gene to be present in all three of these BAC clones, this exon 2 must belong to 
HSD3B\|/1. Therefore, the 48kb fragment does not fit into the Xhol map as 
HSD3Bi|rl but the 12kb fragment does.
Only two more bands remain to be incorporated into the BAC 1 Xhol restriction map, 
one of these is 4.5kb and the other 4.8kb. The 4.5kb fragment is also present in 
BACs 22, 29 and 7, therefore it can be positioned next to the 1.8kb, and the 4.5kb 
fragment which contains SP6 vector arm indicating the end of the clone. Again, there 
are fragments that have not been discussed here. These have either been discussed 
earlier in connection with HSD3B2 or HSD3B\j/2 or they will be discussed in 
connection with genes further along the contig.
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Fig. 4.15 A: PFGE o f Xhol restriction digests o f BACS 7, 29, 22 and 1, hybridised with exon 2, 
exon 4, T7 and Sp6 oligos.
B: Xhol restriction map including the orientation o f HSD3Bt|f 1.
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Orientation and restriction mapping ofHSDSBl:
This gene was found on BAC clones 29 and 7 by gene-specific PCR (Fig. 4.5). 
When these clones were digested with Hindlll and hybridised with the conserved exon 
4 oligonucleotide, only one band (1.6kb) was observed from BAC 29, whereas four 
bands were detected from BAC 7 (Fig. 4 .16A). Although four bands were expected 
from BAC 7 (i.e. HSD3B\|/2, HSD3B\|/1, HSD3B1 and HSD3B\}/3), two were 
expected from BAC 29 (HSD3B\j/l and HSD3B1). This raised several questions: 
Did the 1.6kb fragment from BAC 29 represent both HSD3B\|/1 and HSD3B1 exon 4 
fragments and if so, what gene did the i.4kb fragment from BAC 7 represent, or, was 
it possible that BAC 29 did not contain HSD3B1 exon 4, only HSD3B\(/1 exon 4? To 
anwser this, the sequence of the 1.4kb fragment from BAC 7 was determined by 
subcloning into pUC18. HSD3B1 sequence was obtained from this subclone. 
Therefore, it was possible that BAC 29 does not contain HSD3B1 exon 4 sequence and 
that exon 4 sequence of HSD3B1 was only present on BAC 7. This deduction is 
supported by the restriction digests of BAC 29 hybridised with conserved exon 2 and 
exon 4 oligonucleotides (Fig. 4.9). Only one exon 4 fragment can be detected in 
every digests, whereas two exon 2 fragments can be seen in more than one of the 
digests. Also, as discussed in relation to HSD3B\|/1, the Xhol digest of BAC 29 
probed with conserved exon 2, exon 4, T7 and SP6 oligonucleotides (Fig. 4.14A) 
indicated that BAC 29 contained exon 2 fragments at the ends of the genomic insert. 
From this information, the Xhol restriction map can be further extended to include the 
orientation of HSD3B1 (Fig. 4.16B). There is an Xhol site present between exon 2 
and exon 4 of HSD3B1, which can be deduced from BAC 7 Xhol restriction map (Fig. 
4.15A). There is a fragment of approximately 48 kb in BAC 7 which contains an exon 
2, this band represents HSD3B1 exon 2.
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Fig. 4.16 A: Agarose gel indicating H indlll restriction digests of BACS 31, 21, 7, 29, 1 and 30.
probed with conserved exon 4 oligonucleotide. * indicates the band that was subcloned. 
B: Xhol restriction map including the orientation of HSD3B1. This is the complete Xhol 
restriction map for section 1.
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LEFT SIDE OF M AP
HSD3B\i/5 H S D 3 B #  HSD3B\i/3
9GF11 32EG4
31
21
This section considers the HSD3B genes HSD3B\|/3, HSD3B\)/4 and HSD3B\]/5. A 
brief summary of the significant results concerning the left side of the cluster is 
presented below.
GENE: COMMENT:
HSD3Bt|/3 This member of the 3B-HSD gene family was not orientated due to the 
lack of informative restriction sites (Fig. 4.17B).
HSD3B\|/4 HSD3B\i/4 was orientated from the breakpoint position of BAC 31. 
BAC 31 does not contain HSD3B\|/4 exon 2 (Fig. 4.18B).
HSD3B\|/5 This gene was not orientated. A possible orientation is proposed (Fig.
4.19B), however the lack of exon 4 sequence for HSD3B\[/5 prevented 
confirmation of this.
Orientation and mapping ofHSD3Bij/3:
HSD3B\|/3 was assigned to BACS 7 and 21 by gene-specific PCR (Fig. 4.5). Xho I 
digests probed with conserved exon 2, conserved exon 4, Sp6 and T7 oligonucleotides 
indicated that HSD3B\[/3 was situated within BACs 7 and 21 on fragments of 65kb and 
70kb respectively (Fig. 4.17A). This was deduced from the construction of the Xhol 
maps of BACs 7 and 21, in relation to the other HSD3B genes. These fragments were 
too large for the vector arm probes to be beneficial and the orientation was not 
determined. The 65kb fragment from BAC 7 contained exon 2, exon 4 and SP6, the 
70kb fragment from BAC 21 contained exon 2, exon 4 and T7. To determine the 
orientation of HSD3B\i/3 it would require using markers within BAC 7 insert 
sequence, possibly using HSD3Br|/4, the next gene along, as a starting point. 
HSD3Bij/3 was incoiporated into the Xhol restriction map (Fig. 4.17B).
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Fig. 4.17 A: PFGE o f Xhol restriction digests o f BACS 31, 21 and 7 hybridised with conserved exon 
2, conserved exon 4, T7 and Sp6 oligonucleotides.
B: Xhol restriction map indicating the position o f HSD3BH/3.
Orientation and mapping of HSDSBxpd:
The orientation of HSD3B\)/4 was determined by subcloning a fragment from Hind III 
digest of BAC 7 hybridised with conserved exon 2 oligonucleotide (Fig. 4.7, see 
section 4.2.4). A 5kb Hindlll fragment from BAC 7 was unidentified and was 
therefore subcloned into pUC. The sequence obtained from the subclone was 
HSD3B\|/4 exon 2. The gene-specific PCR data indicated that HSD3B\|/4 was present 
only on BAC 31 and 21, not BAC 7 (Fig. 4.6). However, the gene-specific PCR 
primer pair for HSD3B\|/4 was designed to exon 4 (Fig. 4.1 A) and it was concluded 
that HSD3Bt|/4 exon 2 was present on BAC clones 7 and 21, not BAC 31, whereas 
HSD3BV1/4 exon 4 was present on BAC clones 21 and 31 and not BAC 7. This is 
confirmed in Fig. 4.9 where only one exon 2 band can be detected in each lane when 
BAC 31 is digested with a range of restriction enzymes and hybridised with the
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conserved exon 2 oligonucleotide. From Fig. 4.18A, an Xhol restriction map of BAC 
clones 7, 21 and 31 was constructed and HSD3Bii/4 was incoiporated into the map in 
the correct orientation (Fig. 4.18B). Within the Xhol map, HSD3B\|i4 exon 2 is 
present on a 65kb fragment from BAC 7 and a 70kb fragment from BAC 21 (the same 
fragments that contain HSD3B\j/3, Fig. 4.17B). HSD3B\|/4 exon 4 is present on a 
22kb fragment on BACs 21 and 31 and the T7 vector arm is found on the lOkb 
fragment.
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Fig. 4.18 A: PFGE o f Xhol restriction digests o f BACs 31,21 and 7 hybridised with conserved exon 
2, conserved exon 4, T7 and SP6 oligonucleotides.
B: Xhol restriction map indicating the orientation o f HSD3Bvii4.
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Orientation and mapping o f  HSD3Bij/5:
The orientation o f HSD3Bn/5 was not determ ined. It was observed that HSD3B\|/5 
exon 2 was present on a 30kb Xho I fragm ent from  BAC 31, how ever, only one exon 
4 fragm ent (22kb) was detected and it was expected that HSD3B\j/4 exon 4 and \|/5 
exon 4 were present on BAC 31 (Fig. 4.19A). It is possible that both HSD3B\i/4 and 
H S D 3B \|/5  exon 4 sequences are present w ithin this fragm ent and H SD 3B\|/5 is 
orientated in the opposite direction from  the other genes (Fig. 4.19B). A lthough, the 
intensity o f the 22kb fragm ent does not suggest a doublet. Fig. 4.19B indicates the 
Xhol restriction maps of BACs 21 and 31 determ ined from Fig. 4.19A.
HSD3B\j/5 exon 4 sequence was not obtained from the phage clone used to generate 
HSD3B\j/5 sequence (Appendix ii). Sandra Burridge, a collègue in the lab, attempted 
to clone HSD3B\i/5 exon 4 from BAC 31 but detected only HSD3B\|/4 sequence from 9 
clones. RT-PCR data (produced by Sandra Burridge) supplied lOObp of HSD3B\j/5 
exon 4 sequence and w ithin this sequence it was dem onstrated that there was an Ncil 
restriction enzym e site difference between \\f4 and \j/5 (Fig. 4.19C). This was used to 
attem pt to distinguish \j/4 and \|/5 exon 4. Unfortunately, only one band was obtained 
when a N cil/X hol digest was probed with exon 4 oligonucleotide (Fig. 4.19D). This 
could be due to the loss of another fragment from the pulse field gel or it is possible that 
the Ncil site was introduced as a Taq polym erase mutation during the RT-PCR. One 
solution for this problem  w ould be to design an HSD3B\|/5 exon 4 specific probe, if 
more exon 4 sequence could be acquired, and it could be used to determ ine which Xhol 
fragm ent contains HSD3Bi|/5 exon 4 sequence.
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HSD3B\|/5 acagGTACCCAGCTTCTGTTGGAGGCCTGTGTCCAAGCTACAGTGC*I I M I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
HSD3BV|/4 acagGTACCCAGCTTCTGTTGGAGGCCTGTGTCCAAGCTACAGTGCi
Ncil
HSD3BY5 CTTCATCTACACCAGTACCCCAGAGGl l l l l l l l l l l l l l l l l l l l l l l l l
HSD3BV1/4 CTTCATCTACACCAGTACCCCAGAGG
FAGCC
rAGCC
3GGCCC
\GGCCC
D
50kb— 
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3kb—
Ikb—
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Probe; Exon 4
Fig. 4.19 A: PFGE of Xhol restriction digests o f BACs 21 and 31 hybridised with conserved exon 2, 
conserved exon 4, T7 and Sp6 oligonucleotides.
B: Xhol restriction map showing possible orientation o f HSD3Bi|/5.
C: 5' exon 4 sequence for HSD3B\|/4 and HSD3B\jt5 indicating the N cil site present in 
HSD3B\j/5. Intronic sequence in lower case.
D: Agarose gel showing BACS 31 and 21 digested with Xhol and N cil, probed with 
conserved exon 4 oligonucleotide. Lanel - Xhol; lane2 - Xhol/Ncil
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4.2.8 Investigating the human genome further for 3B-HSD sequences 
using human-mouse somatic cell hybrids
The availability of a panel of human-mouse and human-rat somatic cell hybrids 
overlapping the entire human genome except chromosome 1, provided an opportunity 
to determine if there were 36-HSD sequences outwith chromosome 1 (appendix iii). 
PCR primers were designed to amplify all identified human 36-HSD genes but not the 
mouse or rat HSD3B genes (the sequence of these oligonucleotides can be found in 
section 2.6.2). PCRs were attempted under stringent annealing conditions and one 
cell hybrid (H A H ) gave an amplification product of the expected size (850bp; Fig. 
4.20). HAH contains chromosomes 4, 5, 6, 8, 11, 20 and 21.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
l.Okb —
Fig. 4.20 Agarose gel indicating PCR amplification products obtained from a panel o f human-mouse 
somatic cell hybrids using primers specific to human 36-HSD. Lane 1 - H A l 1, lane 2 - 
H A 221, lane 3 - HA232, lane 4 - HB29, lane 5 - HB33, lane 6 - HB35, lane 7 - H B l l l ,  
lane 8 - HB 142.2, lane 9 - H B 181, lane 10 - JVOl, lane 11 - HR40C8, lane 12 - rat 
genomic DNA control, lane 13 - mouse genomic DNA control, lane 14 - human genomic 
DNA control, lane 15 - no template -ve control.
The product obtained from H A H  was cloned into T-vector, recombinants were 
screened for inserts by PCR and positive clones were sequenced. From 9 sequences 
obtained, 5 were HSD3B\|/4, 1 was HSD3B\)/2, 2 were HSD3B1 and the last was 
HSD3B\j/l. This suggests that HAH is contaminated with at least chromosome Ip 13 
and the above data indicates that no other 36-HSD sequences exist outwith 
chromosome 1.
4.2.9 Attempts to orientate the 36-HSD genomic contig with respect to 
the centromere.
To attempt to orientate the 36-HSD gene cluster with respect to the centromere on 
human chromosome 1, the genetic markers D1S514 and D1S534 were utilised. 
Microsatellite marker D1S514, also known as AFMal51za5 (Genome database (GDB) 
accession identification GDB:2(X)157) is a single copy CA dinucleotide repeat sequence
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located 177cM from the end of the short arm of chromosome 1 at position lpl3.1. The 
microsatellite marker D1S534, or CHLC.GATA12A07.778 (GDB:686478) is a single 
copy GATA tetranucleotide repeat sequence, centromeiic to D1S514. Both D1S514 
and D1S534 micosatellite markers are closely linked to the 36-HSD gene family, 
therefore PCR primers pairs designed to each marker were used to screen the genomic 
clones from the 36-HSD contig. It was envisaged that one of the markers may be 
identified on a genomic clone allowing the orientation with respect to the centromere to 
be determined. Unfortunately, no PCR amplification products were obtained for 
either of the markers with any of the genomic clones, therefore, the orientation of the 
36-HSD gene family with respect to the centromere was not obtained from these 
experiments. It is possible that fluorescent in situ hybridisation (FISH) analysis using 
probes to HSD3B2 and HSD3Bi|/5 (HSD3B genes situated at either end of the cluster) 
may provide the anwser to this orientation question.
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CHAPTER 5 
Hybrid selection
5.1 INTRODUCTION
By establishing the genomic contig for the 3B-HSD gene family it was now possible to 
ask the following questions; what other genes (if any) can be localised to this region 
and are these genes unidentified members of the 3B-HSD gene family? Within this 
chapter, I will briefly describe the methods developed to identify transcribed sequences 
from particular genomic regions and discuss why I chose to use hybrid selection. I 
will then present my results from the selection experiments.
One of the earliest techniques devised to identify coding regions within a genomic clone 
was cross-species hybridisation or “zoo blots”. This was based on the observation 
that coding sequences would be much more conserved between species compared to 
non-coding sequences. This analysis involved hybridising a genomic clone to DNAs 
from a variety of species; generally coding sequences would hybridise at higher 
stringency with the genomic DNAs than non-coding sequences. The distinct 
disadvantage of this method is that it will not detect genes that have diverged 
significantly between species. However, this technique was used successfully in the 
identification of the dystrophin gene involved in X-linked Duchenne Muscular 
Dystrophy (Monaco e ta l ,  1986).
Another early technique used to identify genes was to use specific detection of human 
repetitive elements such as Alu repeats from somatic cell hybrids containing a particular 
chromosome. Approximately 10% of human mRNAs have human specific, highly 
repeated sequences in their 3' non-coding region. In 1986, a cDNA library constructed 
from a somatic cell hybrid containing only human chromosome 21 was screened for 
Alu repeats by Neve et aL (1986). However from this screen only 3 clones from a 
library of ~1 million were identified. A limitation of this type of screen is that it 
identifies only genes expressed in the hybrid cell, and genes that have repeats in their 3' 
untranslated regions. A recent modification of this strategy is to use unspliced, 
heterogeneous nuclear RNA (hnRNA) isolated from the hybrid cells. This removes the 
requirement of repeat elements in the mature RNA; intron sequences are more likely to 
contain repeats. This method depends on the half-life of the intermediates, the presence 
of repeats in the introns and the proximity of the introns to exon sequences.
Some mammalian genes have been isolated by selection for CpG islands. In the 
mammalian genome cytosines in the CpG dinucleotide are highly methylated. 
However, a small fraction contain unmethylated cytosines, and these have been shown 
to occur as discrete "CpG islands" (Larsen et aL, 1992). These CpG islands have 
been associated with expressed sequences, as CpG méthylation often inhibits
108
transcription, and can be detected by cleavage with rare cutting restriction enzymes. 
Hpall is sensitive to méthylation and only cuts CpG doublets that are unmethylated; the 
fragments obtained are known as Hpall tiny fragments. By looking for these, large 
stretches of DNA can be checked for the presence of CpG island clusters. A 
disadvantage of this technique is that the region involved must be analysed by pulse 
field gel electrophoresis (PFGE), the DNA fragments have then to be cloned and 
examined for transcribed sequences, and cDNA clones representing these sequences 
have to be isolated.
Northern blot analysis is another method that can be used to detect expressed sequences 
contained within a genomic clone. The genomic clone can be used as a probe to screen 
RNA derived from different tissues. A major disadvantage of this technique is that 
YACs are too complex to reliably identify transcripts. Phage and cosmids have 
successsfully detected transcripts, so Y AC clones could be subcloned and the 
subclones used as probes. However, subcloning and subsequent testing of every 
subclone for hybridisation is quite labour intensive. Another disadvantage is that the 
transcript must be present in the tissue that the RNA has been derived from to be able to 
detect it at all.
Screening cDNA libraries using genomic clones as a probe is a technique commonly 
used to identify new genes. YACs, BACs, PI clones, phage and cosmid clones can 
all be directly labelled and used to screen a cDNA library. Using this method multiple 
transcripts can be identified from a single screen, but there are a number of distinct 
disadvantages. DNA from the genomic clone of interest must be isolated in sufficient 
quantity and purity to be used for labelling, and this can be difficult especially with 
Y AC clones. The probe involved will be complex and will contain a large number of 
repetitive sequences, which could lead to weak signals, increased background and false 
positives. The problems can be alleviated to a certain extent by pre-hybridising the 
probe to COT 1 DNA or sheared human DNA to block the repetitive sequences. 
Clones that contain short exons or clones that are poorly represented in the library may 
be missed altogether. It is unlikely that a conventional cDNA library of ~1 million 
clones will adequately represent all the transcripts expressed in the tissue since it will 
probably not contain the lower abundance transcripts (Morgan et al., 1992), although 
using a normalised cDNA library (by reassociating the abundant cDNAs and removing 
them) would help to overcome this problem (Patanjali et a l ,  1991). Another problem 
associated with screening a cDNA library is that, as in northern analysis, the gene in 
question must be expressed in the tissue from which the library is made. More than 
one library could be screened, but that makes this type of experiment extremely labour 
intensive, especially when more than one probe is involved. PCR pre-screens have
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been used to identify the library with the greatest potential of yielding positive cDNAs 
with a particular probe, and probe-pooling may be adopted (Harshman et aL, 1995). 
Primers are designed for each probe, and PCR amplification is attempted for each 
library. Probes that give a faint product or no product can be pooled, i.e. probes are 
grouped according to their relative representation in the different libraries avoiding 
problems of pooling well-represented probes. This experiment will also identify which 
probes give strong signals with a certain library, allowing preferential screening to be 
undertaken. Although there are certain disadvantages of library screening it will still 
detect genes with cryptic splice sites, genes that lack CpG islands, genes that are not 
transcribed in somatic cell hybrids, and genes that have highly diverged between 
species, all of which may be missed by other reported methods for finding expressed 
sequences.
A stategy was devised by Duyk et al. (1990), and further developed by Buckler et al. 
(1991) that involves the identification of exons from random pieces of genomic DNA, 
this is known as exon trapping. The stategy is based upon RNA sequences containing 
functional splice sites. The genomic DNA is “shotgun” cloned into a vector that 
contains functional splice donor and acceptor sites. The clones are then propagated in 
E.coli and transfected into COS cells. When the cloned DNA contains an exon, 
splicing ocurrs between the vector and the genomic DNA. RNA is then isolated from 
the cells, and cDNA is synthesised and amplified using primers to the splicing vector. 
A unique DNA fragment is obtained where correct splicing has occured (see Figure 
5,1). Theoretically this procedure should identify all internal exons from a region of 
interest and has been applied with great results (Chen et al., 1996). Flowever it is 
technically complex, and as it simply requires the presence of splice donor and acceptor 
sites, false positives can be encountered.
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SV40 __>Bgal 5’ ss Cloning site 3 ’ ss Bgal
    ~ i       pS P L i
] Genomic fragment containing exon
i
Transfection into COS cellsi
Cytoplasmic RNA isolationi
Ia AAAAA cDNA  synthesis (RT) 
PCR amplification 
PCR amplified product containing introduced exon
i
i
Clone and sequence
Figure 5.1. Exon Trapping. Genomic fragments are cloned into a pSPLl plasmid and transfected into 
cos cells. An exon present in the genomic fragment in the proper orientation will be spliced into the 
mature RNA and will be present in the amplified product flanked by known sequence (Modified from 
Buckler et aL, 1991).
Recently, direct cDNA selection or “hybrid selection” techniques have been devised. 
These methods employ the sensitivity of PCR, with specific selection of cDNAs by 
hybridisation to large genomic regions. The first strategy was developed by (Lovett et 
aL, 1991). The basis of this was the hybridisation of an entire cDNA library to an 
immobilised genomic clone. Y AC DNA was isolated by excision from a contour- 
clamped homogeneous electric field gel, digested with Mbol and immobilised onto 
nylon filter discs. cDNA inserts were amplified from a oligo d(T)-primed fetal kidney 
library using primers designed to the library vector. The amplified inserts were 
preblocked with sheared total human DNA, pBR322 DNA and yeast DNA. This 
reduced non-specific hybridisation of repetitive elements, vector sequences and yeast 
sequences. The blocked cDNA was then hybridised in solution with the filter
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containing the genomic Y AC DNA. Non-specific hybrids were removed, and selected 
cDNAs were eluted, which were amplified using the primers used to amplify the cDNA 
at the onset, and either cloned into a phage vector or subjected to further selection (see 
Figure 5.2). Parimoo et al.{l99ï)  developed a similar technique. Their method 
differed only in that to prevent nonspecific hybidisation the immobilised genomic clone 
was blocked rather than the cDNA, and they used a highly complex competitive DNA 
mixture including a human chromosome 15 library, a genomic repetitive sequence 
library, rRNA-specific clones, Poly(dI)-poly(dC), and yeast DNA. Also, a set of 
nested primers was used to amplify and reamplify the eluted cDNA to reduce the chance 
of PCR artefacts.
Purified YAC
i  OImmobilised on filterim-
d  um ------------- ^  HybridiseiAmpiifiable cDNA population
(blocked for repeats) Remove non-specific cDNA by washing
[=3--------cm
Elute specific DNAs c m  c m
▼
PCR and clone
Figure 5.2. Direct selection with genomic clone immobilised onto nylon filter. (Modified from 
Lovett et a i ,  1991)
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More recent methods maintain both hybridisation partners in solution which allows 
better control of the hybridisation conditions compared to filter hybridisation (Korn et 
a l,  1992, Morgan et a l ,  1992). Morgan et a l  (1992) used this method to isolate novel 
cDNAs encoded by the regions suiTOunding the human IL-4 and IL-5 genes. Double 
stranded cDNA was digested with Mbol and ligated to a linker/adaptor oligonucleotide. 
YAC DNA was also digested with M bol and ligated to a second oligonucleotide 
linker/adaptor. The YAC DNA and the cDNA were then sepai*ately amplified by PCR. 
A 5' biotinylated primer was used for the YAC amplification. Cotl DNA was used as a 
blocking agent by mixing with the starting cDNA (Cotl DNA is highly enriched in 
intermediate repeats and does not increase the overall sequence complexity of the 
mixture compared to total genomic DNA). Blocked cDNA was then hybridised in 
solution with the biotinylated YAC DNA. YAC DNA plus bound cDNAs were 
captured by streptavidin coated magnetic beads, and the beads were removed from the 
solution using a magnet. Selected cDNAs were eluted from the beads, amplified and 
either cloned or subjected to another round of enrichment (see figure 5.3).
cDNA digested and ligated to 
linker I, pre-blocked with 
COT-1 DNA
C3- —CZI 
C D -
Digested YAC DNA ligated to linker II 
BEZ] e z ib
-CD
-CD
Btsa EZ3b\  /
Hybridise in solutionI
Capture YAC and 
cDNA hybrids on 
Streptavidin beads
bH z z z H q
Recycle
Elute cDNAs
I
Evaluate
Figure 5.3. A biotin/streptavidin capture system for direct selection. (Modified from Morgan et al. 
1992)
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Rattier et al. (1995) made a few more modifications to this procedure and used PI 
clones, BACs and cosmids as genomic probes, rather than YACs. After digestion, the 
clones were treated with exonuclease III to minimise competitive renaturation of the 
probe during hybridisation. Also, the genomic clone preparation did not require 
amplification, as differences in amplication may bias representation of the clone 
sequences. Finally, cDNA synthesis involved two separate primers for first and 
second strand synthesis, which improves cloning efficiency and allows some PCR 
artefacts to be easily identified.
There are several advantages of hybrid selection. First, it is rapidly accomplished. 
Second, this method tends to normalise the frequency of the transcripts encoded by the 
genomic clone (especially when it is supplied in limiting amounts) and it has greater 
enrichment factors for rare transcripts than abundant ones. The abundant cDNAs will 
quickly saturate their genomic target, leaving the majority of cDNAs in solution. Thus 
the net result should be an approximate normalisation of the abundant cDNAs 
downwards and the low abundance transcripts upwards. Since the isolation of rare 
cDNAs is as important as the isolation of abundant ones, enrichment of these is a great 
advantage of this technique over screening conventional libraries which may not even 
contain these transcripts. Third, it is more robust than screening with labelled probes 
and it has a much higher signal to noise ratio mainly because it is easier to quench 
sequences by blocking to prevent nonspecific hybridisation. Fourth, it is less sensitive 
to the size of the clone used for selection. Cosmid, BAG or PI DNA is more 
favourable than YAC DNA because it is less prone to deletions and chimerism and is 
readily sepai'able from E.coli DNA, whereas the presence of degraded yeast DNA from 
higher molecular weight yeast chromosomes, especially ribosomal sequences, can 
cause contamination problems. These sequences show strong homology to human 
ribosomal RNA sequence, and so many enriched cDNAs may be of ribosomal origin 
and not from the region of interest. This problem can be overcome either by screening 
the enriched sublibrary with a ribosomal probe to identify ribosomal DNA containing 
clones, or pre-blocking the YAC DNA with total yeast DNA (as above), or by cutting 
the yeast genomic DNA prior to isolation of the YAC. By employing one of these 
methods, the selection efficiency of YAC clones compared to cosmid clones is only 2- 
fold in favour of the cosmids (Korn et a l,  1992). Eventually all genomic sources will 
result in an enrichment of the cDNAs encoded by the insert.
There are a few limitations with hybrid selection. The first is that it does not usually 
retrieve complete coding sequences for genes; rather, it provides a route to finding 
expressed sequence tags (ESTs) which can be used as probes to isolate the gene. 
Thus, screening a library is probably a second step in the process. However, it is
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preferable to screening a library directly as abundance normalisation permits rarer 
ti'anscripts to be found more easily. The second potential problem is the co-selection of 
pseudogenes which select cDNAs which belong to genes located somewhere else in the 
genome. This can be sorted by sequencing the cDNA and the corresponding genomic 
fragment, or using the products of exon-trapping as probes to discriminate against 
processed pseudogenes (Korn et al., 1992). Thirdly, it is limited when the 
transcription pattern of the gene of interest is unknown. cDNA from many different 
tissues or developmental stages may have to be tested. However it is possible to test 
the cDNA from more than one tissue at a time by ligating on different oligonucleotide 
linker/adapters and using specific primers for PCR amplification of selected cDNAs 
from the different tissues (Lovett et a l ,  1991).
5.2 METHODS AND RESULTS
The purpose of this chapter was to explore the genomic contig generated in Chapter 4 
for unknown expressed sequences. To do this, hybrid selection was applied to attempt 
to isolate expressed sequences from a cDNA library using biotinylated genomic clones.
5.2.1 Preparing the cDNA
The chances of a successful experiment are dramatically increased by creating the best 
source of cDNA. Any source of cDNA can be used in this experiment as long as it can 
be amplified by PCR. Oligo (dT) primed libraries, normalised libraries, Mbol digested 
oligo (dT) primed cDNA and a combination of oligo (dT) and random primed libraries 
have all been used. Different groups have treated the starting cDNA differently, for 
example, Lovett et a l . {1991) amplified inserts from an oligo (dT)-primed fetal kidney 
cDNA library whereas Morgan et al. (1992) digested oligo (dT) with Mbol and ligated 
linker oligonucleotides. Using cDNA inserts that have been amplified from the vector 
results in bias against large cDNAs if the original was full length rather than random 
primed. Digesting the cDNA with a restriction enzyme fragments the full length 
cDNAs into smaller fragments and removes an intermediate cloning site and possible 
loss of some transcripts. However, by digesting the cDNA it probably would not be 
possible to determine how many individual transcription units the enriched cDNAs are 
derived from. An additional step to convert each fragment to a full length would be 
necessary, either by returning to the full length starting cDNA or using random primed 
cDNA as the starting material which would retain some overlap between clones after 
selection. One other problem with fragmenting the cDNA would be the loss of genes
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because of the lack of internal restriction sites. Therefore using noiTnalised libraries or 
random-primed libraries would eliminate these problems. However, the quality of a 
cDNA sub-library created from the enriched cDNAs depends on the size of the inserts. 
It is advantageous to work with clones that are as long as possible as these would carry 
more information and be easier to group into genes.
The first decision in making the cDNA hbrary was to identify the tissue of origin of the 
mRNA. In this case, the placenta was selected as it is a major steroidogenic tissue and 
it is a complex tissue which expresses a huge variety of genes. It was also available 
within seconds of delivery which is a feature that applies to few human tissues except 
cultured cells. In addition, the placenta expresses large amounts of 3B-HSD type I and 
therefore would make the ideal control for the selection experiments using the genomic 
clones isolated in Chapter 4. It was expected that the 3B-HSD transcripts within the 
cDNA population would be enriched by the selection process.
Total RNA was isolated from normal full-term placenta (obtained from the Queen 
Mother's Maternity Hospital, Glasgow) using Tri-reagent (Sigma). Poly (A)+ mRNA 
was isolated using the FastTrack mRNA isolation kit (InVitrogen) and the InVitrogen 
Copy kit was utilised to synthesise double-stranded, blunt-ended cDNA. All of the 
above were used exactly according to the manufacturers recommendations. The cDNA 
was synthesised using a 1:1 ratio of oligo dT and random primer. This would produce 
a mixture of full-length and random primed cDNAs. The oligo dT clones may provide 
more infoimation and the random primed clones may produce overlaps and result in 
more than just 3' untranslated sequence. However, it is possible that some genomic 
contamination may be introduced using the random primers. The cDNA synthesised 
was tested by PCR using primers designed to 3B-HSD type I (type I and D; section 
2.6.2) and glyceraldehyde phosphate dehydrogenase (GAPDH). 3B-HSD type I 
transcripts are abundant in the placenta, and GAPDH is a housekeeping gene expressed 
in every tissue. Both sets of primers resulted in a strong signal from the cDNA 
produced (Fig. 5.4A).
Next, the cDNA was either digested with Alul or ligated to the linkers immediately. 
This resulted in two cDNA populations. One contained short fragments and eliminated 
the bias against longer full-length cDNAs in the PCRs, and the other produced longer 
clones that may contain more information. The linker used was designed by Dr. Gen'y 
Graham from the CRC Beatson Laboratories, Glasgow. The sequences of the 
oligonucleotides used to produce the linkers were:
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A: 5' TAG TCC GAA TTC AAG CAA GAG CAC A 3'
B: 5' CTC TTG CTT GAA TTC GGA CTA 3'
These oligonucleotides produced a linker with sticky overhangs to prevent self­
annealing. Their sequence did not result in hairpin loops and the linker contained an 
EcoRI site to facilitate subsequent subcloning. The oligonucleotides were synthesised 
and chemically phosphorylated by Gibco-BRL. The linker was generated by mixing 
equal amounts of A and B, heating to 70 °C and then allowing the oligonucleotides to 
anneal gently to one another as the solution slowly returned to room temperature, this 
produced duplex kinase linkers. The linkers were then ligated to the undigested or 
digested cDNA (with an excess concentration of linkers in the solution) using blunt- 
ended ligation buffer to increase the efficiency (0.66 M Tris-Cl, pH 7.6, 50 mM 
MgC12, 50 mM DTT, 1 mg/ml BSA, 10 mM hexaminocobalt chloride, 5mM 
speimidine-HCl) and the ligation solution was incubated at 16°C overnight.
The unincorporated linkers were separated from the linker ligated cDNA by gel 
electrophoresis using low melting point agarose. The linker ligated cDNA was excised 
from the gel (Fig. 5.4B) and the gel slice was used directly as the template in PCR. 
The shortest oligonucleotide (B) was used as the PCR primer (Fig. 5.4C). The excess 
primer and nucleotides were removed from the amplification product using a Microcon 
30 column (Amicon) and this PCR amplified linkered cDNA was used as the starting 
material for hybrid selection.
The linkered undigested cDNA was used as the starting material because, as expected, 
it produced longer amplification products (smear ranged from 150 to 500bp compared 
to 150 to 300bp with Alul-digested cDNA) and, because the range was less than Ikb, 
concern about biased amplification of long transcripts was unnecessary.
B
1 2  3 4
l.Okb —  ^
500bp—
Linkered cD N A [
Unincorporated [  
linkers
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Fig. 5.4 A; Agarose gel indicating PCR amplification products obtained from double-stranded, blunt- 
ended cDNA (Lane 1 - 36-HSD type I primers, lane 2 - 3B-HSD type I primers, no 
template control, lane 3 - GAPDH primers, lane 4 - GAPDH primers, no template 
control).
B: Linkered cDNA electrophoresed to remove unincorporated linkers. White box indicates 
the area o f the gel slice excised containing the linkered cDNA.
C: Agarose gel indicating PCR amplification o f Alul digested linkered cDN A  and undigested 
linkered cDNA. Oligonucleotide B used as PCR primer; duplicate PCRs shown on each 
gel.
5.2.2 Preparing the genomic clone
The major advantage of using biotinylated genomic DNA and streptavidin magnetic 
beads is that both hybridisation partners are in solution, and this allows better control of 
the hybridisation kinetics compared to filter hybridisation as mentioned above. Also the 
magnetic beads (Dynabeads M-280, Dynal) used by Korn et al. (1992) and Morgan et 
al. (1994) are monodispersed and thus follow uniform kinetics when subjected to a 
magnetic field. Different solid supports have been tested for capturing the biotinylated 
genomic DNA including avidin-agarose, streptavidin-agarose and biotin cellulose but 
magnetic beads coated with streptavidin showed less non-specific binding of nucleic 
acids (Korn et a i ,  1992)
There are different ways that biotin molecules can be introduced into genomic clones: 
random priming, photobiotinylation, nick translation or PCR amplification of the 
genomic clone using biotinylated primers. Nick translation has the advantage that the 
amount of product equals the amount of starting material and it fragments the genomic 
clone ready for hybridisation. Also, an even incorporation of biotin molecules is more 
desirable for optimum binding efficiency.
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The genomic clone used in the first selection experiments was BAC 21. This is a large 
BAC clone (235kb), present at the left side of the cluster, containing only three 36- 
HSD genes and a lot of gaps which may contain something unexpected (see section 
4.2.6). BAC 21 DNA was nick-translated using the nick translation kit from Gibco- 
BRL using a mixture of 0.18mM dTTP and 0.02mM B iol6dU TP (Boehringer 
Mannheim). One quarter of the reaction mix was electrophoresed on an 1% agarose 
gel, and a faint smear within the appropriate range (500bp to 2kb) was observed (Fig. 
5.5). The remaining reaction mix was ethanol precipitated to remove unincorporated 
biotin molecules, and resuspended in sterile water.
It is interesting to note that although nick translation was the best protocol to use for 
BAC clones (BAC DNA is easy to isolate in large quantities), if YAC clones were used 
it would be preferable to digest the YAC DNA, ligate linkers onto the ends and PCR 
amplify using a biotinylated primer. This method has the advantage of starting from 
limited amount of DNA, although it may create a bias against longer fragments.
BAC 21
2.0kb — ^
500bp —
Fig. 5.5 Gel electrophoresis o f biotinylated BAC 21 nick translation products. A faint smear can be 
observed between 2kb and 500bp.
5.2.3 Hybridisation
Before hybridisation, the cDNA was pre-blocked with Cot 1 DNA to reduce the 
chances of selecting repeated sequence. Equal amounts of PCR-amplified cDNA and 
COT 1 DNA were mixed, heated to 95°C and incubated with hybridisation buffer (final 
concentration - 0.75 mM sodium chloride, 20 mM sodium phosphate (pH 7.4), 5 mM 
EDTA, 5xDenhardt's solution, 0.6% SDS) for 4 hours at 65°C. The blocked cDNA 
was mixed 20:1 with the denatured biotinylated BAC and hybridisation buffer at 65°C 
for approximately 65 hours.
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After 65 hours, the hybrids generated were isolated by Dynal streptavidin magnetic 
beads. This procedure was followed exactly as recommended by Dynal. Briefly, the 
hybridisation mix was incubated with the beads at room temperature for 15 minutes, the 
beads were subjected to 2 washes of IxSSC, 1% SDS at room temperature and then a 
further 3 washes using IxSSC, 0.1% SDS at 65°C. The cDNA was eluted using 
sodium hydroxide, neutralised by Tris and finally desalted using a Microcon 30 column 
(Amicon), then resuspended in sterile water.
The eluted cDNA was PCR-amplified using oligonucleotide B as PCR primer (Fig. 
5.6A). The first round of selected amplified cDNA was purified by a Microcon 
column as above, then re-blocked with Cot 1 DNA and subjected to another cycle of 
selection with biotinylated BAC 21, exactly as before. The eluted cDNA from the 
second round of selection was also PCR-amplified, and this time distinct bands were 
beginning to emerge within the PCR products (Fig. 5.6B).
1st 1st St. -ve B
l.Okb—
300bp —
2nd 1st St. -ve
1 .Okb —
300bp —
Fig. 5.6 A: Agarose gel indicating PCR amplification o f eluted cD N A  from first round of selection.
Oligonucleotide B was used as the primer. St. indicates starting cD N A  population and 
-ve indicates no template PCR control.
B: Agarose gel indicating PCR amplification o f eluted cDN A  from second round of 
selection. Oligonucleotide B was used as the primer. St. indicates starting cDNA  
population and -ve indicates no template PCR control.
5.2.4 Analysis of eluted cDNA
The amplified cDNA eluted from the second round of selection was cloned into T- 
vector. The resulting subclones were examined for inserts by single-colony PCR (Fig. 
5.7A). Clones were selected for sequencing by hybridising the single colony PCR 
products to a 36-HSD cDNA probe, a Cotl probe and a BAC 21 hybridisation probe 
(Fig. 5.7 B,C and D). Clones that were negative for 36-HSD and Cotl but positive 
for BAC 21 were deemed "interesting" and were therefore sequenced. Some 36-HSD
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clones were sequenced to confirm their sequence and also to check for unknown 
sequences. Sequencing data are discussed in section 5.2.6.
1 6kb —
8 1 7 9 2
1 .okb —
BAC 21 selected clones
B
1.6kb — I #
8 1 7 9 2
1.6kb
BAC 21 probe
D
1.6kb —
1.6kb —
8 1 7 9 2
I 4
###
I 6kb —
8 1 7 9 2* * * * *
36-HSD cDNA probe Cot-1 probe
Fig. 5.7 A: Agarose gel o f single colony PCR products from the BAC 21 subclones, generated from 
PCR-amplified second round o f selection DNA. This selected for BAC 21 subclones 
with inserts. Primer used was oligonucleotide B (section 5.2.1).
B: Southern analysis o f BAC 21 selected cDNA clones (panel A) hybridised with BAC 21 
probe
C: Southern analysis o f BAC 21 selected cDNA clones (panel A) hybridised with 3B-HSD 
cDN A  probe
D: Southern analysis o f BAC 21 selected cDN A  clones (panel A) hybridised with Cot-1 
DNA probe
* represents the clones that were sequenced.
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The eluted cDNA was investigated for enrichment of 36-HSD sequences and loss of 
non-specific transcripts by PCR using 36-HSD specific primers and GAPDH primers. 
It was expected that the 36-HSD signal would increase and the GAPDH signal would 
decrease in the first and second rounds of selection, and this is what was observed 
(Fig. 5.8). The starting cDNA population resulted in 2 products from the 36-HSD 
specific primers, one at 400bp and the other at 270bp (Fig. 5.SA). These represent the 
genomic and the cDNA copy of 36-HSD respectively. The primer pair used (type I 
specific and D; section 2.6.2) span across intron I which is present in the 400bp 
genomic product but absent in the 270bp cDNA product. This could suggest genomic 
contamination in the cDNA library, or it may be due to RNA transcripts which have not 
been spliced correctly. This is likely to be due to the high nucleusxytoplasm ratio 
found in the placenta. The 400bp genomic product disappears in the eluted cDNA 
from the first and second round of selection. Only the 270bp cDNA product is 
observed; the reason for this is unknown.
A control experiment was undertaken in which the genomic clone was nick translated as 
described, but without the addition of biotinylated dUTP. The hybrids created in this 
experiment should not bind to the magnetic beads; however, an amplification product 
was observed from the eluted material using oligonucleotide B as primer (Fig. 5.SC). 
This eluate did not amplify with the 36-HSD specific primers (Fig. 5.8A), and 
therefore the amplification products observed in Fig. 5.8C probably represent non­
specific binding of DNA to the magnetic beads. This was supported by a positive 
amplification using the GAPDH primers, similar to the starting cDNA. No GAPDH 
product was observed from either of the selected cDNAs (Fig. 5.SB).
A - 36-HSD specific primers
St. 1st Con. 2nd -ve
1 .Okb —
500bp —  
300bp—
B - GAPDH specific primers 
St. 1st Con. 2nd -ve
l.Okb —
500bp—
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Con. St. -ve
Ikb —
500bp —
Fig. 5.8 A: Agarose gel showing PCR amplification o f cDNA populations using 3B-HSD specific 
primers
B: Agarose gel showing PCR amplification o f cDNA populations using GAP-DH specific 
primers
C: Agarose gel showing PCR amplification o f control experiment with no biotinlyated 
dUTP in the nick translation reaction mix. Oligonucleotide B used as primer,
(St. - starting cDNA, 1st - cD N A  eluted from 1st round o f selection, Con - cDN A  eluted 
from control experiment, 2nd - cDNA eluted from 2nd round of selection, -ve - no 
template control)
These data indicate that the 36-HSD transcripts (specific) were enriched after the first 
and second round of selections and that the GAPDH transcripts (non-specific) were lost 
after selection by BAC 21. This is what we would expect, and it provides an initial 
indication that the hybrid selection experiments have worked.
5.2.5 Further experiments
The hybrid selection protocol was repeated for BAC clones 7 and 30 allowing the entire 
36-HSD cluster from the BAC contig to be investigated. The placental cDNA library 
was used as starting material and the procedure was repeated exactly as described for 
BAC 21. BAC 7 and BAC 30 DNA was biotinylated as before (Fig. 5.9A), first and 
second rounds of selection were undertaken and the second round of amplified eluted 
cDNA was cloned into T-vector (Fig. 5.9B). Single colony PCRs indicated subclones 
with inserts, and these were screened with the specific BAC clone hybridisation probe 
and the 36-HSD cDNA probe (Figs. 5.10 and 5.11). Again, clones negative for 36- 
HSD and positive for BAC clone 7 or 30 were sequenced. The sequence data are 
discussed in section 5.2.6.
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One further experiment was carried out as a control to analyse the enrichment of 36- 
HSD transcripts from these selection experiments. Using O.D. estimates of DNA 
concentration, equal amounts of starting cDNA, first cycle of selection cDNA and 
second cycle of selection cDNA were applied in triplicate to a slot blot and hybridised 
with 36-HSD type I cDNA (Fig. 5.12). These clearly showed that 36-HSD 
transcripts were enriched in the first round compared to the starting cDNA, and even 
more after the second round of selection. The same slot blots were re-probed with a 
GAPDH hybridisation probe to illustrate a decreased signal corresponding to selection; 
however the amount of DNA in the slot blots was too low to detect any signals. This 
is similar to the situation observed with the starting cDNA hybridised with 36-HSD 
cDNA. However, the subsequent enrichment of 36-HSD transcripts is clear and 
provides an indication that the selection process has been successful.
7 30
3.0kb—
1 .Okb —
500bp —
B
3.Okb —
30
2nd 1st 2nd 1st St. -ve
l.Okb —
500bp —
Fig. 5.9 A: Gel electrophoresis o f  biotinylated BAC 7 and 30 nick translation products. A faint 
smear can be observed between 2kb and 500bp.
B: Agarose gel o f PCR amplified 1st and 2nd round eluted cD N A  for BACs 7 and 30 (St. - 
starting cDNA, -ve - no template control)
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1.6kb —
11 12
1 .okb —
BAC 7 selected clones
B
1.6kb —
1.6kb —
11 12
l é jÊÊm.44
13 10 14
BAC 7 probe
11 12
1 6kb —
13 10 14
1,6kb —
36-HSD cDNA probe
Fig. 5.10 A: Agarose gel showing single colony PCR amplification products from the BAC 7 
selected clones , generated from PCR-amplified second round o f selection cDNA. 
Primer used was oligonucleotide B.
B: BAC 7 selected clones (panel A) hybridised with BAC 7 probe 
C: BAC 7 selected clones (panel A) hybridised with 3B-HSD cD N A  probe 
* represents the clones that were sequenced.
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22 23 15
1.6kb
1 6kb —
BAC 30 selected clones
B
1.6kb —
22 23 15 ★ ★ ★ 16 24 17
19 20 21
1 6kb —
BAC 30 probe
18
4
1.6kb —
1,6kb —
22 23 15 16 24 17
19 20 21
Mil • # •  »
36-HSD cDNA probe
Fig. 5.11 A: Agarose gel o f single colony PCR amplification products from the BAC 30 selected 
clones, generated from PCR-amplified second round of selection cDNA. Primer used 
was oligonucleotide B.
B: BAC 30 T-vector selected clones hybridised with BAC 30 probe 
C: BAC 30 T-vector selected clones hybridised with 36-HSD cD N A  probe 
* represents the clones that were sequenced.
BAC 7 BAC 30
36-HSD cDNA probe 36-HSD cDNA probe
Fig. 5.12 Slot blot (in triplicate) o f equal amounts of the starting and the selected populations of 
cDNA hybridised with 36-HSD cDN A  probe (St. - starting cD N A , 1st - first round of 
selected cDNA, 2nd - second round o f selected cDNA).
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5.2.6 Sequencing d a ta  
BAC 21:
From the BAC 21 hybrid selection experiment, 38 T-vector subclones containing 
products from the second round of selection were analysed (Fig. 5.7). Of these, 9 
clones hybridised to the 36-HSD cDNA probe, 15 clones were positive for BAC 21 
and negative for 36-HSD cDNA (although some of these clones only produced a weak 
signal for BAC 21) and 1 clone contained COT-1 repeated sequences. Some of these 
clones were sequenced; these are marked * and numbered on Fig. 5.7. Clones 1-7 
were "unknown" (i.e. positive for BAC 21 but negative for 36-HSD and COT-1) and 
clones 8 and 9 were 36-HSD cDNA positive.
The sequence obtained from clone 8 was 36-HSD type I which was expected, however 
clone 9 contained 36-HSD type II sequence. Until now, it was believed that type I 
was the transcript expressed exclusively in the placenta (Labrie et a t ,  1991), however 
type II transcripts were detected at low concentrations from the placenta by RT-PCR 
(Sandra Burridge, personal communication). Therefore, these data have determined 
that although type 136-HSD is the major expressed isoform of 36-HSD in the placenta, 
type II transcripts are present and can be detected.
The sequence from clones 1 and 4 resulted in type I 36-HSD also. However, the 
sequence obtained was from intron II, which explains why these clones did not 
hybridise with the 36-HSD cDNA probe. These sequences may have arisen from 
genomic DNA contamination within the cDNA library or from unspliced RNA as 
discussed earlier. Sequence from clone 2 aligns precisely with exon 7 of IGF-II 
nucleotide sequence (Fig. 5.13A), sequence from clone 3 aligns with human 
mitochondrial DNA for loop attachment (Fig. 5.13B), and sequence from clone 5 is 
human placental lactogen hormone sequence (Fig. 5.13C).
A :
S e q . 2 7 9
I G F - I I 1 6 3 1
S e q . 2 1 2 9
I G F - I I 1 6 8 1
S e q .  2 1 7 9
I G F - I I 1 7 3 1
S e q .  2 2 2 9
I G F - I I 1 7 8 1
 ACACACGCATGCACAGCACACATGAACACAGCACACACAAACACACAGCA 1 2 8111 Util 11 Mill 11 Mill 11 Mill 11 Mill 11 Mill 11 U
I I
  CACCTGCACACACACATGCGCACACACACGCAC 1 8 1 3
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B:
S e q .  3  
M i t o .  
S e q .  3  
M i t o . 
S e q .  3  
M i t o .  
S e q ,  3  
M i t o .
2 7  TANCACGATTAACCCAAGTCAATAGAAGCCGGCGTAAAGAGTGTTTTAGA 7 6I  : M l l i l l l l l l l l l l j l l l l l l l l l l l M M M I I I M I i l l l M I I
3 2 7  TCACACGATTAACCCAAGTCAATAGAAGCCGGCGTAAAGAGTGTTTTAGA 3 7 6
7 7  TCACCCCCTCCCCAATAAAGCTAAAACTCACCTGAGTTGTAAAAAACTCC 1 2 6I l  11 U l l l l  11 H I  I I I  11 N I  I  I I  I  M i l l  I I  I  H I  I I 111 H I  I I I I
3 7 7  TCACCCCCTCGCCAATAAAGCTAAAACTCACCTGAGTTGTAAAAAACTCC 4 2 6
1 2 7  AGTTGACACAAAATAGACTACGAAAGTGGCTTTAACATATCTGAACACAC 1 7 6H I  I I 11 U l l l l  U l l l l  11I I I I I I
4 2 7  AGTTQACACAAAATAGACTACQAAAGTGGCTTTAACATATCTGAACACAC 4 7 6  
1 7 7  AATAGCTAAGACCCAAACTGGGATTAGATACCCCACTATGCTTAGC 2 2 2I I M i l l
4 7 7  AATAGCTAAGACCCAAACTGGGATTAGATACCCCACTATGCTTAGC 5 2 2
S e q . 5  1  AGCCGCCGGACTGGGCAGATCCTCAAGCAGACCTACAGCAAGTTTGACNC 5 011I I 11 U l l l l  I U l l l l  11 U l l l l  11 M l  I I 11 M i l  1111 U I I U
H P L  5 0 1  AGCCGCCGGACTGGGCAGATCCTCAAGCAGACCTACAGCAAGTTTGACAC 5 5 0
S e q . 5  5 1  AAACTCGCACAACCATGACGCACTGCTCAAGAACTACGGGCTGCTCTACT 1 0 0I  I I I  11 U l l l l  I M l  I I I  11 U l l l l  11 M l  II11 M i l  I I 11 M i l  I I
H P L  5 5 1  AAACTCGCACAACCATGACGCACTGCTCAAGAACTACGGG2TGCTCTACT 6 0 0
S e q . 5  1 0 1  GCTTCAGGAAGGACATGGACAAGGTCGAGACATTCCTGCGCATGGTGCAG 1 5 0I I  U  I I  U l l l l  I I  U I I U  I U l l l l  I  I  U l l l l  I  U l l l l  I  I U l l l l
H P L  6 0 1  GCTTCAGGAAGGACATGGACAAGGTCGAGACATTCCTGCGCATGGTGCAG 6 5 0
S e q . 5  1 5 1  TGCCGCTCTGTGGAGGGCA 1 6 9I I I  U l l l l  I  H I M  I M l
H P L  6 5 1  TGCCGCTCTGTGGAGGGCA 6 6 9
Fig. 5.13 A: A lignm ent o f clone 2 with exon 7 of IG F-II (G enbank no. - x07868).
B: A lignm ent o f  clone 3 with hum an m itochondrial D N A  for loop attachm ent sequence 
(G enbank no. - x62996).
C: A lignm ent o f clone 5 with hum an placental lactogen sequence (G enbank no. jO O llS).
These sequences probably arose from  non-specific binding to the Dynal Streptavidin 
m agnetic beads. W e know from  the control experim ent excluding biotin that some 
non-specific binding of DNA to the D ynal Streptavidin beads did occur (positive PCR 
am plification from  eluted cDNA, Fig. 5.8C) and IG F-II has been localised to human 
chrom osom e 11, m itochondrial D N A  is extra-chrom osom al and hum an placental 
lactogen (HPL) is present on chrom osom e 17. H ow ever, it is not necessarily  
surprising that H PL was selected, as H PL is the m ajor protein synthesised in term 
placental tissue. Seeburg et a/.(1977) estim ated that H PL m RNA constitutes 5% of 
poly (A)-h isolated from  the placenta .
It was formally possible that sequences related to IGF-II, mitochondrial DNA and HPL 
are present on BAC 21. However, this is quite unlikely as the signal of these clones 
for BAC 21 was quite w eak (Clones 2, 3 and 5 in Fig. 5.7B). To determ ine if this 
was the case, blots would have to be attem pted with larger probes from  these genes to
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BAC 21 to assess the presence of long stretches of homology. To prevent non­
specific binding of DNA to the magnetic beads, Dynal recommend treating the particles 
with 50 mM of sodium pyrophosphate, either alone or as a component in the binding 
and / or washing buffer. Therefore, for further experiments this may have to be 
included.
The sequence obtained from clones 6 and 7 did not match any identified sequences 
deposited into the databases. The sequence from clone 6 revealed that two cDNA 
fragments were cloned into T-Vector simultaneously since a perfect inverted repeat of 
linker sequence was identified within the sequence (Fig. 5.14). Bases 1-139 
represent one cDNA frgament (cDNA A) and bases 182-337 represent the other (cDNA 
B).
1 TCTATCCATC CCATCATCCC ATCCATCCAT CCTATCCATC CATCCCATCC 
5 1  ATCCTATCCA TCCCATCCAT CCATCCATTC ATCCCATCCA TCCCATCCAT
1 0 1  TCATCTATCC ATCCATCCTA TCCATCCCGT CCATTCATCT AGTCCGAATT
1 5 1  CAAGCAAGAG CTCTTGCTTG AATTCGGACT A5AGAGGCCC GCTGTTATGC
2 0 1  TNHNGCTCAC a g g c t c a c c c  t g a c a g t c c t  g g g g c t c c c c  c t c g t g g t t g
2 5 1  GTTTTAAGAA AGGGCGTGAC ATGGTGAGAC TAGTTTGGAG AGAACTCTGG
3 0 1  CAACACTGCT GAGGATAGGT TTCATGGGTG ACTCTCC
Fig. 5.14 Sequence obtained from subclone 6 using vector primer T7. Boxed sequence outlines
linker sequence. Bases 1-139 represents cDNA fragment A and bases 182-337 represents 
cDNA fragment B.
cDNA fragment A appears to be a repeated sequence, therefore, it is unlikely that this 
represents part of an expressed gene. However, additional sequence data would be 
necessary to confirm this. cDNA fragment B did not match anything in the nucleic 
acid databases, and before further analysis of this sequence can be undertaken, more 
sequence data will need to be obtained. Clone 7 sequence is indicated in Fig. 5.15 and 
similar to cDNA fragment B, additional sequence data is essential before further 
sequence analysis can take place.
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1 TTTAGACAGG ACTGGGTATT GGCACATAAT TCCCAAGCAC ACACTTTCTC
5 1  AAGCCAGAAA CCTGGATGGC AGCCCCCCAC TCCGCCCACC TATCATTCAG
1 0 1  CGCTACCAAC TTTACCTCCA CAACACCTCT TGAATGTGT
Fig. 5.15 Sequence obtained from subclone 7 using vector primer T7.
BAC 7:
For BAC 7, only one "unknown" clone was detected (negative for 36-HSD but positive 
for BAC 7) with 32 36-HSD clones from a total of 38 subclones analysed (Fig. 5.10). 
The "unknown" clone and only 4 36-HSD clones were sequenced, clones 10 and 11-14 
respectively.
Clone 10 contained 36-HSD type I intron sequence, similar to clones 1 and 4 from the 
BAC 21 selection experiment. Clones 11-14 all contained 36-HSD type I as expected. 
It was not unexpected that BAC 7 has selected only 36-HSD sequences. This BAC 
clone contains 4 36-HSD genes and part of HSD3Bt|/4 (section 4.2.7) and the 
restriction mapping for BAC 7 indicated that there were not many gaps in this clone 
where new sequences could be found.
BAC 30:
The BAC 30 hybrid selection experiments produced 12 "unknown" clones (negative for 
36-HSD and positive for BAC 30) and 19 36-HSD clones (Fig. 5.11). 7 "unknown"
clones were sequenced, clones 15-21, and 3 36-HSD clones, clones 22-24.
The 3 36-HSD clones sequenced, clones 22-24, contained 36-HSD type I sequence as 
expected, and clones 18, 19 and 21 contained 36-HSD type I intron sequence as 
described previously for clones 1 and 4. Clones 16 and 17 produced 36-HSD intron 
sequence also, but not from 36-HSD type I or type II. It is likely that these clones 
contain sequence that belongs to one of the identified pseudogenes, however it is 
impossible to identify which gene as the intron sequence for each of the pseudogenes is 
not known.
Clone 15 and clone 20 contained the same new sequence, which was not 36-HSD 
sequence and did not match any of the sequences in the nucleotide databases. Fig. 
5.16 presents this sequence and indicates the open reading frames present within the 
fragment. No significant open reading frames (ORF) can be detected, although the 
ORF in reading frame A contains 48 amino acids and ends only because the sequence
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data ends and not because of a stop codon. Similar to subclones 6 and 7 from the 
BAC 21 selection experiments, additional sequence data will have to be obtained before 
further analysis can be undertaken. This sequence is different from the sequence of 
either of the unidentified clones selected by BAC 21 (clone 6 or 7).
CCAAGCAAAACCCCAGGCATGACTCCTTTTCTCAGCTGCCCTTGGCAATCACATAATTTC
GGTTCGTTTTGGGGTCCGTACTGAGGAAAAGAGTCGACGGGAACCGTTAGTGTATTAAAG
a  P S K T P G M T P F L S C P  W Q S H N F
b  Q A K P Q A *
G K Q N P R H D S F S Q L P L A I T *
d  * S G K A I V Y N -
e  * M I  E -
f  L L V G P M
CATCCTCTCTGCCCCTGGTGGGAGGGGAGGAGCACACCTGGCCAGCCTCCAGCATGAATT
GTAGGAGAGACGGGGACCACCCTCCCCTCCTCGTGTGGACCGGTCGGAGGTCGTACTTAA
a  H P L C P W W E G R S T P G Q P P A *
b
c  M N  C -
d  G D E R G R T P P S S C V Q G A E L M
e  M
f
GGCTAGTGCTTGCTCCTCTGTCTCCCTATCACAGCTGCAAGTATCCTGTAGATTGTAGTT
CGGATCACGAACGAGGAGACAGAGGGATAGTGTCGACGTTCATAGGACATCTAACATCAA
a
b
c  L V L A P L S P Y H S C K Y P V D C S F -
d
e
f
TTCTGCTGCTAGACTGGTTTCTiAGGTCATCTCTGCTAACCCAAAGCACATTCCAATGGGT
AAGACGACGATCTGACCAAAGTTCCAGTAGAGACGATTGGGTTTCGTGTAAGGTTACCCA
a  M G
b
c  L L L D W F Q G H L C *
1 8 1 --------------------+ -------------------- + ---------------------+ -------------------- + -------------------- + --------------------- + 2 4 0
d
e
f  * V P K L T M E A L G F C M
TTCAGTTTCTTGCTGCTCCTGTGGGATCCAGGGCACTGTTCACAATGCTGTCTGCATCCA
AAGTCAAAGAACGACGAGGACACCCTAGGTCCCGTGACAAGTGTTACGACAGACGTAGGT
a  F S F L L L L W D P G H C S Q C C L H P
b
c  M L S A S S -
d  * N R A A G T P D L A S N V I S D A D
e  * L A T Q M W -
f
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GCTGGCTAGT301 + 310
CGACCGATCA
a  A  G * -
b
c  W L -
3 0 1  + 310
d  L Q S  T -
e  S A  L -
f  * _
Fig. 5.16 Sequence of subclones 15/20 indicating the open reading frames identified from all 6 frames 
(a- f).
5.3 CONCLUSIO N S
Fig, 5.17 summarises the sequence data obtained from the BAG 21, BAG 7 and BAG 
30 hybrid selection experiments. The selection experiments did not detect any 
previously identified genes that could be localised to chromosome lp l3 , although 
sequences were obtained that may be part of an unidentified gene. These sequences 
(from clones 6, 7 and 15/20) do not resemble sequences deposited into the databases. 
Future studies should examine these in more detail; obtain more sequence, confirm that 
they originate from their respective BAG clones by hybridising longer stretches of 
sequence to the genomic clone involved, and then isolate the cDNA or genomic clones 
if required.
It is clear that the selection experiments have been successful. Enrichment of 3B-HSD 
transcripts in the selected cDNA can be detected by PGR (Fig. 5.8A) and in slot blot 
analysis (Fig. 5.12), and a decrease of GAPDH transcripts was observed from PGR 
(Fig. 5.SB). However, it could be refined slightly; for example, by adding sodum 
pyrophosphate to reduce non-specific binding of DNA to the magnetic beads and 
restricting the priming of cDNA synthesis to oligo dT to decrease the genomic 
contamination in the cDNA library. In addition, the study of the 3B-HSD contig 
should be extended to establish whether other genes are present within or surrounding 
the 3B-HSD gene cluster. Additional clones should be sequenced and analysed from 
the BAG selections and the Y AC clones should be utilised, in particular Y AG IG D ll 
which extends furthest from the cluster.
132
1p13.1 HSD3BV1/5 H S D 3 B #  HSD3Bv|/3 HSD3B1 HSD3B\ir1 HSD3Bvi/2 HSD3B2
21 ----
3B-HSD type I 
36-HSD type II
3 non-specific/possible pseudogene sequences (IGF II, 
mitochondrial loop attachment DNA, hPLH)
2 unidentifiable sequences
i 30
3B-HSD sequence 
1 unidentifiable sequence
313-HSD sequence
Fig. 5.17 Summary of sequence data obtained from selection experiments involving BAG clones 21, 
7 and 30.
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6.1 Characterisation of new members of the 3B-HSD gene family
Two forms of 3B-hydroxysteroid dehydrogenase A5/A4 isomerase (3B-HSD) have 
been identified in humans and these enzymes are products of two distinct genes, 
HSD3B1 and HSD3B2 (Lorence et aZ., 1990a, 1990b, Rheaume et al., 1991, Lachance 
et a l,  1990, 1991). However, several observations suggested that more than two 
HSD3B genes existed in the human genome. Human genomic DNA digested with a 
range of restriction enzymes and hybridised with 3B-HSD type I cDNA probe indicated 
several hybridisation bands. The pattern and intensity of these bands indicated the 
existance of additional HSD3B sequences possessing a high degree of similarity to 
HSD3B1 and 2 (Russell, 1993, Lachance et a l, 1990). Furtheimore, novel 3B-HSD 
sequences were discovered during mutation screening experiments within our 
laboratory (Russell, 1993). 3B-HSD exon 3 PGR amplification products were 
analysed by denaturing gradient gel electrophoresis (DGGE) and products with 
different migration patterns from type I or type II were detected. These products were 
subsequently cloned and sequenced, and novel 3B-HSD sequences were revealed. 
This information prompted our laboratory to screen two À gem ll human genomic 
libraries for sequences similar to 3B-HSD type I and II (McBride et a l ,  1995, McBride, 
1996).
The result of the library screens was the identification of 5 new 3B-HSD sequences. 
The library screens were undertaken by Martin McBride, 2 of the sequences identified 
were characterised by Martin (\|/1 and \j/4), 2 were characterised by myself (\j/2 and \j/3, 
Ghapter 3) and the fifth sequence was analysed by Nicola Graig (\l/5). The 5 
sequences identified indicated a 3B-HSD gene family with 7 members including type I 
and II, with 84.4% - 94.5% nucleotide identity to the coding sequence of HSD3B1 
(Table 6.1). The order of the exons were the same and the lengths of the introns were 
indistinguishable from HSD3B1 and 2 (sections 3.2.4 and 3.2.9). However, 
although the sequences contained ATG codons in an equivalent position to the initiator 
codon of HSD3B1, each sequence had stop codons within the sequences 
corresponding to the reading frames of HSD3B1 and 2. HSD3Bi|/4 and t|;5 had stops 
at residue 16, \|/2 had a stop at residue 42, \(/3 had a stop at residue 143 and \|/1 had a 
stop at residue 173 (see appendix ii). RNA products were detected by RT-PCR from 
\|/4 and \|/5 and the transcripts showed alternative splicing that created frameshifts 
between exons 3 and 4 and/or inserted intron sequence (Sandra Bunidge, personal 
communication). The location of mutations in HSD3B2 associated with 3B-HSD 
deficiency suggested that more than the first 318 amino acids out of 371 are essential 
for the protein to function as a 3B-HSD enzyme (Morel et a l ,  1997, section 1.8.3).
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We therefore concluded that the new sequences identified were unprocessed 
pseudogene members of the 3B-HSD gene family.
Type II Type I 19-4
3B-HSD w4
4-3
3B-HSD \i/5
2-7
3B-HSD v 3
24-4
3B-HSD \gl
8-3
3B-HSD \|/2
Type II - 93.5% 90.5% 89.4% 91.5% 88.24% 85.4%
Type I 91.6% 91.6% 91.5% 8&8% 87.0%
19-4
3B-HSD \|/4
- 94.5% 91.3% 87.3% 85.4%
4-3
3B-HSD w5
- 89.4% 90.3% 88.3%
2-7
3B-HSD \i/3
- 88.3% 84.4%
24-4
3B-HSD \|/1
- 88.7%
8-3
3B-HSD \|/2
Table 6.1. Nucleotide sequence similarity of clone segments homologous to the 3B-HSD type I and II 
exons.
6.2 3B-HSD cluster at chromosome lp l3 .1
Each of the pseudogenes were localised to chromosome Ip 13 by fluorescent in situ 
hybridisation (FISH) by Norma Moii'ison from the Medical Genetics department at 
Yorkhill hospital (McBride et ah, 1995, personal communication). Therefore, the 
next stage in the analysis of the 3B-HSD gene family was to attempt to order the genes 
by mapping each sequence to clones isolated from YAC and BAG genomic libraries. 
Individual HSD3B genes were assigned to Y AG and BAG clones using locus specific 
PGR primers (Fig. 6.1; sections 4.2.2 and 4.2.3). The assignment of the genes to 
BAG clones was validated by restriction fragment analysis. Each BAG was digested 
with a variety of restriction enzymes and hybridised to conserved exon 2 and exon 4 
oligonucleotides (section 4.2.4). Sequence conservation frequently yielded restriction 
fragments of identical size. These fragments were detected by the presence of HSD3B 
bands at identical postions from non-overlapping BAG clones. Their identities were 
either confirmed by probing with specific oligonucleotides or the bands in question 
were subcloned and sequenced. The orientation of HSD3B1, 2, \|/1 and i|/4 was 
determined by the position of restriction sites and the positions of the breakpoints in 
BAG clones 29, 7 and 31 (section 4.2.7). Lack of time and convenient restriction 
sites prevented the determination of the orientation of \|/2, \|/3 and \|/5.
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The estimated length of the entire contig is 500kb with the 3B-HSD gene cluster over a 
centrally-placed 235kb fragment (Fig, 6.1). This is consistent with the previous 
estimate of 290kb based on SacII restriction analysis (Morrissette et al., 1995). YAC 
IG D l 1, contains HSD3B\|/2 and HSD3B2 and is estimated to extend a further 170kb 
beyond HSD3B2. Restriction digests of YAC IG D ll hybridised with full-length 
type I cDNA showed only two bands, which suggested that only the two 3B-F1SD 
genes identified were present on this clone (section 4.2.6). Restriction digest analysis 
and hybridisation of conserved oligonucleotide probes in exon 2 and 4 to the BAG 
clones contained within the genomic contig failed to detect further HSD3B sequences. 
Each BAG clone indicated the expected number of bands for the genes already 
identified (section 4.2.5). These data suggest that the cluster is probably complete as 
far as sequences homologous to HSD3B are concerned, espeeially as 7 x genome 
equivalents were examined during the library screens to find the 5 HSD3B 
pseudogenes and HSD3B1 and 2.
The functional genes HSD3B1 and 2 are in direct repeat, approximately 90kb apart and 
are separated by pseudogenes \j/l and \|/2. This is the first report of the physical 
distance between HSD3B1 and 2; furthermore, the arrangement of these two genes in 
direct repeat and separated by a 90kb fragment containing HSD3B\|/1 and 2 precludes 
these expressed genes from having a shared promoter. However, the present data 
does not exclude the possibility of a shared enhancer for 3B-HSD gene expression, 
similar to the locus control region of the globin genes (Grosveld et al., 1993).
1p13.1 HSD3B\|/5 HSD3B\|/4 HSD3Bi|/3 HSD3B1 HSD3B\|/1 HSD3B\i/2 HSD3B2
1 0 0 k b 1 2 0 k b
X XX
1 1 0 k b
E X X
1 7 0 k b
21
9GF11
32EG4
31
1GD11
2 9 722
Fig. 6.1 Genomic map of 3B-HSD gene family at human chromosome lp l3 .1 , constructed by 
restriction analysis of overlapping YAC and BAG clones.
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6.3 Hybrid selection
Hybrid selection experiments were established to examine the 313-HSD gene cluster for 
novel, unidentified sequences (Chapter 5). These could be further members of the 313- 
HSD gene family or unrelated genes closely linked to the cluster. Briefly, the 
selection experiments were attempted by generating a placental PCR-amplifiable cDNA 
library which was hybridised to biotinylated genomic clones. The genomic clone- 
cDNA hybrids created were isolated by streptavidin magnetic beads, PGR amplified, 
cloned and sequenced. Three BAG clones were chosen to use in the seleetion 
experiments (BAGs 21, 7 and 30) to allow the entire 313-HSD gene cluster to be 
investigated. The selection experiments resulted in successful enrichment of HSD3B 
sequences which was observed by PGR and slot blot analysis, however, no previously 
identified gene sequences were localised to this region of the HSD3B family. Novel 
sequences were detected but it was not resolved whether these sequences were from 
unidentified genes or not. To determine whether these sequences represent 
unidentified genes further experiments would be essential; these would include 
additional sequence analysis of the clones obtained, confirmation that the sequences 
originate from the genomic clone in question and isolation of cDNA or genomic clones. 
In addition, the hybrid selection experiments could be expanded to include YAG 
IG D ll, which may detect further sequences at the HSD3B2 end of the cluster; and 
cDNA libraries from other tissues could be included in the screen, for example, the 
prostate, the liver and other steroidogenic tissues.
6.4 3-ketosteroid reductase and C27-3B-HSD
Rodent 313-HSD families contain genes which encodes for 3-ketosteroid reductase 
enzymes (de Launoit et al., 1992, Glarke et a l,  1993 and Abbaszade et a l,  1995), 
these enzymes convert 5-keto-5a-androstanes into 313-hydroxy steroids. From this
study, no evidence of this enzyme in humans was detected. There is considerable data 
in the literature that the human prostate gland contains 3B-ketosteroid reductase activity 
involved in the inactivation of the potent androgen dihydro testosterone (Amet et a l,  
1992; Trapp et a l ,  1992; Abalain et a l ,  1989; Tunn et a l ,  1990). The 3B-HSD 
enzyme (type I, type II or unidentified isoform) expressed in human prostate was 
unknown, however, RT-PGR analysis of the prostate gland for 3B-HSD transcripts 
resulted in the detection of type II 3B-HSD (section 3.2.12). 3B-HSD type II does 
have KSR activity when expressed from cDNA in transfected tissue culture cells with 
NADH the preferred cofactor (Lorence et a l ,  1990, Rheaume et a l ,  1991). 
However, the ketosteroid reductase activity in prostate was shown to have a three-fold
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preference for NADPH as cofactor (Trapp et a l, 1992), which is the prefeiTed cofactor 
for the rodent KSR enzymes. If there is a human enzyme with exclusive ketosteroid 
reductase activity, it is reasonable to conclude that it is not a member of the 3B-HSD 
family located in the cluster at chromosome lpl3.1 and that it is sufficiently diverged to 
be undetected by homology probing. This is in contrast to the mouse KSR enzymes 
which have been shown to be part of the cluster identified on mouse chromosome 3, a 
region syntenic with human chromosome lp l3  (Bain et al., 1993). Using 3B-HSD 
PCR primers conserved throughout the human gene family identified, human-mouse 
somatic cell hybrids did not reveal any 3B-HSD sequences outwith chromosome one 
(section 4.2.8). However, if the KSR is sufficiently diverged then it may not be 
detected by these experiments.
C27-3B-HSD is an enzyme involved in bile acid synthesis and a deficiency of this 
enzyme can lead to abnormal bile acid synthesis and fatal liver damage. Buchmann et 
al. (1990) described familial giant cell hepatitis associated with deficiency of C27-3B- 
HSD. C27-3B-HSD catalyses the same reaction as C i9/2i-3B-HSD and it is generally 
believed that the gene for this enzyme is a member of the 3B-HSD gene family, 
although the gene has not yet been cloned. However, by studying the segregation of 
HSD3B1 and 2 in a consanguineous family affected by C27-3B-HSD deficiency, 
(Russell et at., 1995) showed that the activities of the C27 and the C l9/21 enzymes are 
encoded by genes that are not in genetic linkage. Therefore, it is probable that this 
member of the 3B-HSD gene family is not present within the cluster identified on 
chromosome lp l3 .1 .
It is likely that genes for C27-3B-HSD and the 3-KSR enzyme would be identified by 
expression cloning rather than experiments involving homology with the known 
members of the family. This has been described within the 17B-HSD gene family. 
To date, five 17B-HSD enzymes have been discovered (Luu-The et ah, 1989; Gast et 
al., 1989; Wu et al., 1993; Geissler et al., 1994; Adamski et al., 1995 and Zang et a l, 
1995), type II and type III 17B-HSD cDNAs were expressed cloned as attempts to 
isolate the genes using radiolabelled type I were unsuccessful. Indeed, after the 
characterisation of these genes a pairwise comparison of the amino acid identities 
between the three isozymes indicated only 23%. In addition, the genes that express 
the enzymes within the family are not localised to the same chromosome. Type I has 
been localised to chromosome 7q21 (Luu-The et a l,  1989), type II to chromosome 
16q24 (Casey et a l,  1994), type III to chromosome 9q22 (Geissler et a l ,  1994), the 
chromosomal localisation of type IV is unknown and type V has been localised to 
chromosome 10pl4,15 (Zang et a l,  1995).
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6.5 Comparisons of the human and rodent 3B-HSD gene families
The characterisation of the human 3B-HSD gene family enables us to question why 
rodents have more functional 3B-HSD enzymes. To date, there have been 6 functional 
genes identified in mouse (Payne et a l, 1997), 4 functional genes in rat (Simard et a l, 
1993) and 3 in hamster (Rogerson et a l,  1997). Both rodents and humans have a 
peripheral isoform of 3B-PISD (rat IV, mouse III/VI and human I) and an 
adrenal/gonadal isoform (rat I, mouse I and human II) and these enzymes seem to play 
the same role in each mammal. The other enzymes present in rodents are either the 
KSR specific isoforms or additional dehydrogenases/isomerases which are expressed 
in the liver and kidney also (Table 1.1). It is unknown why rodents have more 
functional 3B-HSD genes than humans. It is possible that the rodent liver and kidneys 
play a more steroidogenic role than humans. There is a lack of data available on the 
role of the rodent liver and kidney in steroidogenesis. Little is known about the 
expression of 3B-HSD in these tissues except that a number of 3B-HSD isoforms are 
expressed and the expression of these isoforms is sexually dimorphic and in some 
cases sex-specific (Keeney et a l,  1993a; Keeney et a l, 1993b; Naville et a l,  1991). 
Rat III, mouse V and hamster II are expressed in the male liver only. It is possible to 
speculate that the rodent liver has developed to metabolise the high amount of 
exogenous steroids which may be consumed from their diet of plants and seeds.
6.6 The origin of mutations found in HSD3B2 associated with 3B-HSD 
deficiency
3B-HSD deficiency is an autosomal recessive disease resulting in congenital adrenal 
hyperplasia which impairs steroidogenesis in both the adrenals and the gonads. 
Patients exhibit varying degrees of adrenal insufficiency associated with 
pseudohermaphroditism in males and mild virilisation or normal sexual differentiation 
in females (Simard et a l,  1995). The availability of the sequence of the pseudogenes 
and their map order with respect to the type I and II genes allows us to question 
whether any of the mutations that have been reported in the type II gene could be due to 
homologous recombination or gene conversion. These mechanisms of genetic 
recombination are responsible for mutations observed in 21-hydroxylase (cytochrome 
P450c21; Collier et a l, 1993) and aldosterone synthase (cytochrome P 450cll; Lifton 
et a l, 1992a; Lifton et a l,  1992b).
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Genetic deficiency in 21-hydroxylase is responsible for approximately 90% of cases of 
congenital adrenal hyperplasia (New, 1994) and it is reported that carriers of 21- 
hydroxylase deficiency attain frequencies of 10% in world populations studies (Witchel 
et al., 1997). The enzyme converts progesterone into deoxycorticosterone and 17- 
hydroxyprogesterone into 11-deoxycortisol (see Fig. 1.3). The gene for 21- 
hydroxylase (CYP21B) has been localised to chromosome 6p21.3 along with a highly 
homologous pseudogene (CYP21A), both genes contain 10 exons and 9 introns with 
98 and 96% homology respectively (Higashi et al., 1986; White et al., 1986). The 
genes are on tandemly repeated DNA segments approximately 30kb long containing 2 
other duplicated genes, namely C4A and C4B, which encode protein components of 
serum complement (Sinnott et al., 1990). White et al.{l994) concluded that greater 
than 90% of mutant alleles in P450c21 deficiency have arisen by interlocus sequences 
exchanges such as unequal crossover and gene conversion-like events. 75% of these 
are mutations copied from deleterious mutations in the pseudogene, suggesting a gene 
conversion mechanism. Gene conversion describes a non-reciprocal transfer of 
sequences between a pair of non-allelic or allelic DNA sequences. The mechanism of 
this transfer of sequence is unknown, but one possible mechanism suggests the 
formation of a hetero duplex between a DNA strand from the donor and a DNA strand 
from the acceptor (Fig. 6.2). These sequences will be similar but not identical and 
DNA repair mechanisms may "coiTect" the DNA strand of the acceptor to the same 
sequence as the complementary strand of the donor. Subsequent replication of the 
acceptor strand and sealing of nicks will complete the conversion. Analysis of one 
mutation involved in 21-hydroxylase deficiency suggests that the conversion tract may 
be a maximim of 390bp (Collier et a l, 1993).
Homologous recombination events are involved in P 4 5 0 c ll deficiency disease. 
Deficiency of P 4 5 0 c ll is the second most common cause of congenital adrenal 
hyperplasia and accounts for 5% of adrenal defects (White et a l ,  1987). Two 
homologous P450cll enzymes are encoded by the C Y P llB l and CYP11B2 genes on 
chromosome 8q21-22 (Mornet et al., 1989). C Y P llB l encodes P 450cll which is 
expressed in the zona fasciculata and reticularis and is required for cortisol biosynthesis 
whereas CYP11B2 encodes P450cl8 which possesses three activities required for 
aldosterone synthesis in the zona glomerulosa (see section 1.7). A dominant form of 
inherited hypertension (dexamethasone suppressible hypertension) is caused by 
unequal crossover between the C Y P llB l and CYP11B2 genes (Lifton et a l,  1992). 
This results in a hybrid gene which the 5' end of C Y P llB l fused to the coding region 
of CYP11B2, placing the P450cll promoter upstream of P450cl8. This results in 
mineralocorticoid secretion from the zona fasciculata and leads to hypertension.
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Fig. 6.2 Mismatch repair of a heteroduplex as a possible mechanism for gene conversion. One of 
the strands from the donor sequence forms a heteroduplex with the complementary strand of 
the acceptor sequence, displacing the other acceptor strand. Mismatch repair enzymes 
recognise the mispaired bases and "correct" the sequence so that the acceptor sequence is 
converted into the complementary strand of the donor. Replication of the acceptor strand 
results in completion of the conversion. Modified from Strachan and Read, 1996.
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There have been 24 deleterious mutations described in 36-HSD type II which are 
responsible for 36-HSD deficiency (Morel et a l,  1997). 22 of the mutations are
indicated on the sequence alignment in appendix ii. From the mutations shown, 6 are 
found within the pseudogenes (Table 6.2) raising the question whether the mechanisms 
involved in the origin of the mutations in P450c21 and P 4 5 0 c ll deficiencies are 
relevant to 36-HSD. However, in no cases of 36-HSD deficiency is there more than 
one base change in common with a pseudogene and it is believed that gene conversion 
results in modification of a segment of sequence from the donor sequence. This does 
not exclude the possibility that a single base conversion event may take place.
Another aspect of the mutations involved in 36-HSD deficiency has been observed that 
may further argue against conversion. Sequence analysis of the pseudogenes 
determined that 4 out of 6 mutations result from a CpG dinucleotide present in the 
normal HSD3B2 sequence and this CpG is conserved in at least 2 of the other members 
of the gene family (Table 6.2). In contrast, the remaining mutations did not have 
counterparts in \|/l-5  or HSD3B1, and none were located at CpG sites. CpG 
dinucleotides are extremely mutable and usually lead to transitions (Cooper and 
Youssoufian, 1988). Transitions (conversion of a pyrimidine to a pyrimidine or 
purine to purine) are unusually common in both coding and non-coding DNA. This is 
partly due to the instability of cytosine residues in the CpG dinucleotide, where the 
cytosine is often methylated at the 5' carbon atom and 5-methylcytosine is susceptible 
to spontaneous deamination to thymidine. As a result, the CpG dinucleotide is a 
hotspot for mutation and it is believed that the mutation rate for the CpG dinucleotide is 
about 8.5 times higher than that of the average dinucleotide (Cooper et a l ,  1995). 
This greatly reduces the probability that a new HSD3B2 mutation at a CpG site will 
have diverged from a mutation in the CpG site of a pseudogene that has been fixed 
eaiiier in the evolution of the cluster. It is noteworthy to add that the CpG sites that are 
mutated in HSD3B2 are usually conserved in the other family members.
HSD3B2
Exon
Mutation CpG in 
normal
HSD3B2 allele
Mutation present 
elsewhere in cluster
base in normal HSD3B 
allele conserved in other 
family members
2 G323A no \]/3 yes
3 G129A yes M/5 yes4 G8A no \j/4 yes4 G91A yes \|/3, \i/4 HSD3B1, HSD3B\i/24 G130A yes \|/1 yes
4 C482T yes \l/3 yes
Table 6.2: HSD3B2 mutations shared with \|/I-5; location of CpG sites.
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A final piece of evidence which supports the argument against conversion was that 
haplotype studies indicated that mutation G 129A (see appendix ii, exon 3) did not arise 
independently in 3 apparently unconnected families but arose by descent from a single 
common ancestral mutation (Simon McCartin, personnal communication). This 
suggests the evolution of a single event throughout the families rather than gene- 
conversion-like mechanism occuring independently in each family. In conclusion, 
there is no evidence for gene conversion or unequal crossing over as a mechanism 
contributing to the known HSD3B2 mutations.
6.7 Evolution of the 31Î-HSD gene family
The evolution of a multicellular complex organism probably involved a gradual increase 
in genome size and this increase in genome size must have taken place without 
compromising the functions of the DNA already present. Gene duplication allows 
sequences to diverge relatively rapidly without affecting the function of the gene 
product, because one gene at the duplicated locus is surplus to requirement and this can 
diverge rapidly due to the absence of selective pressure to maintain function. The 
diverged sequence may acquire a new function but most likely will acquire deleterous 
mutations and degenerate into a non-functional pseudo gene (Strachan and Read, 1996). 
This mechanism is represented in Fig. 6.3.
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pressure
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Fig. 6.3 Gene duplication can lead to the formation of genes with a novel function or non-functional 
pseudogenes (vertical bars within the boxes represent mutations). Modified from Strachan and Read, 
1996.
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Tandem gene duplication results from unequal crossing over events between similar 
sequences on different chromosomes or sister chromatids. Clustered gene families 
often result from tandem gene duplication, a good example of this is the globin gene 
families (Goodman et al., 1987). The globin genes have duplicated from a single 
ancestral gene to form a highly-coordinated gene family with developmental and tissue- 
specific expression. The initial duplication event from a single ancestral gene is rare 
(Maeda and Smithies, 1986) and it is likely that the unequal crossover or sister 
chromatid exchange occured at regions of little homology, following mispalring of 
nonallelic repeats such as Alu repeats (Cross and Renkawitz, 1990; Hu et al., 1991) 
Once gene families have expanded it is believed that recombination events will become 
more frequent because of the repetitions in the sequences.
Different mechanisms of recombination can occur within a gene family, these will either 
allow divergence or homogenisation of the sequences. Concerted evolution occurs 
by intragenomic sequence exchanges within a DNA sequence family by means of 
unequal crossover, sister chromatid exchange and gene conversion (Liao et a l, 1997). 
Such non-allelic sequence changes between the members of a gene family will tend to 
drive the family towards homogeneity. In contrast, the "birth and death" process 
allows gene families to duplicate with some duplicated genes maintained to create a new 
or additional function, and others are deleted or become non-functional by deleterious 
mutations (Nei et a l, 1997). This model of gene family evolution produces a gene 
family with highly homologous genes and a substantial amount of pseudo genes. For 
example, it is likely that the immunoglobin gene families evolved via the "birth and 
death" model as these genes strive for divergence, whereas gene families such as the 
ribosomal genes follow concerted evolution where a large quantity of the same product 
is produced (Nei et a l, 1997).
With respect to the 36-HSD gene family, it is likely that the "birth and death" process 
applies for divergence of the family, in contrast to concerted evolution which creates 
homogeneous sequences. This gene family contains functional and pseudogene 
members, which is consistent with the "birth and death" process. With concerted 
evolution, there is a tendency to see "patching" of the sequence, with some regions 
highly homologous and other regions more diverged, this does not seem to apply to the 
sequences identified in the 36 family. Sequence comparison of the 36-HSD gene 
family indicates that base changes between members are found throughout the 
sequences and are not restricted to groups within the family.
The relationship between the nucleotide sequences in the 36-HSD gene family was 
determined by weighted parsimony analysis of the alignment between the exon
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sequences (Fig. 6.4). Branch lengths indicate the number of informative nucleotide 
substitutions in the data set. This analysis suggests that seven human sequences are 
more closely related to one another than to the mouse or the rat which indicates that they 
expanded after the divergence from the common ancestor with rodents, as previously 
noted for HSD3B1 and 2 by Abbaszade et al .(1995). The position of the ATG codon 
in type II compared to type I and the pseudogenes (the ATG in HSD3B2 is located one 
codon downstream from HSD3B1 and \|/l-5) is consistent with the pseudogenes 
having a more ancient origin than the divergence of HSD3B1 and 2. Pseudogenes 
\{/4 and 5 show the closest homology to HSD3B1 and 2 and are both expressed as 
RNA in several tissues. This suggests that either these pseudogenes are more recently 
duplicated or have been more recently released from the selective pressures of the 
expression of a functional enzyme.
The phylogenetic tree demonstrates that several duplications took place during the 
evolution of the 36-HSD gene family. One such event gave rise to the KSR enzymes 
in the rodent family, resulting in the evolution of two distinct functional groups of 
enzymes, the KSR specific enzymes (rat III, mouse IV and V) and the 
dehydrogenases/isomerases (rat I, II, IV and mouse I, II, III and VI). Investigations 
into the macaque 36-HSD gene family may yield important information to the 
expansion of the 36-HSD gene family. It is expected that there may be an expanded 
36-HSD gene family in macaque as there is evidence to suggest the expression of 36- 
HSD in peripheral tissues such as the liver and kidney (Martel et a l,  1994).
The precise mechanism of the 36-HSD gene family expansion is unknown. We can 
speculate on possible pathways of duplications and genetic recombinations, however 
some additional information is required to determine the exact mechanism. For 
example, comparison of the upstream region of HSD3B1 and 2 shows a marked 
divergence in upstream sequence (see appendix i, upstream from base 1280, type I) 
which is consistent with type I and type II having different regulatory elements leading 
to differential tissue expression. Therefore, sequence data from these upstream 
regions of the pseudogenes may provide significant information which may allude to 
the pathway of gene family expansion. Furthermore, by obtaining the intron 
sequences from the pseudogenes and the orientations of all 7 genes the mechanism of 
expansion of the 36-HSD gene family may become apparent.
145
Trout
100
98
100
100
Mouses 
—  Mouse2
Mouse 1
99 Rat1
Rat2
Rat 4
100
100
Mouse4
Moused
Rats
88
62
77
Macaque 
• Type2
Type 7
56 1//^
- W5
60
-  Iff 2
y/1
- y/3
Bovine
Figure 6.4. Weighted parsimony analysis of an alignment between expressed mammalian cDNAs and 
human exon homologue DNA sequences (\|/l-\|/5). Branch lengths represent the number of informative 
nucleotide substitutions in the data set. Bootstrapping percentages greater than 50% are shown on 
internal nodes (based on 1000 replications with the input order shuffled randomly on each replication). 
Reproduced with kind permission from Martin McBride.
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6.8 Concluding remarks
The 36-HSD gene family contains 7 members; 2 previously identified functional genes 
(HSD3B1 and 2), and 5 novel unprocessed pseudogenes (HSD3B\}/l-5) identified by 
screening two human genomic libraries with 36-HSD type I cDNA. A YAC and BAG 
genomic contig established the order of the 36-HSD genes at chromosome lp l3 T , and 
the orientation of HSD3B1, 2, \|/1 and \|/4 was determined by restriction analysis and 
the position of the endpoints of three genomic clones within the contig. The estimated 
length of the contig is 500kb with the 36-HSD gene family over a centrally-based 
235kb fragment. No further members of the gene family were detected by extensive 
restriction analysis of the cluster or from hybrid selection experiments. No member of 
the 36-HSD gene family was discovered that may be a candidate to encode a human 3- 
ketosteroid reductase or 36-C27-HSD. However, it is likely that these genes contain 
sufficiently diverged sequence from the 7 identified 36-HSD genes, and therefore, it is 
not surprising that experiments involving homology with the other members of the 
family have not detected these genes. Expression cloning experiments would 
probably result in the cloning of the 3-ketosteroid reductase and 36-C27-HSD.
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CHAPTER 8 
Appendices
Appendix i 
Type I (genbank accession number ni38180; exons are boxed):
1 TCTGTGAACT TAAACTAGAC CAGGAGAAAT CTGCAAGTGC AATTTGAATT
5 1 GTGCCCTTGT TCAGTAAATC CATCTGGAGG GAAATCCATG TAAGCCCATT
1 0 1 ATCTCCTCTC TCAGACTATC ATTTGAAATG TTGCTGCTGT CTTACAAAAT
1 5 1 TTAGAAATTT GCAATGGTGA CAGCTCCAAT CACTTAGTTT TATGTGAGGT
2 0 1 GACTTTCTTT CCTACCCAAT ATATCTGAAA CCTCAATGGT CATTTGCCCC
2 5 1 TGGAGAGCCC TGGGTTCCTA GATGAACAAC ATCATTGAAG GAAAGCTATC
3 0 1 TGGTGATAAC CACTTAATGA TATGGCCTGT ATCACAAGAG TGGGGATTTG
3 5 1 TGGTTGTATG CCCCAATGAC TCTTATCATA GGTGTTCGAA CTTATCCATA
4 0 1 TTTTTGGCTG CAAAACGATT CTCAGCAAAT TCTTGAACTG GACATACTGT
4 5 1 GAATGCTTCT GAAGCCTATG CCCCAGAACT GCCCAAATAT CACCGCCATA
5 0 1 AGCTTCCCAA GACACTTTAC TCAAAAAAAT TGAAATATAA TTTACATGCA
5 5 1 TTAAAATGCC CAGGTCTTCA GTGTTCAGTT CAGTGGAACT TGACAGTTAT
6 0 1 ATATGCCCAT GTAAGTAGCA CCCCAAAAAA GATATAGACC ATTTCCGTCA
6 5 1 CTCCAGAAAG TTGTTTTCTG CCTGTTCCCT GTTAATTCCC TGACCTTCCC
7 0 1 CCAATCTACC TCATAGGCAA CTACTTCCTG ATTTTTATTC CCACAGTTCT
7 5 1 CATTTTATTT CTATATTTCT CTAATTTTTT CTTCTAAGAT CTCTGTGGTT
8 0 1 CTGGATATAT ATTTAAATAT AAAATTATTT TGAAATGAAG TTTTGTGCAG
8 5 1 GGAGTACAGA AAAATTGACC GTTGATTGTC TCTGTTGTTT ATTTTTCTAT
9 0 1 TTCATGATTT TCATTATTTT TATTATTGGC TTACATTTAT TAATTTTGTT
9 5 1 TTTTTTTTTC ACTCGTTTTT CACATTTTTT TTTTTTTTTT TTGAGATGGA
1 0 0 1 GTCTTGCTCT GTCACCCAGG CTGAATGGCA GGGGCACCAT CTCAGCTCAC
1 0 5 1 TGCAACCTCT GCTCCCGGGT TCAAGCAATT CTCCCACCTC AGCCTCCGAA
1 1 0 1 GTAGCTGGGA TTACAGGTGC CCGCCACTGC ACCGGGCTAA TTTTTGTATT
1 1 5 1 TTCAGTAGAG GTGGGGTTTC ATCATGTTGA CCAGCTGGTA TCAAACTCCT
1 2 0 1 GACTTTGTGA TCTGCACGCC TCAGCCTCCC AAAGTGCTGG GATTACAGGC
1 2 5 1 GTGAGCCACT GCACCCAGCC CCGTTTTTCA GGATCCCATA GGAGGAGAGA
1 3 0 1 GCAATGAGTA CATGGCCAGA GATCAAAGTG ATAAGGGTTG GGCCAGAAGC
1 3 5 1 CACAGTGCAT AAAGCTTCAG ACTTGCCACA GGAAATGAGG TGAGAAGTAC
1 4 0 1 GTCCACTCTT CTGTCCAGCT TTTAACAATC TAACTAATGG TTAGAGATTT
167
1 4 5 1 TTCATTTTCT TTCAGCTACT CCTGCAGTGG TGGGGACACA GAATGTTTGC
1 5 0 1 AAAAAAAATG GGGTGGAGGA AAATGAGGCA TCTGTGTGAG TATATAACCA
1 5 5 1 TTTGACATCT CTTTTTAGCC CTCTCCAGGG TCACCCTAGA ATCAGATCTG
1 6 0 1 CTCCCCAGCA TCTTCTGTTT CCTGGTGAGT GATTCCTGCT ACTTTGGATG
1 6 5 1 GCCATGACGG GCTGGAGCTG CCTTGTGACA GGAGCAGGAG GGTTTCTGGG
1 7 0 1 ACAGAGGATC ATCCGCCTCT TGGTGAAGGA GAAGGAGCTG AAGGAGATCA
1 7 5 1 GGGTCTTGGA CAAGGCCTTC GGACCAGAAT TGAGAGAGGA ATTTTCTAGT
1 8 0 1 AAGTAAACTT GGGTCATGGG TGTGTGGTTC CATCTTAAAC ACTGCATGTA
1 8 5 1 TGTGGGGGGA GATGGACCTT GTCTAGCAAG TTATTGAAAT TTGTAGCCAA
1 9 0 1 ATCTAAGCCA ATCTCACATC CAAAGTCATC AAGAAATAAA TATTAAATAG
1 9 5 1 TATAAAATGG CATAGTATGA AAGATACTGG GTGGGATTTC CAGAGACTAG
2 0 0 1 ATTCTGGCCC TGACCCAGAA CTTGAGAAGC AGCCACCTCA GCCTCCAGGC
2 0 5 1 CTCTTTTCTT CTCATCTAGA AAATCCCACA TCAGTTCTTT GTCTTGTCTG
2 1 0 1 CAACTCTTTT ATGTTCTGAA GCTTTTGTCT TGGCAATTGC TGTACAACAT
2 1 5 1 TCATAAAGGA CACTATTACC CTGGAGACCT CACCAATGGG TCATTGTCTC
2 2 0 1 TCTAGAACGT GCCAGGCTGT GTTTTGTTTT GCAGCTTCCT TAGTATCCTT
2 2 5 1 TGTGAGGGCA AAATAAAAGG AAGTTAAGGT AAAGATGAGT GTATAAGTGG
2 3 0 1 GTGTGTGTGA CAGAGAGAGA GGAAAACAAT AAGGGGGAGA GAGAGTCGGG
2 3 5 1 GAGAGAGAGT CGGGGAGAGA GACTCAGAGA GAGAGACAAT GAGAAAGACA
2 4 0 1 GAGAAATAAT GAAAAATATA TAGTGAGAGA GAGAGCATCA GTGAGAGAAT
2 4 5 1 GTGTGTGCAC AGTGCACAGC ACAGAGCAGA GACAGAGTAA GAGGCAGTAT
2 5 0 1 AAGGCCAGAC ATGCCTCATT TAGATTTTGC ATATATGGCT TTTTTTTAAA
2 5 5 1 AAAAAAAAAA CAAAACATTT ACCTCTGTTG CTCATCATCA AAAAGAAATT
2 6 0 1 GACTGCAGAA TTTTCTGTGG CAACTCCTTG TACAAATGGC CCCAAGAGGC
2 6 5 1 AGGTAGAAAA GGCATCACAT CCAACAGGAC AATGAACGCA TCAAGGTCCG
2 7 0 1 GAATCACAAA GCAACATGCT AAGGCCATCT GATTGATGCG TAGCAGAGCT
2 7 5 1 CAGACCAGAG CTTTATCCAT AGGCTATTTC ACCTGGCCCC AGAGCTGATG
2 8 0 1 CTTGGCAAAG TGGATCTTCA GTCTCTCCCT TTGCTCCTTG GTGTGCCCCA
2 8 5 1 AAACAATTCC CTGTCCTCCT CCCCAACCCA GGGGATTTGG GGGACTGTGT
2 9 0 1 GTCTACATGT GGGCTCTGGC TGCCCAGAGG TCCTGCCCTG CCCACAGAGA
2 9 5 1 ATCCCCCACT TGACAGCACT CAGGGACCAC ACCCAACACT CTACTTTTGC
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3 0 0 1 TCTTCTCTGA CCTCTTGAAA TGTTCGATTT CTTCCACCCT CTGTTTTAAT
3 0 5 1 GTTGTCTTTG ATAAACAAAT ATGAAATGCT TATAATCCTT GCCTGTGTCT
3 1 0 1 CAGCAATATT TGCAATTTAA CATCTGAAGC CAGAAAAAAG CAATGCTCAG
3 1 5 1 CCTAGAGGTA TTGTTCCCCT ATGGTAAAAA TGCAGATCAT ATAATAGACA
3 2 0 1 GGCAGGGATC TGTATGAAGA TAAAAACAGA GAAAGCATTC AGTGTTCTTT
3 2 5 1 TTGTGCCAGG CACTTGGCCA AAGGTTTGCC AACTCATTTG CTCCTCATAA
3 3 0 1 GAAGCCTATG AGATCGGTAA TATTATCCTC CTTTTTTAAA GATGAGGAGA
3 3 5 1 TAGAAACAGA GAGGTTAGTT AACTTTTTGA AGGTCCCACA GTTAGCATAT
3 4 0 1 GGCAAAGCTA GATTTGAACC CAGACAGACT AGTGCAGCAT CTGTGCTCTT
3 4 5 1 AAGCAGTAGT TTGTCTTACA GCTCCTTTAG GCCTTCCTCT AGCCCAACTT
3 5 0 1 ACACCATAAA AGCAACTCCA TTTAGTCTAC ATAAAACACT TGCCAAGTCT
3 5 5 1 ACAGTGCCTT GGAGAAGAAG GGAGCCATGA CTTCATCAAC AAAGTACCTT
3 6 0 1 TTCCTAGTCC CTCTAGATCC CTGGGAACTC ACTGGGGAAG AGTCCTTTTC
3 6 5 1 TCTCAGCTTT GGACTTCTTC CACTTTGACA CTCCTTTGAG CCAGTCTGTC
3 7 0 1 TGAAGTGGCA GCAAAGAAGA AGCAGAGGAA GGCAGCAGGA AGGGCAGAGG
3 7 5 1 TGGAACTAGA ACCAGAGAAC ATCCCACTCT CAGGCTGTTA CCCACATCAC
3 8 0 1 CACCAGCAGC CTCTTCCCTG ACTCCCCCAC TCCAGGACCT TCTTGGAGTT
3 8 5 1 GCCTGACAAC GGGAAGAGGT TGGGAGTAGA CAAAACATGG CAGAGGCATC
3 9 0 1 AGGAGAGCAA GTGGTCCTGC TTGTACCCCA GGAAGGAATT TCTCCAGCTT
3 9 5 1 CGAATTTTTC ACTCTGAATT TTGCTCTCAC TGGTCTTTGG TCTTTGTTGC
4 0 0 1 CAATTTCAGT TAAACTGGCT TATTCTTTGG AAAAGAATGA TATTAAACAA
4 0 5 1 CAGAAAAGTT GATATTAAAC AGCCAGTCCT GCACCTGGTG TACAGGGTAC
4 1 0 1 AAGCTTGGAG GCAGGGTGGG CGTGTTTAAG CCTTCACTAG AAACGTGACC
4 1 5 1 TTAGATCTGT CCCTTAACCT CTCTGAGACT CAGTTTCCTC ACTGATAAAG
4 2 0 1 TGGGACTCAG AATACCTACC TCATGAGATA GCTGTAAAAA GAAATAAATA
4 2 5 1 TCCTGTAAGT TGCATACAGA TGATAAAGCA CAAACAAGTG TAGAGTATTT
4 3 0 1 ATCCAAGCTC CATGTAGCAT GGTGTTCATT TTGTGGGCTA ATTCCAGGTG
4 3 5 1 ACAACCTTAC TGGCAGCGTC ACTTCCTGTG GATTTCAGAG GAACCTGAAG
4 4 0 1 ACATTGATGT TGTAACCACT GCCTCCAGCT AGACAGCTGC GATGTTAGTT
4 4 5 1 CATTGGTGGT TAACTCATTT TCAGCATTGC TACCTGCTTT TGATGATATC
4 5 0 1 TGATAATAGT TTTCCAGGGA AATTCATCAT TGAAGCCCAC CCACAATTCC
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4 5 5 1 TGAGTAATGA CTCCACTCTC CTCCCAGTTG CCCAAGCAGG AAACTGTAGG
4 6 0 1 GGTGATTTTA TCTTCTCCTT TTCCTATCAG CTCAGATCCA ATAGGTACCA
4 6 5 1 GGACCTTCAA GGTAAGGTCT GAAATTCAAA CCTGGTATAT CTCTCCCCTC
4 7 0 1 CTCTGCTTCC ACTGCTGGAC CCTGCTTCCA GTCCTCATCG AAACTTTGGC
4 7 5 1 ACAGACATTC TGATTAATCA CTTGATCATC AGTCTTTCTC AAATCCCCTA
4 8 0 1 TACCAGTCCA TTTTATATCC TCAAGCCAAG ATTAACTTCC TACACCACAA
4 8 5 1 CCCTGCTTTT GTTCCTTTTT TTGTTGTTGC TTGTGTGGTT TTCTTTTTTT
4 9 0 1 T T T T T T T T T T T T T T T T T T T T T T T T T T T T T T TTTGAGACAA GGTGGTCTTG
4 9 5 1 CTCTACCACC CAGGCTAGAG TGCAGAGGTG TGATCTTGGC TCACTGCCAG
5 0 0 1 GAACCAGAGA CCCCAGCCTC CATTTATCCT CCCACCTCAG TCTGCAGAGT
5 0 5 1 AGCTGGGACT GCAGGCAGGC ACATGCCACC ATGCCCAGCT ATTTCATGTA
5 1 0 1 TTTTAATAGA AATGGGATTT GCCCATGTTG TCCAAGCTGG TCTCAACCTC
5 1 5 1 CTGCGCTCCA GTGATCCATC CATCACAGCC TCCCAAAGTG CTGGAATAAC
5 2 0 1 AGGCATGAGC CACGGGGCTT GGCCTTTTTG TCATTTTATT CCAAATATAA
5 2 5 1 ATAAGGGGTT TTCTTTAACA TGATGCTGGA GTCCCAAAAT TATGATTCTA
5 3 0 1 TACATGATTT CTCATTACTT ACAGAATTAA CTTCAAACTT TTCCCTCATA
5 3 5 1 CTCTCTACAA TCACACTACT CTCCTTAGAA AATTTGATGG GCTTCCCATG
5 4 0 1 ACTCTAGCAA TGCTTATATT CCAGGCATAC CTGACAGCTC ACTGCTCAGA
5 4 5 1 TTACTTTTCT AAAATGAGAT GGGAGAGAAA CAGATGTTTG CTCTTTCCAA
5 5 0 1 GAAATTGATA CACATGCTGA TTTCTGTGCC TTTTTTACTT GTTCTTTCCG
5 5 5 1 TAGAATGTAC ACCCTCCACT CTAACACCCT ACTCTAACCA TCCTTGAACA
5 6 0 1 CCTATGTAAC ATCACCTTTA TCAGAAAACT TCTCAGCCAG ATACAGAAAT
5 6 5 1 CATTCCAATG ACCTGACCTG TGTTCACACA GAACTCCAGA ACAAGACCAA
5 7 0 1 GCTGACAGTG CTGGAAGGAG ACATTCTGGA TGAGCCATTC CTGAAGAGAG
5 7 5 1 CCTGCCAGGA CGTCTCGGTC ATCATCCACA CCGCCTGTAT CATTGATGTC
5 8 0 1 TTCGGTGTCA CTCACAGAGA GTCTATCATG AATGTCAATG TGAAAGGTAT
5 8 5 1 GGTAGGCTGG GGAGGAGATG CAGCAAGGTG GGGAATTAAG GATCACAAAG
5 9 0 1 AAGGGCCAGG AAGGGAAGAG AAGTCCCTCC ACTGAACACC TGCTGTGCTC
5 9 5 1 TGGGCCAAGT GCCTTTGCTG ATCACTACGA ATAGGAGAGT TCAAGACTGC
6 0 0 1 TAACTTTAGT TTTTTAGATG ATAAAACTAG GACTGAGAGA GGGCAAGTAA
6 0 5 1 CTTGTCCAAG GTCCCCCAGG TAAGTAAGCA GGTAGGAGAG TTAGACTTTA
6 1 0 1 AACTCATCCC TGTGTGACTC CAAAGGCTCT TTCTACTGTG ACTCCAAAAG
170
6 1 5 1 CTCTTTCTAC TGTGGTTCCA ATCAAAAGTC AACTAATTTC TGACTTCAGA
6 2 0 1 CTCTTGATAC CCAGACACCC CTTGCCTCCC AGGCCAGAAG CAGACCTTGC
6 2 5 1 AGGTGCCACT GTAGTCACCA TTTTGAACCT TGTGTGTAGG CTGATGAAAA
6301 CATTCAGAGC CCTCCTGCCC ACCTCAAACA AAAAGTCCTC TCGAGAGAAC
6 3 5 1 TAGCAAAGCT GGTTCACAAG GTCTGTCAGG ACAGAATTAT CCAGCACATG
6 4 0 1 CCTTCCCACA ATATTTTTTT AACAGTGAGA TTTTTCCAGT ATCAAGAATA
6 4 5 1 CAGTCTCTTC AGCTCACCAC AGGGCCTACT ATTCCAGAGC CGTTTTCAGC
6 5 0 1 CAGGTGCCCA AAGTGCACCC TCATTTAATC TTCATCCCTT AAATGCTTGG
6 5 5 1 CGTTTCCTTT CAAAGTATGG CTTTCCAACT ACCTTAAATT CAGACACATT
6 6 0 1 TCCTTAAGGA ATCTTCTCAG AAATCTCACC CTCTGATCTC CAGAGTCCAG
6 6 5 1 TCTCTTCAGC ACCATAGCAC CCCAAACCCC GGCCTGGCCC TCCGCATTTA
6 7 0 1 GTCTACTCTG ACTCTTTTTC CAAAGCAACC AATTGCTTTT GAGTCTCCAG
7 7 5 1 GTACACACAC ACACACATCC ATGAAACCCA AAAGTCTAGA AATTCTTACT
7 8 0 1 CTCCAGAACC CACATGTCAG TTTCTCTTCA TTTTGGTATT TTTCTTATGG
7 8 5 1 CTGTAGTACG ACCAAATCTC AGACAGAACC ACAGAAGAAT GTACCCTGAG
7 9 0 1 TCTGTTACAA CCACCATATT TGGGAGTGGG GGGTGGGGCA CATAGATCTG
7 9 5 1 TGTTCGTGGT TGGCACCTCT TAGGGATATA TCCTGACAGT GACAATATGC
8 0 0 1 TCTTCATGGA CAGGTACCCA GCTCCTGTTA GAGGCCTGTG TCCAAGCTAG
8 0 5 1 TGTGCCAGTC TTCATCTACA CCAGTAGCAT AGAGGTAGCC GGGCCCAACT
8 1 0 1 CCTACAAGGA AATCATCCAG AATGGCCATG AAGAAGAGCC TCTGGAAAAC
8 1 5 1 ACATGGCCCG CTCCATACCC ACACAGCAAA AAGCTTGCTG AGAAGGCTGT
8 2 0 1 ACTGGCGGCT AACGGGTGGA ATCTGAAAAA CGGCGGCACC CTGTACACTT
8 2 5 1 GTGCCTTACG ACCCATGTAT ATCTATGGGG AAGGAAGCCG ATTCCTTTCT
8 3 0 1 GCTAGTATAA ACGAGGCCCT GAACAACAAT GGGATCCTGT CAAGTGTTGG
8 3 5 1 AAAGTTCTCC ACTGTTAACC CAGTCTATGT TGGCAATGTG GCCTGGGCCC
8 4 0 1 ACATTCTGGC CTTGAGGGCC CTGCAGGACC CCAAGAAGGC CCCAAGCATC
8 4 5 1 CGAGGACAGT TCTACTATAT CTCAGATGAC ACGCCTCACC AAAGCTATGA
8 5 0 1 TAACCTTAAT TACACCCTGA GCAAAGAGTT CGGCCTCCGC CTTGATTCCA
8 5 5 1 GATGGAGCTT TCCTTTATCC CTGATGTATT GGATTGGCTT CCTGCTGGAA
8 6 0 1 ATAGTGAGCT TCCTACTCAG GCCAATTTAC ACCTATCGAC CGCCCTTCAA
8 6 5 1 CCGCCACATA GTCACATTGT CAAATAGCGT ATTCACCTTC TCTTATAAGA
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8 7 0 1 AGGCTCAGCG AGATTTGGCG TATAAGCCAC TCTACAGCTG GGAGGAAGCC
8 7 5 1 AAGCAGAAAA CGGTGGAGTG GGTTGGTTCC CTTGTGGACC GGCACAAGGA
8 8 0 1 GAACCTGAAG TCCAAGACTC AGTGATTTAA GGATGACAGA GATGTGCATG
8 8 5 1 TGGGTATTGT TAGGAGATGT CATCAAGCTC CACCCTCCTG GCCTCATACA
8 9 0 1 GAAAGTGACA AGGGCACAAG CTCAGGTCCT GCTGCCTCCC TTTCATACAA
8 9 5 1 TGGCCAACTT ATGTTATTCC TCATGTCATC AAAACCTGCG CAGTCATTGG
9 0 0 1 CCCAACAAGA AGGTTTCTGT CCTAATCATA TACCAGAGGA AAGACCATGT
9 0 5 1 GGTTTGCTGT TACCAAATCT CAGTAGCTGA TTCTGAACAA TTTAGGGACT
9 1 0 1 CTTTTAACTT GAGGGTCGTT TTGACTACTA GAGCTCCATT TCTACTCTTA
9 1 5 1 AATGAGAAAG GATTTCCTTT CTTTTTAATC TTCCATTCCT TCACATAGTT
9 2 0 1 TGATAAAAAG ATCAATAAAT GTTTGAATGT TTAATGTGGA GGGAGGTGTG
9 2 5 1 AGTTATGTTA ATACATACTT TCCTCCTTTC TCCTTCTTTT CCAGGTATTG
9 3 0 1 CCATCTCCAA TTTAGAAGAG TAGCATAAAA CCTGGGTTGG GGAGAGGGCA
9 3 5 1 GAGTAGTGGG AGGGCCAGGA AGGGCGATGA AGACTGAATA AGCTCTACTA
9 4 0 1  CCTT
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Type II (genbank accession number m77144; exons are boxed):
1 TTAATAAACA TTTAAGCCAA TAATAAAAAT AATGAAAATC ATGAAATAGA
5 1 AAAATGAACA AACAATAGAG ACAATCAGTG GTCAATTTTT CTGTACTCCA
1 0 1 TGAACAAAAC TTCAGTTCAG AATGATTTTA TATTTAAATA TATATCCAGA
1 5 1 ATCACAAAGA TCTTAGAAGA AAAAATTAGG AAAATATAGG AATAAAGTGG
2 0 1 GAACTCTGTG GGAATAAAAA TCAGAAAGTA ATTGCCTACC AGGTAAACTC
2 5 1 GGGGGAGGGC AGGCAATTGA CTAAGAACAG GCAGATAAAA CTTTCTGGAG
3 0 1 TGAAGGAAAT GGTGGTCTTG TTTTCGTTGG TACTTACATG GACATATATA
3 5 1 ACTGTCAAGG TTCATTGACA ATGAACACTT AAGTGTACAC TGAACGCTTA
4 0 1 AGATCTGGGC CTTGTAATGC CCAGATTACA TCTACTTAAA AAAACTACAT
4 5 1 CTCTATTTTT TTAAGTAGAG AAAAGTGTCT TGGGGAGTTT ATGGCAGTGA
5 0 1 TGTTTGGGCA GACTGGGGCA TAGGTTTCAG AAGCATTCAT AGCATCTTCA
5 5 1 GTTCAACAAT TTGCTAAGAA TGGTTTTGCA GCCAAAAATG TAAGATGAGT
6 0 1 GCAAATATCT ATGATTAGAG TCATTGGGCA TACAACTACA AATCCCCACA
6 5 1 CTTGTATTAC AGGCCATATG ATTAATTCGT TATCACTAGA TACCTTTCCT
7 0 1 TCAATGAGGT TCTTCCATTA GGAACCCAGA GCTCTCCAGG GAAAAATTGC
7 5 1 AATTGAGGTT TTGGATATAT TGGGTGGAAA AGAAAGTCAC CTCACATAAA
8 0 1 ACTTAGTGAT TGGAGCTGTC ACCATTGAAA ATTTCTAAAC TTTGCAAGAC
8 5 1 AGCAGTGACG TTTCAAATGA CACTCTCAGA GAGTTGATAA TGGGCTAAAA
9 0 1 TAGATCTCCC TCCAGGTGGA TTTACTGTAC AAGGACAACA TTTACATTGC
9 5 1 ACTTGGAGAC TTCTCCCAGT TTGGTTTAAG TTCACAGATT GCAGATCCCA
1 0 0 1 GACAGCTGGT ATCAACTGAC CAGTGTTCTG TTAAGGCTAA AGCCAAGACT
1 0 5 1 CTTTATCACA CTGTGGCCTT AAGATTGGAT TTCTCTTCCT GTTCCTGGGA
1 1 0 1 AGAATTAGAG ATATAACCTA AAGGTCACTA TTATTCTGAG AAAAGGGATT
1 1 5 1 CTGGAGGAGG AGGGAGCAAT GAGTATGTGG CAGGAGTTCA AGGTAATAAG
1 2 0 1 GGCTGAGACA CAAGCCACAG AGCATAAAGC TCCAGTCCTT CCTCCAGGGA
1 2 5 1 TGAGGCAGTA AGGACTTGGA CTCCTCTGTC CAGCTTTTAA CAATCTAAGT
1 3 0 1 TACGGTTAGA GCTTTCTCCT TTTCTTTCAA CTACTCCTGG CAGTTGTGGG
1 3 5 1 GTCATGGAAT TTTTGTAAAA AATGGGGTGG AGGAAAATAA GGCATCTGCT
1 4 0 1 GAGTGTATAA CCATTTTACC TCTTGTTTTT AGCCCTCTTC TGGGTCACGC
1 4 5 1 TAGAATCAGA TCTGCTCTCC AGCATCTTCT GTTTCCTGGC AAGTGTTTCC
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1 5 0 1 TGCTACTTTG GATTGGCCAC GATGGGCTGG AGCTGCCTTG TGACAGGAGC
1 5 5 1 AGGAGGGCTT CTGGGTCAGA GGATCGTCCG CCTGTTGGTG GAAGAGAAGG
1 6 0 1 AACTGAAGGA GATCAGGGCC TTGGACAAGG CCTTCAGACC AGAATTGAGA
1 6 5 1 GAGGAATTTT CTAGTAAGTA AACTTGAGTC ATGGGTCTGT GGCTCCATCT
1 7 0 1 TAAACTCTGC ATGGGTGTGG GGAGGTTGAC CTTGTCTAGC AAGTTAAGGA
1 7 5 1 AAGTTGTAGC CAAATGAAAG CCAGTCACAC ATCTAAAGTC ATCAGAAAGG
1 8 0 1 AAATAGAATA AAATGGTATA GTGTGAAAGA TACTGGATGG GGTGTCCAGA
1 8 5 1 GACTGGATTC TGGCCCTGAC GCAGAACTTG AGAGGCAGCC ATGTCAGCCT
1 9 0 1 CAAGGCCCCT TTTCTTCTCT TCTAGAGAGT CACACATGAG TTCTCCTTCT
1 9 5 1 TGTCTACAAC TCTTATGTTC TGAAGCTTTT TGTCTTGGCG ATTGCTGTGC
2 0 0 1 GACATTCACA AAGGAGATCA TTTACCTGGA GACCTCACCA GTGGGTCCTG
2 0 5 1 CCTGTCTAGA CTGCCCCAGG CTTCATTTCA TTTTATAGCT TCCTTAGTAT
2 1 0 1 CTTTAGTGAG GGCAAAATAA AAGGAAGTGA AGGTACGGAT GTGTGTGTAA
2 1 5 1 TTGTGTGTGT GTGTCAGACA GAGAAAGAAA ATGAGGGGGA AAGAAGGTCA
2 2 0 1 GAGACAGAGA ATGAGAAAGA CAGAGAATGA ATGAGAAAGA TAGTGTGAGG
2 2 5 1 GAGAGCATCA GCAAGAGAGA GAGAGTGAAA GTGAGAGAGA TCATCAGTGA
2 3 0 1 GAGAGAGAGA AAGAGAGAAA GAGAGCATGC ACAAGTGCAC AGCACAGAGC
2 3 5 1 AGAGACAGAG TAAAAGGCAG TATGAGGCCA ACATGCCTCA TTTATATTTC
2 4 0 1 TCATATATAG CCTTTTTAAA AAAAAACCAT TTGTATCTGT TGTTCAATAC
2 4 5 1 TCCAAATAAA TTGACTGCAG AATTTGCTGT AGTAACTCTT TGTGCAAATA
2 5 0 1 ACCCTGTGAG GAAGGTAGAA AAGGGGTCAC CTCCAACTGG ACAATGAACC
2 5 5 1 CATCAAGTTC CAGAAACATA AAGTTACTTG CCAAGAACAG CTGATTAATG
2 6 0 1 TGTAGCAGAG CTCAGACCAG AGCTTCATTC CAGAAGCTTC ATCACTTGAC
2 6 5 1 CCCCGGGCTA ATCCTTGGTG GGTCTTCAGT CTCTCCCTTT GCCTCTCTGT
2 7 0 1 GTGCCCCAAA CCAATTCCAT GTTTTCCTCC CAACCCAGGG GACTGGGGGA
2 7 5 1 ACTATGTATC TTCTTCATGC AGGTTCTGGC TGCCTAGAAG GTCCTGCCCT
2 8 0 1 GTTCACACAG AAGCTCCCCT TGACACTCTC CTCTTCTTTC ACTCTTCTCT
2 8 5 1 GACCTCTTTA AATGTCCAAT TTCCTCCACT CTCTGTTCTA ATAGTGAACA
2 9 0 1 GATATTAACA CATGACTGAT ATTAAATGTT TGTAATCCTT ATGTCTCAGC
2 9 5 1 AATATTTACA ATCTAACATC TGATACCAGG AAAAAGCAAT GCTCAGTCTA
3 0 0 1 GAGGAAGAGT TCTGCTATGG TGAAAATGCA GGGAGCATAA TGGATGGGCA
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3 0 5 1 GGGCCTGTAT GAAGATAAAA ACAGAGAATC CTTTCAGTGT TCTTTCTGTG
3 1 0 1 CCAGGCACTG TGCTAAAGGT TTTGCATGTG CTGACTCATT TACTTCCCAT
3 1 5 1 AACAACCCTA TGAGATGGGT AATACTATTA TCCTCCTTTT TTATAGATGA
3 2 0 1 GGAGACAGAC ACAGAGAGGT TAATCAACTT GTCGAAGGTC CCAAGTTAGA
3 2 5 1 TTACGGCAAA GCTGGATTTG AATCCAGGCA GTCTAGTGCA GCTTCTGTGC
3 3 0 1 TCTTAAGTAG TAGTTTGTCT AGCAGCTTCT CTGAGCCTCC CTCCAGCCCA
3 3 5 1 ACACACAACA CAAAAGCAAC TGAATTTAGT CTACATGAAA CACTTGCCAA
3 4 0 1 GTCCACAGTG CCTTGGAGAA GGAGGGAGCT AAGACTCCAT GAAAAATTGC
3 4 5 1 GCTTTTCTGG TCTCTCTAGA TCCATGGAAA CTCACCGGGG AAGAGTCATT
3 5 0 1 TTCTATCGGC TTTGGACTTC TGCTATGAAA TGGCAATTGC TTTGAGCCAG
3 5 5 1 TCTGTCTAAA GTCGGCAGCA AAGGAGAAGC AGATGAAGGG AGTAGAAAAG
3 6 0 1 GTAGAGGTGG AAATACAACC AGAGAAAATT CCACTCTCGG GGCTGACACC
3 6 5 1 CACCTCCTCC CCAGCAGCCT CTTCCCTGCC TCCACCATTC CAGGGCCTTC
3 7 0 1 TTGGAGTTGC CTGACAGTGG GAAGGGGCTG GGAGTAGACA AAACAAGGCA
3 7 5 1 GAGGCATCAG GAGAGCAAAT GGTCCTGCCT GTAACCCAGG AAGGAATTTC
3 8 0 1 TCCAGCCTTG AATTTTTCAT TCTGAATTTC GCTCTCACTG TTCTTTGGCC
3 8 5 1 TTTGTGGGCA TTTTCAGTTA AACTGGCTTA TTCTTACTCT TTCTCAGAAA
3 9 0 1 AGTTGATTCT AAACAGCTAT TCCTGCACCT GGGGTACAGG GTACAAAAAT
3 9 5 1 GGCAGGTGGA ATGGGCAGGT TTGAGCCTTC ACTAGAAAAT TGACTTTAGA
4 0 0 1 TCTGTCCCTT AACCTCTCTG AGCCTCAGTT TCCTCACCAA TAAAGTGGGA
4 0 5 1 CTCAGAATAC CTACCTCACG AGATAGCTGT AAAAGGAAAT AAGCAAGCTG
4 1 0 1 TGAGCCGTAT GCAGATTATA AAGCACAAAT GAGTGTAGAG TATTTATCTG
4 1 5 1 AGCTCCATGT AGCATGGTGT TCATTTTGTG GGCTAATTCC AGGTGACAAC
4 2 0 1 TTTACCGGCA GCGTCACTAC CTGTGGATTT CAGAGGAGCC TGAAGATATG
4 2 5 1 GATGTTACAT CCGCTGCCCT TGGCTAGACA TTAGACAGCT GAGATGTTAG
4 3 0 1 TTCATTGGTG GCTAACTCAT TTTCAGCATT GCTATCTGCT TTTTATGATA
4 3 5 1 TCTGATAAAA GTTTCTCAAT GAAA.TTAATC ATTTAAGCCC ATCTGCAATT
4 4 0 1 CCTGAGTAAT GGCTCCACTC TCCTCCCAGT TGCCCAAGCA GGAAACTGTA
4 4 5 1 AGGGTGATTT TGTCTCCTTT TCCTCTCATC CCAGCTCCAG TAGGTACCAG
4 5 0 1 GACCTTCAAG GTGAGGTCTG AAATTCAAAC CTGGAGTGCA TCTCTCCCCT
4 5 5 1 CCTCTGCTTC CACTGCTGGA CCCTGGTTCC AGTCCTCATC TAAACTTTGG
4 6 0 1 CACAGACATT CTGATTAATG TCTTGATCAC CTGGCTTTCT CATTTCCCCT
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4 6 5 1 ATACCAGTCT GTTTTATATC CTCAAGCCAA GGTAAACTTC CTACGCCACA
4 7 0 1 ACTCTGCGTC TGTTTATCTT TTATTATTAT TACTATTATT ATTATTATTA
4 7 5 1 TTATTATTAT TATTTTGAGA CAGGGTCTTT CTCTGCCACT GAGGCTAGCA
4 8 0 1 TGCAGTGGCA TGATCTCAAT TCACTGCAAC CTCCACCTCC CAGACTCCAT
4 8 5 1 CCATCCTCCT GCTTCAGGTT TGTGATTAGC TGGGACTATA GGCACATACC
4 9 0 1 ATCACGCCCA GCTAATTTTT GTAATTTTAG TAAAGACAGG GTTTTGCCAT
4 9 5 1 GTTTTCCAGC CAGACCTCCA CCTCCAGAAA TCAAGTGATT CACCACCTCA
5 0 0 1 GAGTCCCAAA GAGCTGGAAT TACAGGAATG AGCCACTGCA CCCGGCCTGT
5 0 5 1 TTCTCTACTT ATTCCAACAT AAATAAGGGT TTTTCTTTGA CATGGTGCTG
5 1 0 1 GAGACCCAAA ATCATAATTC TATACATGAT TCCTCATCGC CTACAGAATT
5 1 5 1 AAATTCAAAC TTTCCCTCTT ATACCCAACT CTCCACAATC ACTCTATTCT
5 2 0 1 CCATAAAAAA TTTGGTGAGT CTCCCATGAC TCTAGCAATG CTTATATTTC
5 2 5 1 ACGGATGTGT GACAATTCAC TGCTCACATT ACTTTTCTGG AATAAGATGG
5 3 0 1 GGTAGAAACA GATGTTTGCT CTTTCCCAAT AAACTGCTAC ACATGCTGAT
5 3 5 1 TTCTGTGCTT TTGTTTACTT GTTCCTTTTA TGGAATGTAG TACACCCTCC
5 4 0 1 ACTCTAATAC CCACACTCTA ATCTCTTTGA GCACCTATGT AACATCGCCT
5 4 5 1 TTATCAGAAA ACTTCCCAGC CAGATCCAGA AATCTTTCCA ATGACCTGAC
5 5 0 1 CTGTGTTCAC ACAGAGCTCC AGAACAGGAC CAAGCTGACT GTACTTGAAG
5 5 5 1 GAGACATTCT GGATGAGCCA TTCCTGAAAA GAGCCTGCCA GGACGTCTCG
5 6 0 1 GTCGTCATCC ACACCGCCTG TATCATTGAT GTCTTTGGTG TCACTCACAG
5 6 5 1 AGAGTCCATC ATGAATGTCA ATGTGAAAGG TACAGTAGCC TGGGGAGGAG
5 7 0 1 ATAAAACAAG TTGGTTAAAT GAGGATCAGA AAGAAGGACA AGAAAGGGAA
5 7 5 1 GAGAAGTCAC TCCATTGAAC ACCTGCTGAG CTCTTGGCCA AGTGCCTTTG
5 8 0 1 CTGATCACTA CTGACTGGGG AGTTCAAGGC TGGTAACCTC AGTTTTTTAG
5 8 5 1 ATGAGAAAAC TAGGGCTGAG AGACAGCAAG TAACTTGTCC AAGGCCCCAA
5 9 0 1 AAGTAAGTAA GTAAGTAGGA GAGTTAGACT TTAAACTCAC TCCTGTGTGA
5 9 5 1 CTCCAAAGGC TGTGGAAGCT CTTTCTACTG TGGCCCCAAT CAAAAGTCAA
6 0 0 1 CTAAACTCCA ACTTCAAATT CACGATATCC AGCTACTCCT TGGCTCCCGG
6 0 5 1 GGCCAGAATC AGACCTTCCA GGTGCCACCA TAGTCATCAT TTTGAACCTT
6 1 0 1 GTGTGTAGGC TGATGAGAAC ATTCAGAGTC TTCCTGCCCA CCTCAAAGAA
6 1 5 1 GTCCTCTCAA GAGAACTAGC AAAGCTGGTT CACAGAGGTC TGTCAGGACA
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6 2 0 1 GAATTATCCA GCACATGCCT TCCCATAATA TTTTCTTAAC AAAAAGAGTT
6 2 5 1 TCCCAGTGTC CAGAATACAA TCTCTTCAGC TCACCACAGG GTCTACTATT
6 3 0 1 ACAGAGCCAT TTCCTGCCAG GTGCCCAAAG TGCACCCTCA TTTGATCCAC
6 3 5 1 ATTTTTTAAA GGAATCTTGC CATGCAGTCT CACCCTCTGA TTCCCAGAGC
6 4 0 1 CCAGTCTCTT CAAAACACAG CTCCCCACTG CTGGCCTGAC CCTCCACATT
6 4 5 1 CAGACTACCC AAACTCCTTT TATAAAGCAA CTAATTGCTT TTGAGTCTCC
6 5 0 1 AGCACTGTCT AAAAAAACAA ACAAAAAAAA AACCTTTCCA GTTTCTACAT
6 5 5 1 AGCCATACCC CTAAGTACCG CTATAGTTCA AGGAGTGTGC TAAGAGTGAA
6 6 0 1 TAGTTTTTTG TTTTAATTTT GACTTTCCAC AGCTCCCAAA AACAAGGGAT
6 6 5 1 AAGAAATGAC AAGGGGAGTG TTAGAGGCGT CTGTTTCTTA AAACCATTAT
6 7 0 1 CACTCCCGGG CTTAGAAAAT ACTTCACAAT GATGGCCATT TCATGAGGCT
6 7 5 1 GTCTCTCCAG AAACTCAAAT TGCACAGAGA CTTTAAAAGT GGCTAAGAAT
6 8 0 1 ACAAAATAAG TAAATAAAAA TGATCCTTTG CCTAGGAAAT TCCTTCCTTC
6 8 5 1 TTCAAGGGAA GACACTCCAG ATACCTCCAT GAGCTTTGCT TCCACACAGC
6 9 0 1 TCAGGTGATG CTGACAGGTC TTCCCAGTGC AGGTGTTATC AGCAGAGGGC
6 9 5 1 ACACTCCCTC CCCAGTCCTC CACCAGGCTC CACAGGAAAT GCCAGGGCAG
7 0 0 1 GATTTAAAGG AAGGTTTATC ACCCCCACTT TATATAACTG GGTAACAGAG
7 0 5 1 TCATAGCCAG AATTGGAAGC AGCTTTTCCA GGGAACACAC AATCAGGAAA
7 1 0 1 GGAGTGTGGG TTTCCAGCAT CTCCCCACAA CCCACTGTTT GCTCGATGAC
7 1 5 1 TCCAGGGATG GTCTTTGTGA CAAAGTTTTA TTAATCCATT GCAAAATGAG
7 2 0 1 AAAAATACCA GCAATTCTAT GTATATCTAA GAGTGTATAT TGCCTATATT
7 2 5 1 CAACTGTGAA TTTGTGTGTG TAACACAAAT TCTTCCACTG CCCTTTCTTG
7 3 0 1 CCTAAGGACT GATTGGGACT GTTCATATTC TCAGAGTATA GCCTCCTGAT
7 3 5 1 TTTTTAGATT TTAAATGATC TGTCTTTAAT TGTATTGATG ACAAATCATA
7 4 0 1 CTTTTTCAAT ATCCTTACTT GGCAAAAAAT AAAGTGATTA CCCTAGGTCC
7 4 5 1 TTTTCCAAAA TTAAAGTGTG TGTGTATATA TATATATGTA TATATATATG
7 5 0 1 TATATATATA TATGTATATA TATGTATATA TATATATGTA TATATATATG
7 5 5 1 TATATATATA TGTATATATA TATGTATATA TATATATTTT ATAATATATA
7 6 0 1 TATATATATA CACACACGTA TACATACACA CACACACACA C AC ACC AC AC
7 6 5 1 ACAAACATAG GTCCATGAAA CCCAAAAGTC TAGAAATTCT TGCTTTCTAG
7 7 0 1 AACCCAAATG TCAGTTTCTT TTTATTTTTG TGTTTTTCCT ACGGCTGTAT
7 7 5 1 CATGACCCAA TCTCAGTCAG AGCCACAGAA GAATGCACCC TGAGTCTGTT
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7 8 0 1 ATAACCACTG CACTTGGGAG TGGGGAGTGG GGCACATGGA TCTGTGCATG
7 8 5 1 TGGTTGCAGC TCCTTTGGGA TATTTCCTGA CACTGTCATC ATGCTCTTCG
7 9 0 1 TGGGCAGGTA CCCAGCTACT GTTGGAGGCC TGTGTCCAAG CCAGTGTGCC
7 9 5 1 AGTCTTCATC TACACCAGTA GCATAGAGGT AGCCGGGCCC AACTCCTACA
8 0 0 1 AGGAAATCAT CCAGAACGGC CACGAAGAAG AGCCTCTGGA AAACACATGG
8 0 5 1 CCCACTCCAT ACCCGTACAG CAAAAAGCTT GCTGAGAAGG CTGTGCTGGC
8 1 0 1 GGCTAATGGG TGGAATCTAA AAAATGGTGA TACCTTGTAC ACTTGTGCGT
8 1 5 1 TAAGACCCAC ATATATCTAT GGGGAAGGAG GCCCATTCCT TTCTGCCAGT
8 2 0 1 ATAAATGAGG CCCTGAACAA CAATGGGATC CTGTCAAGTG TTGGAAAGTT
8 2 5 1 CTCTACAGTC AACCCAGTCT ATGTTGGCAA CGTGGCCTGG GCCCACATTC
8 3 0 1 TGGCCTTGAG GGCTCTGCGG GACCCCAAGA AGGCCCCAAG TGTCCGAGGT
8 3 5 1 CAATTCTATT ACATCTCAGA TGACACGCCT CACCAAAGCT ATGATAACCT
8 4 0 1 TAATTACATC CTGAGCAAAG AGTTTGGCCT CCGCCTTGAT TCCAGATGGA
8 4 5 1 GCCTTCCTTT AACCCTGATG TACTGGATTG GCTTCCTGCT GGAAGTAGTG
8 5 0 1 AGCTTCCTAC TCAGCCCAAT TTACTCCTAT CAAGGCCCCT TCAACCGCCA
8 5 5 1 CACAGTCACA TTATCAAATA GTGTGTTCAC CTTCTCTTAC AAGAAGGCTC
8 6 0 1 AGCGAGATCT GGCGTATAAG CCACTCTACA GCTGGGAGGA AGGCAAGCAG
8 6 5 1 AAAACCGTGG AGTGGGTTGG TTCCCTTGTG GACCGGCACA AGGAGACCCT
8 7 0 1 GAAGTCCAAG ACTCAGTGAT TTAAGGATGA CAGAGATGTG CATGTGGGTA
8 7 5 1 TTGTTAGGAA ATGTCATCAA ACTCCACCCA CCTGGCTTCA TACAGAAGGC
8 8 0 1 AACAGGGGCA CAAGCCCAGG TCCTGCTGCC TCTCTTTCAC ACAATGCCCA
8 8 5 1 ACTTACTGTC TTCTTCATGT CATCAAAATC TGCACAGTCA CTGGCCCAAC
8 9 0 1 CAGAACTTTC TGTCCTAATC ATACACCAGA AGACAAACAA TATGATTTGC
8 9 5 1 TGTTACCAAA TCTCAGTGGC TGATTCTGAA CAATTGTGGT CTCTCTTAAC
9 0 0 1 TTGAGGTTCT CTTTTGACTA ATAGAGCTCC ATTTCCCCTC TTAAATGAGA
9 0 5 1 AAGCATTTCT TTTCTCTTTA ATCTCCTATT CCTTCACACA GTTCAACATA
9 1 0 1  AAGAGCAATA AATGTTTTAA TGCTTAA
178
Appendix ii
Sequences obtained from clones isolated from two human genomic libraries, aligned 
with homologous sequences from 3B-HSD type I and type II (exons 1-4). Triplet 
nucleotides underlined are tr anslational start and stop codons. 36-HSD type II missense 
and nonsense mutations are shown above the aligned sequences in brackets. 
CoiTesponding single nucleotides in the clones HSD3B\|/4, \]/5, tj/l and \|/3 are 
highlighted in bold and underlined. Dashes indicate gaps introduced for alignment. 
Bases coiTesponding to intron sequence in 3B-HSD types I and II are shown in lower 
case.
a) Exons 1 and 2
1 5 0
T y p e  2 GAGGCAGTAA GGACTTGGAC TCCTCTGTCC AGCTTTT-AA CAATCTAAGT
T y p e l . . . . TGAG. . T . G . C C . . . . T .................. ..................... C.
HSD3B\l/4 . . A . T G A C C . . C . . . C T . . . . . T . . . A . . . .................. T .  . T .................. CA
HSD 3BY5 . . ATGGAC. . . C . . C C T . . . . . T . T ............ ............... . ..................... CA
HSD3B\|/2 . . . . TGACC. . C . . C C T . . . . A ..................... . . . . A . . - . . T .................. C .
H SD 3B \j/l . . A . T G . C C . . C . . - C T . . . . . T .................. . . . C . . . - . . . C . . T . . . T.
HSD3B\]/3 NimNmimiNN NmiimNNimN NrsnSINMtWNN. .C ............ .G ............... CA
5 1
T y p e 2
T y p e l
HSD3B\l/4
HSD3B\ll5
HSD3Br}/2
HSD3Br}/l
HSD3Br}/3
100
■k
T A C G g t ta g a  g c t t t c t c c t  t t t c t t t c a a  c t a c t  c c  t g g c a g t t g t
A . T ..........................a .  . . t . . a ............................... g    . .  . . . . . . . g
g. . t . . e t . t a .
 . . a ...................... e t .  . a .
A . T .............................. a . t .  . g .
A . T .  . . g . a ..................t . , a .
A . T .  . e ...........................t .  . a .
. t . g  . .
. . .g  . .
. . . g  . .
. . . g g.
. t t t  . a
-------1 .
------. t
a e e a .
101 1 5 0
T y p e 2
T y p e l
HSD3B\[/4
HSD3BY5
HSD3B\|/2
HSD3B\|/1
HSD3Bl|f3
g g g g t e a t g g  a a t t t t t g t a  a a a a a  t g  g g g t g g a g g a  a a a t a a g g c a
. . . a . . c a . . . .  g . . . .  e ...................a a —.....................................................g .............
a a  . a .........................................e c   a a a .................................................... a  . . .
. a . a ....................................... c .................... a a - ................... a ....................................... a  . .
a . . a t .................................... c .....................a a a ............................ a . t  . . . . . . a . . .
. . —a .........................................e .  . . e . . -------- . .  t ...........................................................
. . . a . . c a ........................... e ...................a — g a  .........................................................g .
1 5 1 2 0 0
*
T y p e 2
T y p e l
HSD3B\j/4
t c t g - c t g a g  
. . . . t g . . . .
t g t a t a a c c a  
. a .....................
t t t t a c c t c t  
. . . g  . . a  . . -
t g t t t t t a g C  
, c .....................
CCTCTTCTGG 
............ C , A . .
. t . . t g . . . . . . . g . t . . . - - ............ c  . . . ............ C . A . .
HSD3B\l/5 . . . . t g . . . . . a ..................... . — . g . t . . . — . t ..................... . — . . . C . A . .
HSD3B\j/2 . . . . t g . . . . .................. a t . . e  . g . t . . kJ c  • ■■■■■>■ . - . . . C . A —.
H SD3B\|/1 . . . . t g c a . . . e . . . . . . . . e ..................... - ........................ T . . . G . C . A T .
HSD3B\l/3 . . . . t g . . . . . . . g .  . . a . - . e  . . c ............ ............ C . . . .
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2 0 1 2 5 0
T y p e 2
T y p e l
HSD3B\|/4
HSD3B\)/5
HSD3B\|/2
HSD3B\|/1
HSD3B\|/3
GTCACGCTAG AATCAGATCT GCTCTCCAGC ATCTTCTGTT TCCTGGCAAG
. . . . C .......................................................   . C ................................................................... TG . .
. . .  A T ......................................................... C ..................................................C ..............G . . .
. . . . C .........................................................C  AGT .
A . . . C ......................A ..............  T . . . C .....................................................................A G . .
T .  . . C ......................A ................................C . . . . G   A  G.  .
. . . . G T .............................................T . . C ..........................................C.  C  G.  .
2 5 1 3 0 0
T y p e 2  TGGTTTCCTG CTACTTTGGA TTGGCCACGA TGGGCTGGAG CTGCCTTGTG
T y p e l  . . . A ............................................... - ..............M !G . C ..........................................................
HSD3B\l/4 ................................. A . T A  AATG . C A ......................................................
HSD3B\j/5  G T ............................................................. A TG . C A .......................................................
HSD3B\l/2 ..........................................C .C ..............................ATG. C A .......................................................
HSD3B\1/1 ................................. A . T C   -  ATG...................................................................
HSD3B\l/3 G  A . . . ATG.................................A . . T ..................
3 0 1
(A)
T y p e  2 
T y p e l
ACAGGAGCAG GAGGGCTTCT GGGTCAGAGG ATCGTCCGCC
....................................   . . . T ....................A ......... A .....
H SD3B\|/4  T ...TAG...................A ................
HSD3B\l/5 ..............................................T ........................... TAG . . T . . . A .....
HSD3BXI/2 ..............................................T ........................................................A . . T . . .
H SD3B\|/1  T .
HSD3B\|/3  A N . T ,
C
,A
, T .  .
. . A .
3 5 0
*
TGTTGGTGGA 
. C ..................
■ C ..................
■ C ................ A
. . . . A . . . .
, AA.  . 
. . AT.
.C . 
. C .
. A
. A
3 5 1 4 0 0
T y p e  2 
T y p e l  
HSD3BX1/4 
HSD3Bl{/5 
HSD3B\)/2 
H SD 3B \j/l 
HSD3B\|/3
AGAGAAGGAA CTGAAGGAGA TCAGGGCCTT GGACAAGGCC TTCAGACCAGA
G.
G,
G.
G,
G,
G,
,A .
CA. .G  ..................................... CC
, . . . .G  . . A .................................
,T . , A .
T y p e 2
T y p e l
HSD3B\|/4
4 0 1  4 3 0* *
AATTGAGAGA GGAATTTTCT A g t a a g t a a a
.GC
HSD3B\[/5  GA.
HSD3B\]/2 
HSD3B\1/1 
HSD3B\l/3
G. . T G A . G .....................................................................
G .............................. A .......................................................
. . . TNTXnxnXTNN N n n n n n n n n n
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b) Exon3
5 0
T y p e 2  c c a a t g a c c t  g a c c t g t g t t  c a c a c a g A G C  TCCAGAACAG GACCAAGCTG
T y p e l  ....................................................................................... A  A ...........................
HSD3B\j/4 ............................................................ n n n n n n  A ...........................
HSD3B\j/5 ............................................................  n n n n n n ..........................................A.............................
HSD3B\|/2   a . . . . c n . c .............................A ................................ A.  . T ...................
HSD3B\|/1....... .................................................................. t t g  A  A . .
H SD3B\|/3 ............................................................ nn n n n n n N N N  NNlXnSINlTN]^^
5 1 100
ACTGTACTTG AAGGAGACAT TCTGGATGAG CCATTCCTGA AAAGAGCCTGT y p e 2
T y p e l
HSD3B\l/3 NNNNTG T.G ................................................. A ,
. .G .....................
. . .G .....................
. ,G . .G .G ................................. ............................ T . ,. . G . . . , . . . G .....................
, , A . . 0 ...........................  T.  ,. . G . . . , . . . G ............ ... . .
T.
101
(A)
1 5 0
T y p e 2  CCAGGACGTC TCGGTCGTCA TCCACACCGC CTGTATCATT GATGTCTTTG
T y p e l  ................................................ A ......................................................................................................C .
H SD3B\|/4 .................. A . G ................ A  T . . . . C ................. A T .............A . C .
HSD3B11/5 .................. A . G ................ A ................................... A .  . . C C  A . . C A . . A . C .
HSD3B\j/2 ..................... G  C .
HSD3B\|/1  A ............A ....................................................C .............................. C A . . . . C .
HSD3B\j/3  A . .  . T . . . . A ............................... T . .  . . C .............................C ..............C.
1 5 1
(G)
200
GTGTCACTCA CAGAGAGTCC ATCATGAATG TCAATGTGAA A G g t a c a g t a  
...........................................................T  t g .  . .
T y p e 2  
T y p e l
H 5D 3B l|/4 ....................................... - - ...............................................
HSD3B\|/5  CA
HSD3B\j/2 .A ..................................... C . . . . T ...............................
HSD3B\|/1  T  CT
HSD3B\|/3  C . . . . T   A.
gg.
2 0 1 2 3 0
T y p e 2  g c c t g g g g a g  g a g a t a a a a c  a a g t t g g t t -
T y p e l  . g ...........................................g c . g .  . . . g . . . g g -
HSD3B\|/4 a .............................................. a . g ........................... g g -
HSD3B\]/5  g . . g .  . . . g . . . g g -
HSD3B\l/2 ...............n n n n  n n n n n n n n n n  n n n n n n n n n n
H SD 3B \j/l  a ............................ g g . g .  . . . g . . . a g c
HSD3B\|/3 t .............................................g c . g ,  . . . g . . . g - c
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c) Exon 4
T y p e  2 
T y p e l  
HSD3B\|/4 
HSD3B\|/2 
HSD3B\|/1 
HSD3B\|/3
1 50
(a )  (G) *
t c t t c g t g g g  cagGTACCCA GCTACTGTTG GAGGCCTGTG TCCAAGCCAG
 a  . . .  a  .......................................C ..............A ......................................................T . .
. t  a .  . t .................................... T ...........................................................................T .C
. . . .  t e ............... g .................................. C ...........................................................................T . C
 a ......................................... A . A G ...............................................................................T . ,
- ........................................................ A . . T .......................... - A  T.  .
T y p e  2 
T y p e l  
HSD3B\j/4
T y p e 2
T y p e l
HSD3B\|/3
51 1 0 0* (A) *
TGTGCCAGTC TTCATCTACA CCAGTAGCAT AGAGGTAGCC GGGCCCAACT
A ............... A . . ............... C . C . .............................. A .................. T.
............... C . C . C C . . T .............................................
. . . . C ............ . C .....................  T ........................
. . . . C . T . . .
1 0 1 1 5 0
■k (A) *
CCTACAAGGA AATCATCCAG AACGGCCACG AAGAAGAGCC TCTGGAAAAC
. . T ............ T .
............... TG. . . . T . C . . . T . .................. CTT ............................
.................. A.  . G . . T T ............ . . T C . A . . . A . . C ............... A ............................
. . . G . . . TGA G ........................ . . T .........................T ......................
1 5 1 200
ACATGGCCCA CTCCATACCC 
......................... C ...........................
T y p e  2 
T y p e l
HSD3B\|/4  TA. G
HSD3B\l/2 ................. T . T G
HSD3B\J/1 ................. T . T G
HSD3B\|/3 . T ................. TG
GTACAGCAAA AAGCTTGCTG AGAAGGCTGT
A C .......................................................................................
A C .......................................................................................
A .....................................T .................................................
A .................................. - ....................................................
A . .G  C . .
2 0 1
(A) (G)
T y p e 2  GCTGGCGGCT AATGGGTGGA ATCTAAAAAA TGGTGATACC 
T y p e l  A .................................C ..............
HSD3B\[/4  CT.
HSD3B\|/2 , A .
HSD3BX1/1  T . .
HSD3B\j/3 ................ A, ,A .
. G . . . . . C . . C . G C . . .
G . ,. . G . . . . . C . . . . G C . . .r . . G . . .
C.  .. T G A . . , . . . . C . . G C . T G
CA ,. . G . . . . .  . A . C . ~ . . T .
2 5 0
*
TTGTACACTT 
C ........................
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T y p e 2  
T y p e l  
HSD3B\|/4  
HSD3B\|/2 . . . .C
H SD3B\|/1 . . . . C
HSD3B^J/3 . . . . C
2 5 1  3 0 0
* (T)  *
GTGCGTTAAG ACCCACATAT ATCTATGGGG AAGGAGGCCC ATTCCTTTCT
. . . .  C . . .  C .................. T G ...........................................................A ................ A ......................
. . . . C G ......................A . T G . T .................................................... A ...........................................
........................ T G ...........................................................A ......................T .................
. . . C T . A . T G C .......................................................A ....................... T . . . A . .
. . .  C T . . . T G .............................. A ....................... A . . . .  T A . A ...............
T y p e  2 
T y p e l
HSD3BX1/1
3 0 1 3 5 0
* (C) {G) *
GCCAGTATAA ATGAGGCCCT GAACAACAAT GGGATCCTGT CAAGTGTTGG
. . . G ............... . . . .  A ............... C.  . . . A . . . . ..................... T . C A .
. . . . A ............ . . . G ............CA.
. A . . A ............ . . A.  . . . T .  . . . A ............... . C ............ ............... C .................
. . . . C . . C . . . . . .  A T T - - ............ ........................... CA.
T y p e  2 
T y p e l  
HSD3B\i/4 
HSD3B\i/2
3 5 1  4 0 0
*G) *
AAAGTTCTCT ACAGTCAACC CAGTCTATGT TGGCAACGTG GCCTGGGCCC
HSD3B11/1 ..........................C
HSD3B\{/3 C  A . . C
. . T . . T ................................................................ T . . .
■ G  A.  A
. . . . C ..............................................................................
. . . A C   G.  . ----------------
. . . -  A ..................................................T . . -
T y p e 2
T y p e l
4 0 1
ACATTCTGGC CTTGAGGGCT CTGCGGGACC 
.......................................................... C . . .  . A ............
(C)
CCAAGAAGGC
H SD3B\|/4  C
HSD3B\l/2 ............................................................
HSD3B\1/1  -  . . .C
HSD3B\|/3  T . . . . G T . T . C
4 5 0
(AA)
CCCAAGTGTC 
.................CA
,T .
,CA
CA
4 5 1  5 0 0
(TAG) (A) (G) (T)  *
T y p e 2  CGAGGTCAAT TCTATTACAT CTCAGATGAC ACGCCTCACC AAAGCTATGA
T y p e l  ............ A . . G ................. C . . T .......................................................................................................
HSD3B11/4  A . .G .......... C . . T ................. C ..................................................................................
HSD3B\l/2 . T . .  . A . . G ............... C . . T ..........................................................................................T . . . .
HSD 3B\|/1 T . . . .  A . . G ............... C ................................................................................................................
HSD3B\j/3  A . .G ............... C . . T ............................................T . T . . T .........................................
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5 0 1 5 5 0
T y p e 2  TAACCTTAAT TACATCCTGA GCAAAGAGTT TGGCCTCCGC
T y p e l  ...........................................C ...............................................................................
HSD3B\}/4  G .................C . T ................................................................. T . .
HSD3B\{/2   T ................... C . . . . C . T . .
HSD 3B\|/1  GC............................ C .................. T . .
HSD3B\|/3 C A ............... G .................C .............A .................... A . .  . - ............... T . .
CTTGATTCCA
5 5 1 6 0 0
T y p e 2  GATGGAGCCT TCCTTTÂACC CTGATGTACT GGATTGGCTT CCTGCTGGAA
T y p e l  ..................... T ..........................T ................................T ....................................................................
HSD3B\|/4 . T ....................  G ................ T ....................C ...............................................................................
HSD3B\l/2 . . . . A ..................... T . . . . T T ................................................................................................G.
HSD 3B\|/1...... G .............................G .................... G ...............................................................................
HSD3B\|/3  C . . G .................... G ...............................................................................
6 0 1 6 5 0
T y p e  2 
T y p e l  
HSD3B\|f4 
HSD3B\l/2 
HSD3B\1/1
H SD3B\|/3 A .C  A ............... G .............  NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
GTAGTGAGCT TCCTACTCAG CCCAATTTAC TCCTATCAAC CCCCCTTCAA
A .........................................................  G ...........................A ..................G . . .G .....................
A ....................................... G . C G . .  G . . . G ................. A . . . G . . G . .  . G .....................
A ...................... C . . . . G .............  G.  . . G .  . . G .  A ...............................G ..................G.
A ........................................G .............  G T .................. T A ............. TG.  . . T .......................
6 5 1 7 0 0
T y p e 2  CCGCCACACA GTCACATTAT CAAATAGTGT GTTCACCTTC TCTTACAAGA 
T y p e l  ..................... T ............................ G ...........................C . .  A ............................................T . . . .
HSD3B\|/4 . . A ............. G,
HSD3B\|/2 . T .....................
HSD3B\1/1 . T .....................
C . .
CA.
CA. G
HSD3B\i;3 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
7 0 1 7 5 0
T y p e 2 AGGCTCAGCG AGATCTGGCG TATAAGCCAC TCTACAGCTG GGAGGAAGCC
T y p e l  ...........................................T ................................................................................................................
HSD 3B\|/4  A  A  T . . .  . T ......................................................
HSD3B\j/2 ...................................................... A ..................................... T ........................................................
HSD3B\|/1  A . T .......................................................
HSD3B\l/3 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
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7 5 1 8 0 0
T y p e 2  AAGCAGAAAA CCGTGGAGTG GGTTGGTTCC CTTGTGGACC GGCACAAGGA
T y p e l  ................................. G ..........................................................................................................................
HSD3B\|/4 .................................... A ................................................................................... T...............................
HSD3B\l/2 .................................... A ...................  A ..........................................................................................
HSD3B\1/1 C .................................A ....................................................................................T . . A ..................
HSD3B\|/3 m m m im n m N  imrnnmrNNmr im N m im m m  m im nsiNN Nim  N im m iN m n m
8 0 1 8 5 0
T y p e 2  GACCCTGAAG TCCAAGACTC AGTGATTTAA GGATGACAGA GATGTGCATG
T y p e l  . . A ............................................................. TGA...............................................................................
H SD3B\|/4  C G ......................................................................
HSD3B\|/2 . . A ...................................................................c .............. NimNNNNNN mmnmNmiNN
HSD3B\|/1  A ...........................................................................................................................................
HSD3B\l/3 NNmnm NNNN NNmnWINNNN NNNNNNNISTNN im N N m im iN N  NimNNNNNNN
8 5 1 9 0 0
T y p e 2  TGGGTATTGT TAGGAAATGT CATCAAACTC CACCCACCTG GCTTCATACA
T y p e l  ...............................................G ...............................G ...........................T ....................C .................
HSD3B\|/4  G .C . . . . G ..........T . . T ......................................... -
HSD3B\j/2 m im nm N N N N  N im m nm N N N  N m rim im m fN  im ism m N N N N  NimimNNNNN  
HSD3B\]/1 ...........................................C G ...............................G ..................T . . T .................T C ..................
HSD3B\j/3 m im im rNN NN  m n m N N N m m  N m im N m n m  NNTsnsnsnmwNN n n n n m j n n n n
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Appendix  iii
Hybrid name: Chromosomes contained within: Mouse or rat:
H A ll
HA221
HA232
HB29
HB33 
HB35 
H B l l l  
H B 142-2 
HB181
JVOl
HR40C8
4, 5, 6, 8, 11, 20, 21
1, 4, 6, 7, 11, 15, 21
3, 4, 6, 11, 14, 15, 16, 21, 22
3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22 
6, 8, 14, 22
3, 4, 8, 14, 17
3, 11, 12, 14, 17, 21
4, 14, 15, 17, 20
2, 3, 6, 7, 8, 11, 12, 13, 14, 15, 17,
18, 19, 20, 21, 22
3, 5, 7, 10, 11, 13, 14, 17, Y
X, 7, 10, 12, 13, 14, 15, 17, 18, 19, 21
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
rat
rat
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